

FEDERAL COURT

BETWEEN:

**NEIL ALLARD
TANYA BEEMISH
DAVID HEBERT
SHAWN DAVEY**

Plaintiffs

and

HER MAJESTY THE QUEEN IN RIGHT OF CANADA

Defendant

AFFIDAVIT OF PAUL DAENINCK

I, Paul Daeninck, medical oncologist, of the City of Winnipeg, in the Province of Manitoba, SWEAR THAT:

1. I am a medical oncologist, employed by CancerCare Manitoba, in the Province of Manitoba and an Assistant Professor in the Department of Internal Medicine at the University of Manitoba. As such, I have personal knowledge of the matters hereinafter deposed to by me, except where same are stated to be based on information and belief and where so stated I verily believe them to be true.
2. I have been retained by the Attorney General of Canada in the above proceeding to provide an expert report for the Court. Attached at **Exhibit "A"** is my expert report, dated October 22, 2014.

3. On June 26, 2014, BJ Wray, counsel for the Attorney General of Canada, provided me with an instruction letter to complete my expert report. Attached as **Exhibit "B"** is a copy of the instruction letter.

4. Along with the instruction letter, BJ Wray also provided me with a chart that sets out the number of licenses that permit individuals to consume marihuana for medical purposes as of December, 2013 as well as the number of grams per day that these license holders are authorized to consume. Attached as **Exhibit "C"** is a copy of this chart.


5. Further, on June 26, 2014, I was provided with a copy of the Code of Conduct for Expert Witnesses. Attached as **Exhibit "D"** is a signed copy of the Certificate Concerning Code of Conduct for Expert Witnesses.

6. Attached as **Exhibit "E"** is a copy of my current Curriculum Vitae.

SWORN before me at the City of
Winnipeg, in the Province of Manitoba,
this 27th day of October, 2014.



A Commissioner for Oaths in and for the
Province of Manitoba


Dr. Paul Daeninck

My Commission expires: July 18, 2016

Expert Report-Medical Marijuana Use

Submitted to the Department of Justice

Oct 22, 2014

Paul Daeninck, MD, MSc, FRCPC
Medical Oncologist, CancerCare Manitoba.

Assistant Professor, Department of Internal Medicine, University of Manitoba
Cross-appointment to the Department of Family Medicine, University of Manitoba.
Consultant in Palliative Medicine, WRHA Palliative Care Program



This is Exhibit "A" referred to in the
affidavit of Dr. Paul Daeninck
sworn before me this 27 day
of October, 2014
T. Vardach

A COMMISSIONER FOR OATHS IN &
FOR THE PROVINCE OF MANITOBA
MY COMMISSION EXPIRES: July 18, 2016

Qualifications

- 1) I graduated from the University of Calgary medical school in 1991, and certified in Internal Medicine in 1995 and completed Medical Oncology training at the University of Manitoba; I spent an additional fellowship year in Edmonton studying Palliative Medicine through the University of Alberta. I have my Fellowship from the Royal College (FRCPC), as well as a Masters of Science, which was completed in 1987 prior to entering medical school.
- 2) I have practiced medical oncology and palliative medicine in Winnipeg since 1998. I presently hold academic appointments with the University of Manitoba in the Dept. of Internal Medicine (Section of Hematology and Medical Oncology), and a cross-appointment with the Dept. of Family Medicine (Palliative Care). I also have an appointment with the WRHA Palliative Care program, to provide clinical care to those on the regional palliative care program.
- 3) I accepted an appointment to the University of Manitoba Medical School as Director of the Longitudinal Theme of Palliative Care, and will be helping to design the new teaching program for undergraduate students.
- 4) I recently was appointed the Royal College Chair of the Advisory Committee of the Conjoint Program of Palliative Medicine. This committee is responsible for the certification of post-specialty training programs across the country, and works cooperatively with the College of Family Physicians of Canada to oversee the 13 programs currently in existence at Canadian universities.
- 5) My clinical practice includes patients with cancer undergoing active chemotherapy, those with metastatic disease requiring treatment of symptoms, and those with advanced diseases of any kind enrolled in our regional palliative care program. I have used prescription cannabinoids in hundreds of patients over the past 16 years, as well as medical marijuana in a few dozen. Due to the nature of my practice (patients with advanced and metastatic cancers), patient turnover is to be expected. Currently, I have documented approximately 20 patients using medical marijuana under the MMPR. These patients include those with cancer undergoing active therapy, those post-therapy but suffering from sequelae of the malignancy or treatment, and a few longer term patients with chronic pain who were initially registered under the MMAR program.
- 6) My own experience in the area of cannabinoids goes back to 2000, when a colleague who was leaving Winnipeg asked me to act as the contact for palliative patients requesting medical marijuana. I undertook my own review of the literature, initially focusing on prescription cannabinoid preparations, which showed some promise in those with symptoms from advanced cancer. I was asked to participate on an Advisory Board for Valeant Pharmaceuticals in the US in their attempt to

bring nabilone back to the US market. Through this, I met others (mostly Canadians who were brought in to advise Valeant) who shared an interest in cannabinoids, and soon after I was invited to join the Canadian Consortium for the Investigation of Cannabinoids (CCIC).

7) I have presented at several symposia, conferences and education fora on the use of cannabinoids in those with cancer and advanced disease under the CCIC banner. I was one of the first members to join the CCIC-sponsored Accredited Cannabinoid Education (ACE), three series of educational programs for medical personnel focusing on the benefits and consequences of medical marijuana use. Over 1400 physicians attended these programs from across the country. I currently sit on the Board of Directors of the CCIC, and continue to be involved with the Membership committee, as well as the committee developing educational activities.

8) I have presented at several conferences as well as continuing education activities on the use of cannabinoids in those with cancer and advanced disease. I have published papers reviewing the use of cannabinoids in oncology. I have also asked to review a soon to be published article in the medical literature related to cannabinoids and medical marijuana use in oncology.

9) I was invited to participate in the expert review of the Health Canada policy on medical marijuana, which eventually became the Marijuana for Medical Purposes Regulations (MMPR). This appointment also led to the revision of the "Information for Health Care Professionals" document, created by Health Canada as an evidence-based guide to medical marijuana use.

10) I most recently was asked to present to the President's Committee on Medical Marijuana for the College of Physicians and Surgeons of Manitoba, and will be involved as a consultant for any longer term work in the area.

11) Over the next 6 months, I will teach on medical marijuana to the Dept. of Family Medicine members as a Continuing Education topic, as well as to a group of family physicians in the Southern Health region of Manitoba. I have also been asked about contributing to a series of public lectures on health topics sponsored by the Dept. of Family Medicine, specifically on medical marijuana. I am also scheduled to present at the Department of Internal Medicine Grand Rounds, and my topic will be the use of medical marijuana.

Questions to be addressed:

- 1) Based on your experience, what are the challenges associated with authorizing the use of marihuana for medical purposes in a clinical setting? What steps ought to be taken by clinicians in order to mitigate those challenges?
- 2) The Health Canada publication, "Information for Health Care Professionals" (http://hc-sc.gc.ca/dhp-mps/alt_formats/pdf/marihuana/med/infoprof-eng.pdf, February, 2013) states that surveys published in peer reviewed journals indicate that the majority of individuals who use marihuana for medical purposes consume 1-3 grams of marihuana per day (p. 24). When, if ever, is it medically appropriate for an individual to consume more than 5 grams per day?
- 3) The attached chart sets out the number of licenses that permit individuals to consume marihuana for medical purposes as of December, 2013 as well as the number of grams per day that these license holders are authorized to consume. In your opinion, what might account for the significant number of licenses that authorize the consumption of more than 5 grams per day?

1) Based on your experience, what are the challenges associated with authorizing the use of marihuana for medical purposes in a clinical setting? What steps ought to be taken by clinicians in order to mitigate those challenges?

12) I see the biggest challenge in authorizing the use of medical marijuana^a is to ensure the diagnosis is correct, and the use is appropriate for the disease and setting. I also feel that appropriate screening of patients is important to prevent or minimize adverse reactions. Many people may get benefit from use of medical marijuana; some should not receive it due to its potential harms.

13) When I discuss the use of medical marijuana with patients, I consider several factors. These include the comorbidities of the individual (medical and psychiatric), concomitant use of other medications, what therapeutic medications the patient has used previously for the condition in question, the benefits and side effects of these medications, and the patient's risk of substance abuse.

14) I advise patients about the possible benefits for the symptoms in question, as well as the possible adverse effects of marijuana. These adverse effects have been described mostly in patients using it for recreational purposes; as such, the amount taken or the concentration of THC used is often not available. Wang et al (1) have described what is known from the use of marijuana for medical purposes. The most common physical side effects are dizziness, dry mouth and drowsiness. Hypotension and subsequent tachycardia may be problematic in patients with pre-existing cardiac disease. A syndrome of hyperemesis (severe and protracted vomiting) following use of marijuana (albeit in people using it for recreational purposes) has been described (2).

15) Acute psychological effects include anxiety and feelings of paranoia, but are generally short lived. This may be associated with marijuana containing higher concentrations of THC (3). Frank psychosis ("bad trip") has also been described, as has the unmasking of schizophrenia (4). This latter point is somewhat controversial, as population studies have confirmed a number of patients with schizophrenia admit to the use of marijuana, but it remains unclear if there is a direct correlation with use and onset of schizophrenia (5,6). As well, family history, genetics, frequency of use and concentration of THC may also play a role.

16) Health Canada has developed a document to help physicians and health professionals better understand the beneficial and negative effects of medical marijuana. I have attached the Health Canada Information for Health Care Professionals as **Annex "A"** to this report. The Health Canada document set out the absolute contraindications to the use of marijuana for medical purposes:

- a) active/current psychosis
- b) active/current schizophrenia

^a Health Canada uses "marihuana" in its literature; the dried cannabis product is also commonly known as "marijuana". This latter spelling is widely used in the medical literature.

c) unstable cardiac disease (hypotension, arrhythmia and syncope)

17) Relative contraindications from the same Health Canada document include pregnancy, those patients with chronic obstructive pulmonary disease (COPD; commonly known as chronic bronchitis or emphysema) or asthma (via the smoking route), those with a history of substance abuse, children under the age of 18, and those with depression or manic illness. Drug interactions with sedative-hypnotics and those drugs that negatively affect the activity of the central nervous system (CNS depressants) can worsen adverse effects, including sedation, memory impairment, delirium and behavioural changes.

18) A recently published document from the College of Family Physicians of Canada (CFPC) provides evidence-based guidance for practitioners who are asked to authorize marijuana for medical purposes. I have attached the CFPC guidance document as **Annex "B"** to this report. The authors of this document put forward several recommendations to help the physician, and they have broadened the list of contraindications, stating that "Dried cannabis is not appropriate for patients who:

- a) are under the age of 25
- b) have a personal history or strong family history of psychosis
- c) have a current or past cannabis use disorder
- d) have an active substance use disorder
- e) have cardiovascular disease (angina, peripheral vascular disease, cerebrovascular disease, arrhythmias)
- f) have respiratory disease or
- g) are pregnant, planning to become pregnant, or breastfeeding."

19) The CFPC guidance document also states: "Dried cannabis should be authorized with caution in those patients who:

- a) Have a concurrent active mood or anxiety disorder
- b) Smoke tobacco
- c) Have risk factors for cardiovascular disease or
- d) Are heavy users of alcohol or taking high doses of opioids or benzodiazepines or other sedating medications prescribed or available over the counter"

20) Thus, patients I see who have a history of psychosis or a family history of schizophrenia are not candidates for medical marijuana. Those with a history of dizziness, hypotension or related cardiac problems are also not ideal candidates, with a higher risk of adverse events. I recommend they not use marijuana, but if their symptoms warranted (poor response or intolerable side effects to other medications), we could consider low dose oral cannabinoids under tightly controlled and monitored conditions. Patients with a history of substance abuse may or may not be candidates for use. Some patients may find marijuana helps with their cravings for other, more dangerous drugs (opioids, cocaine, etc.), while others may not be able to control their use/abuse of marijuana (7, 8).

21) In starting patients on medical marijuana, I think it is important that the indication is valid. Documentation of medical conditions that may be alleviated by marijuana use is necessary, as is the ongoing monitoring of my patients and their outcomes. A document that can be used as "checklist" or as a guide to the medical assessment of the patient requesting medical marijuana has been developed by the CCIC, and is undergoing a rigorous peer validation process. I have attached the draft CCIC Checklist for the Medical Assessment of the Patient Asking about Medical Cannabis as **Annex C** to this report. This checklist can be very helpful for those physicians who have not had much experience with this substance, and ensures the proper documentation of the visit. It includes a list of contra-indications to be assessed, and it has a section for documenting follow up appointments. Dosing (initial and final titration) can be followed, as can functional improvement as part of the follow up visit.

22) The report from the Institute of Medicine in 1999 (9) suggested several broad categories of benefit for the use of marijuana and cannabinoids. Analgesia, nausea in cancer patients and that associated with chemotherapy, appetite stimulation in those with cancer and HIV/AIDS were supported as those where some published evidence was available. Neurodegenerative disorders (especially MS), spinal cord injury, movement disorders, dementia, epilepsy and glaucoma were also discussed, but the evidence to recommend treatment with marijuana was not as strong at the time of its publication.

23) The Health Canada Information for Health Care Professionals document noted above also lists several additional indications for smoked cannabis as defined under the previous Medical Marijuana Access Regulations (MMAR), including some forms of neurodegenerative disease (MS, ALS), pain from spinal cord injury or disease, epilepsy, and pain from severe arthritis (osteoarthritis, rheumatoid arthritis). The clinical evidence for use of cannabis in many other disorders is discussed, but no recommendations are made due to a variety of factors (no clinical studies on humans, small case series, clinical studies with poor methodology, or studies using only pharmaceutical cannabinoids).

24) The CFPC guidance document is even more specific, stating that the evidence is not supportive of using marijuana to treat a variety of pain states commonly seen in primary care, and should only be considered in patients with "neuropathic pain that has failed to respond to standard treatments." It also states that cannabis is not an appropriate therapy for anxiety or insomnia, but that there is some evidence of benefit from the use of pharmaceutical cannabinoids.

25) Patients who I suspect may be trying to substantiate or rationalize their recreational use by claiming "medical" issues are fully investigated before commencing therapy. I ask my patients their complete medical history, including any diagnostic imaging and procedures, surgical history, and medication history. As marijuana has never been recommended as first line therapy for any indication, I ask about the previous treatments for the symptoms in question, including benefits and side effects. I also ask about any previous recreational cannabis use (including

response, both beneficial and adverse effects/events), use of other non-prescription medications, substance abuse history and any history of legal issues or criminal charges related to drug use. If the patient is appropriate for authorization, we will set up a follow-up appointment, where outcomes of use, daily amount used and effectiveness can be documented. Marijuana, like any therapeutic intervention, should result in better symptom control, improved quality of life or an improvement in function for the patient. If none of these can be substantiated, I recommend the use of marijuana terminated and alternative therapies sought.

26) Long term effects and dependence (addiction) are reasons often quoted by physicians to substantiate their reluctance to authorize medical marijuana (10). If patients will be using marijuana for a long term, these will need to be considered and monitored by the provider, and will depend upon the amount used. Daily or higher users may be at a increased risk for issues such as cannabis dependence syndrome, (11,12), chronic cough and increased respiratory symptoms (in smokers [13]) (but no evidence of long-term damage or effects on pulmonary function [14]), evidence of learning and cognitive impairment (daily use for two decades or more [15]), depression (10), and there is some evidence linking behavioural disorders in children whose mothers used cannabis while pregnant (16). These patients should be screened when seen in clinic.

27) Evidence of physical and psychological dependence has been well established in chronic heavy users of marijuana (11,17,18). To date, no evidence has been presented that a dependence syndrome exists in those who use for medical purposes. Interestingly, the endocannabinoid system has been associated with drug taking behaviour and addiction (19). A constellation of symptoms associated with abruptly stopping chronic use is termed drug withdrawal, which is an indication of physical dependence (similar to the symptoms chronic alcoholics or smokers manifest when they go "cold turkey"). Symptoms appear within 1-2 days following discontinuation, peak between days 2 and 6 and generally resolve within 1 - 2 weeks (20). These symptoms include anger, aggression, irritability, craving, anxiety, nightmares or vivid dreams, insomnia or sleep changes, headache, mood changes, chills or shakiness, sweating, stomach pains, and changes in appetite and weight (11,17,21).

2) The Health Canada publication, "Information for Health Care Professionals" (http://hc-sc.gc.ca/dhp-mps/alt_formats/pdf/marihuana/med/infoprof-eng.pdf, February, 2013) states that surveys published in peer reviewed journals indicate that the majority of individuals who use marihuana for medical purposes consume 1-3 grams of marihuana per day (p. 24). When, if ever, is it medically appropriate for an individual to consume more than 5 grams per day?

28) From my experience, most patients who use medical marijuana are doing so to treat symptoms that affect their quality of life and prevent them from pursuing their activities of daily living. These people use enough marijuana (through smoking, vaporization or oral ingestion) to permit them to function and achieve some element of normality, such as minimizing pain or preventing crippling nausea. They generally use 3-5 g a day (some use much less), and only when they need it. There are no medical indications, nor any retrospective evidence, for the use of amounts in excess of 5 g per day.

29) Dosing is an important consideration for patients using marijuana for medical purposes, as well as for doctors and health professionals who authorize its use. But what dose is the right dose? In my experience, the dosing of medical marijuana is the question asked most often by health providers during educational sessions, with many looking for exact daily dosing of cigarettes or edibles. Most patients tell me that they use enough to minimize or eliminate the symptom that is causing them the most disability. Thus, I can see that the dose of marijuana is often connected to the intensity of the symptoms or the condition for which it is being used. Patients suffering from nausea due to chemotherapy will use marijuana before and after their treatment to minimize or eliminate that sensation, and they usually use "only a few puffs". This maybe repeated if the nausea returns, but will not be used again until the next chemotherapy treatment. These patients generally use less than 5 g per day.

30) Patients with chronic and debilitating pain may use marijuana several times a day to bring their pain down to a reasonable level to allow for daily functioning. Again, a few puffs from their cigarette or vaporiser are all that may be needed for relief. But the marijuana benefits may only last 2-4 hours, thus patients need to dose themselves frequently throughout the day, and sometimes during the night (cancer related pain often worsens during the evening and night time hours). If we assume patients with symptoms such as these use marijuana on average 6 times per day (22) then the daily dose could be as much as 3 g per day (based on a average dose of 0.5 g dried cannabis per cigarette).

31) Due to the speed of effect from inhaled or smoked marijuana (effects felt within minutes [9]), patients will often use minimal amounts. Most patients tell me that they only need to inhale 1 to 3 times to obtain benefit. Many people use just enough to make the symptoms tolerable without causing side effects or euphoria ("high" feeling). This has been reflected in the recommendations by Health Canada for the minimal effective dose (Annex A). Support for this from clinical practice is

starting to appear in the medical literature. A recent Dutch study examined the records of over 5000 users enrolled in the Dutch Medical Marijuana program from 2003-2010, and reported the average dose as 0.68 g per day (range 0.65-0.82) (23). A second report, based on records of the Israeli Medical Marijuana program determined that in the period of 2011-2012, patients used approximately 1.5 g of marijuana daily (Annex A).

32) As well as number of inhalations ("puffs"), volume of inhalation ("drag length" or "puff volume") can have some effect on marijuana effectiveness. A few patients claim the increased number of inhalations and bigger cigarettes as a reason for larger daily marijuana usage. However, research has confirmed that puff volume affects exposure, but that breath holding had no effect upon physiologic levels or systematic effects (24). Only my patients who are previous recreational marijuana users have told me that they tend to hold their breath for a few seconds after an inhalation. This is not recommended by the CFPC guidance document (Annex B). Again, this action is not consistent with use by patients for medical purposes.

33) The use of vaporization ("vaping") has also been promoted as a healthier alternative to smoking, as there is no burning of the raw marijuana, of which the combustibles can have harmful properties (25). When heated to an optimal temperature, THC and other cannabinoids are released and collected in a balloon device for later inhalation. Studies (26,27) have shown reproducible levels of cannabinoid delivered via the device. Some patients have said that they need larger doses to get benefit when they use these machines. However, we have evidence that 0.8 g of cannabis containing differing THC concentrations (low to moderate) is effective in treating neuropathic pain; this was reproducible from patient to patient as well as comparing patients to themselves (28). The multinational review of nearly 1000 medical marijuana patients also documented the mean daily amount used for vaporization was 3 g per day (22). Thus, the request for doses larger than 5 g per day is not supported by the research available.

34) Another reason patients offer for higher daily dosing is the use of marijuana in baked goods or other oral forms ("edibles"). At least one publication has postulated, based on absorption studies, that the ingested amount could be 3-5 times higher than the smoked amount (29). Given that the amount of marijuana in a cigarette is 0.5 g (as seen above) this means that ingestion may require up to 2.5 g per individual brownie or cookie. However, my patients who use edibles as a delivery method tell me that one or two brownies/cookies are enough to treat their condition, and the effect lasts for an extended period of time (8 hours or more compared with approximately 2-4 hours for inhalation). We also have evidence to support this. A mean daily intake of 3.4 g was reported in the multinational review (22), and the mean daily frequency was only 1.8 times, less than the inhaled dosing of 5.2-6 times per day. This is more evidence-based support for the maximum daily dose of 5 g.

35) I have recently been made aware of the use of "marijuana oil" or "cannabis oil" by several patients. This product is not sanctioned by the MMPR, and the

Licensed Producers are not permitted to market this. However, there are several websites proclaiming its benefits, but with no hard medical evidence to back up their claims. Several of my patients tell me they use this compound not only for symptoms, but also for the primary treatment of cancer. There is little in the recent medical literature documenting the constituents of this product (30). It is essentially a highly concentrated extraction of the organic components (likely the cannabinoids and terpenes) that can be used therapeutically. The "recipe" calls for a pre-determined amount of dried marijuana in order to produce an appropriate concentration of oil for use. The amount of oil used daily is very low. Instructions given to my patients by their suppliers state the amount is the size of "a grain of rice" orally up to 2-3 times daily. I would expect that a dose of liquid or oil this size is far less than 5 g, the daily limit as set forward by Health Canada.

36) Like many drugs, marijuana contains compounds that interact with specific receptors in the body, many found within the brain and nervous system (31). When high concentrations of cannabinoids are used, or excess dosing is employed, the risk of full receptor blockade with changes in neurotransmission may occur. This is one of the theories for the occurrence of paranoia, anxiety, acute psychosis and even schizophrenic-like syndromes after marijuana use (32,33). This has been seen in controlled trials (reviewed in Annex A) with a range of doses, but consistently with doses greater than 5 mg of oral THC. Thus, those patients with approval for high daily doses (above 5 g) may be at higher risk for undesirable side effects, as well as toxicity. I would also surmise that higher daily use (more than 15 g or the equivalent of 30 cigarettes a day) is incompatible with activities of daily functioning or even sleeping, as the patient would either be smoking/inhaling hourly or more, and likely incapacitated by the constant exposure to the cannabinoid. I see no physical way a "patient" could use more than 15 g per day (potentially 24-48 cigarettes a day), and certainly there is no medical indication for such dosing.

3) The attached chart sets out the number of licenses that permit individuals to consume marijuana for medical purposes as of December, 2013 as well as the number of grams per day that these license holders are authorized to consume. In your opinion, what might account for the significant number of licenses that authorize the consumption of more than 5 grams per day?

37) Most of the licenses were authorized for more than 10 g per day. There are no medical reasons for dosing at that level, which are outlined in question 2 above. Dosing at these levels or above may reflect heavy recreational use by applicants, the opportunity for monetary gain by physicians, the involvement of criminals abusing the system for illegal distribution or diversion, and tampering by the applicants.

38) The appended chart (Amounts and numbers of program participants; **Annex D**) shows many patients were obtaining approval for medical marijuana at more than the recommended level by Health Canada (5 g per day or 150 g per month). If we use the total number of patients approved (25,613) as the denominator, it appears that the vast majority of patients have been approved for more than 5 g per day. Only 26.4% were approved for 1-5 g per day, with the majority of patients approved for daily use of 10 g or more (approximately 56.6%).

39) I can speculate on several reasons for this. First, patients may be trying to legitimize recreational use by claiming some sort of medical condition; chronic back pain is the most frequent diagnosis for using medical marijuana (Annex A). This is also one of the most difficult diagnoses to document via objective diagnostic imaging or blood testing (unlike cancer or diabetes). Patients will inform the physician that they only get relief with a specific amount of marijuana on a daily basis, and thus are approved for this amount. It is also possible that these patients would target practitioners who are inexperienced in the use of marijuana, and could authorize more than the recommended 5 g per day. As mentioned above, the dosing of medical marijuana is the most frequently asked question by health care providers attending educational sessions.

40) The lure of monetary reward has resulted in physicians requesting fees for authorizing medical marijuana. Physicians are asked to complete forms on a daily basis, including insurance forms, disability assessments, driving assessments, etc. Due to the time taken, most physicians will charge a fee to fill these in. Increasingly, these fees are increasing as physicians see this as a time-consuming task. The forms required by the MMAR were quite complicated at first, and later modified to make them simpler. Some physicians see this as an opportunity to bring in extra income, some even doing so in a systematic fashion (34). However, this has led to abuse with substantial financial gains (35). There are several reports in the media exposing these physicians, and provincial colleges have brought disciplinary actions against several (35-37). One physician has been accused of approving upwards of 4000 users (approx. 1/3 of the total approved at that time interval!) in several provinces; he made close to \$500,000 doing this. At the most recent General Meeting of the Canadian Medical Association, the president of the Federation of Medical Regulatory

Authorities of Canada, Dr. Trevor Theman, confirmed that this is not acceptable; he was quoted as saying, "You [Doctors] get paid for seeing the patient, you do not get paid for the prescription." (38).

41) We also know from RCMP reports that organized crime has been involved in the acquisition of user approvals under the MMPR (39, 40). It is well known that the mode of operation of many of these groups is through intimidation. One can speculate that physicians may have been visited by one or several members of such a group and more or less told what to write and how much to approve. A colleague of mine has had a similar experience with gang members coercing opioid prescriptions. These actions would likely not be made public, as threats to the physician, staff or families may have been made, which would result in little or no police reporting of such activity. In addition, organized criminal groups have been reported to recruit "patients" who then present themselves to physicians (sometimes multiple times) willing to approve medical marijuana, resulting in large amounts of marijuana available for criminal distribution or diversion (41).

42) It is interesting to note that with the change in the MMPR, the average authorized daily dose has dropped significantly. A very recent media report stated that since physicians became the "gatekeepers" under the new regulations (MMPR became fully active April 2014), Rona Ambrose, Minister of Health, reported Health Canada records show the average daily dose of marijuana approved is 4 g, substantially decreased compared with the average approval under the MMAR of 17 g (38). This may reflect physicians following Health Canada guidelines, or the absence of other confounders (such as organized crime) in the authorization process. This statement pre-dates the release of the CFPC guidance document (September 2014).

43) Tampering by patients may also have played a role in the discordant amounts approved. A "3" entered under the daily amount approved could have been adjusted to read "30" or even "300"; feedback from Health Canada was not routinely employed, as the office processing approvals quickly became over run with applications early on in the MMAR. Verification of amounts under the MMPR has been required by licensed producers to meet the new regulations. This kind of tampering has been documented previously with opioid prescriptions, especially by those seeking drugs for recreational or diversionary purposes. The use of shared computer records/databases and multi-copy prescriptions were brought in by provincial regulatory agencies to combat this.

References

- 1) Wang T, Collet J-P, Shapiro S, Ware M. Adverse effects of medical cannabinoids: a systematic review, *CMAJ* 2008; 178: 1669-78
- 2) Gali JA, Sawaya RA, FriedenberG FK. Cannabinoid Hyperemesis Syndrome, *Curr Drug Abuse Rev* 2011; 4:241-49.
- 3) Freeman D, Dunn G, Murray RM et al. How cannabis causes paranoia: Using the intravenous administration of Δ 9-tetrahydrocannabinol (THC) to identify key cognitive mechanisms leading to paranoia, *Schizophren Bull* doi:10.1093/schbul/sbu098
- 4) Kuepper R, van Os J, Lieb R, Wittchen H-U, Hoefler M, Henquet C. Continued cannabis use and risk of incidence and persistence of psychotic symptoms: 10 year follow-up cohort study *BMJ*, 2010;342:d738
- 5) Schiffman J, Nakamura B, Earleywine M, LaBrie J. Symptoms of schizotypy precede cannabis use *Psychiatry Res* 2005; 134:37-42
- 6) D'Souza DC, Abi-Saab WM, Madonick S et al. Delta-9-tetrahydrocannabinol effects in schizophrenia: Implications for cognition, psychosis, and addiction *Biol Psychiatry* 2005;57:594-608
- 7) Swartz R. Medical marijuana users in substance abuse treatment. *Harm Reduction J* 2010 7:3 doi:10.1186/1477-7517-7-3.
- 8) Reiman A. Cannabis as a substitute for alcohol and other drugs *Harm Reduction J* 2009, 6:35 doi:10.1186/1477-7517-6-35
- 9) Marijuana and Medicine: Assessing the Science Base Janet E. Joy, Stanley J. Watson, Jr., and John A. Benson, Jr., Editors; Institute of Medicine, National Academy of Sciences, Washington, DC. 1999.
- 10) Farrell M, Buchbinder R, Hall W. Should doctors prescribe cannabinoids? *BMJ* 2014; 348:g2737 doi: 10.1136/bmj.g2737
- 11) Lichtman AH, Martin BR. Cannabinoid tolerance and dependence, in *Cannabinoids, Handb Exp Pharmacol* 2005, 691-718.
- 12) Budney AJ, Moore BA. Development and consequences of cannabis dependence, *J Clin Pharmacol*, 2002;42: 28S-33S.
- 13) Tashkin DP, Baldwin GC, Sarafian T, Dubinett S, Roth MD. Respiratory and immunologic consequences of marijuana smoking. *J Clin Pharmacol*. 2002; 42(suppl):71S-81S.
- 14) Mark J, Pletcher MJ, Vittinghoff et al. Association between marijuana exposure and pulmonary function over 20 years, *JAMA* 2012;307:173-81
- 15) Meier, M. H., Caspi, A., Ambler, A., Harrington, H. and others. (2012). Persistent cannabis users show neuropsychological decline from childhood to midlife. *Proc.Natl.Acad.Sci.U.S.A.* 109: E2657-E2664.

- 16) Richardson, G. A., Ryan, C., Willford, J., Day, N. L. and others. (2002). Prenatal alcohol and marijuana exposure: effects on neuropsychological outcomes at 10 years. *Neurotoxicol Teratol.* 24: 309-320.
- 17) Hall W, Solowij N. Adverse effects of cannabis, *Lancet* 1998; 352: 1611-1616.
- 18) Vandrey, R. and Haney, M. (2009). Pharmacotherapy for cannabis dependence: how close are we? *CNS.Drugs.* 23: 543-553.
- 19) Serrano, A. and Parsons, L. H. (2011). Endocannabinoid influence in drug reinforcement, dependence and addiction-related behaviors. *Pharmacol.Ther.* 132: 215-241.
- 20) Budney, A. J., Hughes, J. R., Moore, B. A., and Vandrey, R. (2004). Review of the validity and significance of cannabis withdrawal syndrome. *Am.J.Psychiatry.* 161: 1967-1977.
- 21) Allsop D J, Norberg, M M, Copeland J et al. The Cannabis Withdrawal Scale development: patterns and predictors of cannabis withdrawal and distress. *Drug Alcohol Depend.* 2011; 119: 123-29.
- 22) Hazekamp A, Ware MA, Muller-Vahl KR, Abrams D, Grotenhermen F. The medicinal use of cannabis and cannabinoids—An international cross-sectional survey on administration forms, *J Psych Drugs* 2013; 45:3, 199-210, DOI: 10.1080/02791072.2013.805976
- 23) Hazekamp A, Heerdink ER. The prevalence and incidence of medicinal cannabis on prescription in The Netherlands. *Eur. J. Clin. Pharmacol.* 2013 Published online April 16, 2013.
- 24) Azorlosa J, Greenwald MK, Stitzer ML. Marijuana smoking: Effects of varying puff volume and breathhold duration. *J Pharmacol Exp Ther* 1995; 272: 560-69
- 25) Earleywine M, Barnwell SS. Decreased respiratory symptoms in cannabis users who vaporize, *Harm Reduction J* 2007; 4:11 doi:10.1186/1477-7517-4-11
- 26) Hazekamp A, Ruhaak R, Zuurman L, van Gerven J, Verpoorte R. Evaluation of a vaporizing device (Volcano) for the pulmonary administration of tetrahydrocannabinol, *J Pharm Sci* 2006; 95:1308-17
- 27) Carter GT, Weydt P, Kyashna-Tocha M, Abrams DI. Medicinal cannabis: Rational guidelines for dosing *IDrugs* 2004; 7:464-470
- 28) Wilsey B, Marcotte T, Deutsch R, Gouaux B, Sakai S, Donaghe H. Low-dose vaporized cannabis significantly improves neuropathic pain, *J Pain* 2013; 14: 136-148
- 29) Aggarwal SK, Kyashna-Tocha M, Carter GT. Dosing medical marijuana: Rational guidelines on trial in Washington state. *Med Gen Med* 2007; 9: 52-60
- 30) Nigam MC, Handa KL, Nigam, IC, Levi L. Essential oils and their constituents XXIX. The essential oil of marihuana: composition of genuine Indian *cannabis sativa* L. *Can J of Chem.* 1965; 43: 3372-76

- 31) Abood ME. Molecular biology of cannabinoid receptors, in *Cannabinoids, Handb Exp Pharmacol* 2005, 81-116.
- 32) Shapiro GK, Buckley-Hunter L. What every adolescent needs to know: Cannabis can cause psychosis, *J Psychosomatic Res* 2010; 69:533-39
- 33) Robson P. Human studies of cannabinoids and medical cannabis, in *Cannabinoids, Handb Exp Pharmacol* 2005, 719-56.
- 34) "New Toronto clinic to offer medical marijuana prescriptions", Isabel Teotonio Mar 31 2014.
http://www.thestar.com/life/2014/03/31/new_toronto_clinic_to_supply_the_demand_for_medical_marijuana_prescriptions.html Accessed Oct 22, 2014.
- 35) How Rob Kamermans made \$500K as Canada's top medical marijuana doctor -until police came knocking" Tom Blackwell, July 26, 2013.
<http://news.nationalpost.com/2013/07/26/how-one-doctor-made-500000-as-canadas-top-medical-marijuana-provider-until-police-came-knocking/> Accessed Oct 22, 2014.
- 36) Report of the Discipline Committee of the College of Physicians and Surgeons of Ontario re: Dr. Rob Joseph Kamermans, published March 27, 2013
- 37) "Regina doctor suspended after prescribing marijuana for cash"
<http://www.cbc.ca/news/canada/saskatchewan/regina-doctor-suspended-after-prescribing-marijuana-for-cash-1.1704142> Accessed Oct 22, 2014.
- 38) "Pot use per patient drops under the fed's new program" Jered Stuffco, Sept 9, 2014 Medical Post, page 16. Accessed Oct 22, 2014.
- 39) "Organized crime exploiting medical marijuana program: RCMP" Canadian Press, reported in July 2, 2013 issue. <http://www.macleans.ca/news/organized-crime-exploiting-medical-marijuana-program-rcmp/> Accessed Oct 22, 2014.
- 40) "Medical marijuana regime open to criminal abuse, RCMP says"
<http://www.theglobeandmail.com/news/national/medical-marijuana-regime-open-to-criminal-abuse-rcmp-says/article16950605/?ord=1> Accessed Oct 22, 2014.
- 41) "Maple Ridge man found with 500 kgs of pot" Monisha Martin, Maple Ridge News Feb 21, 2014. <http://www.mapleridgenews.com/news/246444131.html> Accessed Oct 22, 2014.

Annex A
Health Canada Information for Health Care Professionals
Cannabis (marihuana, marijuana) and the cannabinoids



Health
Canada


Santé
Canada

*Your health and
safety... our priority.*

*Votre santé et votre
sécurité... notre priorité.*

Information for Health Care Professionals

**Cannabis (marihuana, marijuana) and the
cannabinoids**



Information for Health Care Professionals

Cannabis (marihuana, marijuana) and the cannabinoids
Dried plant for administration by ingestion or other means
Psychoactive agent

This document has been prepared by the Controlled Substances and Tobacco Directorate at Health Canada to provide information on the use of cannabis and cannabinoids for medical purposes. **Cannabis is not an approved therapeutic product and the provision of this information should not be interpreted as an endorsement of the use of this product, or cannabis generally, by Health Canada.**

Despite the similarity of format, it is not a Drug Product Monograph, which is a document which would be required if the product were to receive a Notice of Compliance authorizing its sale in Canada. This document is a summary of peer-reviewed literature and international reviews concerning potential therapeutic uses and harmful effects of cannabis (marihuana) and cannabinoids. It is not meant to be comprehensive and should be used as a complement to other reliable sources of information.

This document should not be construed as expressing conclusions from Health Canada about the appropriate use of cannabis (marihuana) or cannabinoids for medical purposes.

Cannabis (marijuana, marihuana) is not an approved therapeutic substance in Canada and has not been issued a notice of compliance by Health Canada authorizing sale in Canada.

Prepared by Health Canada

Date of latest version: February 2013

(May 2013) Addendum to the *Information for Health Care Professionals: Cannabis (marihuana, marijuana) and the cannabinoids* (February 2013 version)

Following the most recent update to this document (February 2013), a study was published in the Netherlands tracking data obtained from the Dutch medical cannabis program over the years 2003-2010. The study reported that in a population of over 5,000 Dutch patients using cannabis for medical purposes, the average daily dose of dried cannabis (various potencies) used was 0.68 grams per day (range: 0.65 - 0.82 grams per day) (Hazekamp and Heerdink 2013). In addition, information from Israel's medical marihuana program suggests that the average daily amount used by patients was approximately 1.5 grams of dried cannabis per day in 2011-2012 (Health Canada personal communication).

Hazekamp, A., and E.R. Heerdink (2013). The prevalence and incidence of medicinal cannabis on prescription in The Netherlands. *Eur. J. Clin. Pharmacol.* Published online April 16, 2013.

TABLE OF CONTENTS

	Page
List of abbreviations	1
Authorship and acknowledgements	3
1.0 The Endocannabinoid System	8
1.1 Cannabis	11
1.1.1 Chemistry and composition	11
1.1.2 Other constituents	11
1.1.3 Stability and storage	12
2.0 Clinical Pharmacology	12
2.1 Pharmacodynamics	12
2.2 Pharmacokinetics	17
2.2.1 Absorption	17
2.2.1.1 Smoked cannabis	17
2.2.1.2 Vapourized cannabis	17
2.2.1.3 Oral	18
2.2.1.4 Oro-mucosal	18
2.2.1.5 Rectal	19
2.2.1.6 Topical	19
2.2.2 Distribution	19
2.2.3 Metabolism	19
2.2.3.1 Inhalation	20
2.2.3.2 Oral	20
2.2.4 Excretion	21
2.3 Pharmacokinetic-pharmacodynamic relationships	21
2.4 Tolerance, dependence, and withdrawal symptoms	23
3.0 Dosing	24
3.1 Smoking	25
3.2 Oral	30
3.3 Oro-mucosal	31
3.4 Vapourization	31
4.0 Potential Therapeutic Uses	31
4.1 Palliative Care	34
4.2 Nausea and vomiting	35
4.3 Wasting syndrome and loss of appetite in AIDS and cancer patients	37
4.3.1 To stimulate appetite and produce weight gain in AIDS patients	37
4.3.2 To stimulate appetite and produce weight gain in cancer patients	37
4.3.3 Anorexia nervosa	38
4.4 Multiple sclerosis, amyotrophic lateral sclerosis, spinal cord injury	39
4.4.1 Multiple sclerosis	39
4.4.2 Amyotrophic lateral sclerosis	42
4.4.3 Spinal cord injury (or spinal cord disease)	42
4.5 Epilepsy	43
4.6 Pain	44
4.6.1 Acute Pain	45
4.6.1.1 Experimentally-induced acute pain	45
4.6.1.2 Post-operative pain	46
4.6.2 Chronic pain	46
4.6.2.1 Experimentally-induced pain	46
4.6.2.2 Neuropathic pain or chronic non-cancer pain	46
4.6.2.3 Cancer pain	50
4.6.2.4 Headache and migraine	52

4.7 Arthritides and musculoskeletal disorders	53
4.7.1 Osteoarthritis.....	53
4.7.2 Rheumatoid arthritis.....	53
4.7.3 Fibromyalgia.....	54
4.7.4 Osteoporosis.....	55
4.8 Other diseases and symptoms	56
4.8.1 Movement disorders	56
4.8.1.1 Dystonia.....	56
4.8.1.2 Huntington's disease.....	57
4.8.1.3 Parkinson's disease.....	57
4.8.1.4 Tourette's syndrome	58
4.8.2 Glaucoma	58
4.8.3 Asthma	59
4.8.4 Hypertension	59
4.8.5 Psychiatric disorders.....	59
4.8.5.1 Anxiety and depression.....	59
4.8.5.2 Sleep disorders.....	61
4.8.5.3 Post-traumatic stress disorder.....	62
4.8.5.4 Alcohol and opioid withdrawal symptoms.....	63
4.8.5.5 Schizophrenia and psychosis.....	64
4.8.6 Alzheimer's disease and dementia.....	65
4.8.7 Inflammation	66
4.8.7.1 Inflammatory skin diseases.....	66
4.8.8 Gastrointestinal system disorders	67
4.8.8.1 Irritable bowel syndrome	67
4.8.8.2 Inflammatory bowel diseases.....	69
4.8.8.3 Diseases of the liver.....	72
4.8.8.4 Metabolic syndrome, obesity, diabetes	73
4.8.8.5 Diseases of the pancreas.....	74
4.8.9 Anti-neoplastic properties.....	76
4.8.10 Emerging potential therapeutic uses	78
5.0 Precautions	79
6.0 Warnings	79
6.1 Tolerance, dependence and withdrawal symptoms.....	80
6.2 Drug interactions	80
6.3 Drug screening tests.....	81
7.0 Adverse effects	82
7.1 Carcinogenesis and mutagenesis.....	82
7.2 Respiratory tract	82
7.3 Immune system.....	83
7.4 Reproductive and endocrine systems.....	85
7.5 Cardiovascular system.....	86
7.6 Gastrointestinal system and liver.....	87
7.6.1 Hyperemesis	87
7.6.2 Liver	87
7.7 Central nervous system.....	87
7.7.1 Cognition.....	87
7.7.2 Psychomotor performance.....	88
7.7.3 Psychiatric effects.....	89
7.7.3.1 Acute psychotic reactions.....	89
7.7.3.2 Anxiety, depression and bipolar disorder.....	90
7.7.3.3 Schizophrenia and psychosis.....	92
7.7.3.4 Amotivational syndrome	94
8.0 Overdose/toxicity	94

References 95

Figure 1
The Endocannabinoid System in the Nervous System 10

Table 1
Pharmacologic Actions of Cannabis 15

Table 2
Relationship between THC Percent in Plant Material and the Available Dose (in mg THC) in an Average Joint 25

Table 3
Approximate Conversion Factors Smoked/Oral Δ^9 -THC 26

Table 4
Quick Reference of Smoked to Estimated Oral Doses of Δ^9 -THC 27

Table 5
Quick Reference of Oral to Estimated Smoked Doses of Δ^9 -THC 28

Table 6
Comparison between Cannabis and Prescription Cannabinoid Medications 29

Table 7
Published Clinical Trials on Smoked/Vapourized Cannabis and Associated Therapeutic Benefits..... 33

List of Abbreviations

2-AG: 2-arachidonoylglycerol
 5-HT: 5-hydroxytryptamine
 ACEA: arachidonyl-2-chloroethylamide
 ACTH: adrenocorticotrophic hormone
 AD: Alzheimer's disease
 AEA: arachidonylethanolamide (i.e. "anandamide")
 AIDS: acquired immune deficiency syndrome
 ALS: amyotrophic lateral sclerosis
 ApoE: apolipoprotein E
 AUC: area-under-the-curve
 B.I.D.: *bis in die* (i.e. twice per day)
 CAMS: Cannabis in Multiple Sclerosis
 CB: cannabinoid
 CBC: cannabichromene
 CBD: cannabidiol
 CBG: cannabigerol
 CBN: cannabinol
 CNS: central nervous system
 CINV: chemotherapy-induced nausea and vomiting
 CNR1: cannabinoid receptor gene 1
 CNR2: cannabinoid receptor gene 2
 CI: confidence interval
 CRPS: complex regional pain syndrome
 CSF: cerebrospinal fluid
 CUPID: Cannabinoid Use in Progressive Inflammatory Brain Disease
 CYP: cytochrome P450
 Δ^9 -THC: delta-9-tetrahydrocannabinol
 DAG: diacylglycerol
 DEA: N-docosatetraenylethanolamine
 DNBSA: dinitrobenzene sulfonic acid
 DSM-IV-TR: diagnostic and statistical manual of mental disorders
 ECS: endocannabinoid system
 FAAH: fatty acid amide hydrolase
 FEV₁: forced expiratory volume in one second
 FVC: forced vital capacity
 HD: Huntington's disease
 HEA: N-homo- γ -linolenylethanolamine
 HIV: human immunodeficiency virus
 HMO: health maintenance organization
 HSV: herpes simplex virus
 IBD: inflammatory bowel disease
 IBS: irritable bowel syndrome
 IOP: intra-ocular pressure
 I.P.: intraperitoneal
 I.V.: intravenous
 KSHV: Kaposi's sarcoma-associated herpes virus
 LDL: low density lipoprotein
 MAGL: monoacylglycerol lipase
 MDS: macroscopic damage score
 MMAR: marijuana medical access regulations
 mRNA: messenger ribonucleic acid
 MS: multiple sclerosis
 MUSEC: Multiple Sclerosis and Extract of Cannabis trial
 NADA: N-arachidonoyl-dopamine
 NAFLD: non-alcoholic fatty liver disease
 NAPE: N-arachidonoylphosphatidylethanolamine

NAT: N-acyl transferase
NIDA: National Institute on Drug Abuse
nM: nanomolar
NNT: number needed to treat
OA: osteoarthritis
OEA: oleoylethanolamide
OR: odds ratio
PAH: polycyclic aromatic hydrocarbon
PASAT: paced serial addition test
PD: Parkinson's disease
PEA: palmitoylethanolamide
PET: positron emission tomography
PPAR: peroxisome proliferator- activated receptor
PTSD: post-traumatic stress disorder
Q.I.D.: *quattuor in die* (i.e. four times per day)
QOL: quality of life
RA: rheumatoid arthritis
RCT: randomized controlled trial
REM: rapid eye movement
RGC: retinal ganglion cells
S.C.: subcutaneous
SCI: spinal cord injury
SNP: single nucleotide polymorphism
SPECT: single-photon emission computed tomography
THC: delta-9-tetrahydrocannabinol
THCA: tetrahydrocannabinolic acid
THCV: tetrahydrocannabivarin
T.I.D.: *ter in die* (i.e. three times per day)
TNBSA: trinitrobenzene sulfonic acid
TRPV1: transient receptor potential vanilloid channel 1
TS: Tourette's syndrome
 μ M: micromolar
VSV: vesicular stomatitis virus
WHO: World Health Organization

Author: Hanan Abramovici Ph.D.

Affiliations:

Research, Synthesis, and Dissemination Division, Office of Research and Surveillance, Controlled Substances and Tobacco
Directorate, Health Canada, Ottawa, ON, Canada K1A 0K9

Email: hanan.abramovici@hc-sc.gc.ca

Acknowledgements

Health Canada would like to acknowledge and thank the following individuals for their comments and suggestions with regard to the content in this information document:

Donald I. Abrams, M.D.

Chief, Hematology-Oncology
San Francisco General Hospital
Integrative Oncology
UCSF Osher Center for Integrative Medicine
Professor of Clinical Medicine
University of California San Francisco
San Francisco, CA 94143-0874
USA

Pierre Beaulieu, Ph.D., M.D., F.R.C.A.

Professeur agrégé
Département de pharmacologie
Faculté de médecine
Université de Montréal
Bureau R-408, Pavillon Roger-Gaudry
C.P. 6128 - Succursale Centre-ville
Montréal, Québec
H3C 3J7
Canada

Paul J. Dacinck, M.D., M.Sc., F.R.C.P.C

Chair, Symptom Management Group
Room L1 101-8, O Block
CancerCare Manitoba
St. Boniface Hospital
409 Taché Ave
Winnipeg, MB
R2H 2A6
Canada

Vincenzo di Marzo, Ph.D.

Research Director
Endocannabinoid Research Group
Institute of Biomolecular Chemistry
Consiglio Nazionale delle Ricerche
Via Campi Flegrei 34
Comprensorio Olivetti
80078 Pozzuoli (NA)
Italy

Mahmoud A. ElSohly, Ph.D.

Research Professor and Professor of Pharmaceutics
National Center for Natural Products Research and Department of Pharmaceutics
School of Pharmacy
University of Mississippi
University, MS 38677
USA

Javier Fernandez-Ruiz, Ph.D.

Full Professor of Biochemistry and Molecular Biology
Department of Biochemistry and Molecular Biology
Faculty of Medicine
Complutense University
Madrid, 28040
Spain

Tony George, M.D., F.R.C.P.C.

Clinical Director, Schizophrenia Program
Endowed Chair in Addiction Psychiatry, University of Toronto
Centre for Addiction and Mental Health
250 College Street, Suite 734
Toronto, ON
M5T 1R8
Canada

Boris Gorzalka, Ph.D.

Professor
Department of Psychology
University of British Columbia
Room 1614
2136 West Mall
Vancouver, BC
V6T 1Z4
Canada

Margaret Hancu, Ph.D.
Professor of Clinical Neurobiology
Columbia University
Department of Psychiatry
1051 Riverside Drive, Unit 120
New York, NY 10032
USA

Matthew N. Hill, Ph.D.
Assistant Professor
Departments of Cell Biology and Anatomy & Psychiatry
The Hotchkiss Brain Institute
University of Calgary
Calgary, AB
T2N 4N1
Canada

Harold Kalant, M.D., Ph.D., O.C.
Professor Emeritus
Department of Pharmacology and Toxicology
University of Toronto
Room 4221, Medical Sciences Building
1 King's College Circle
Toronto, ON
M5S 1A8
Canada

Aron Lichtman, Ph.D.
Professor
Department of Pharmacology & Toxicology
Molecular Medicine Research Building, Room 3042
1220 East Broad St.
P.O. Box 980613
Richmond, Virginia 23298-0613
USA

Mary Lynch, M.D., F.R.C.P.C.
Professor of Anaesthesia, Psychiatry and Pharmacology
Dalhousie University
Director, Pain Management Unit-Capital Health
Queen Elizabeth II Health Sciences Centre
4th Floor Dickson Building
5820 University Avenue
Halifax, NS
B3H 1V7
Canada

Jason McDougall, Ph.D.

Associate Professor
Departments of Pharmacology and Anaesthesia
Dalhousie University
5850 College Street
Halifax, NS
B3H 1X5
Canada

Raphael Mechoulam, Ph.D.

Professor
Institute for Drug Research, Medical Faculty
Hebrew University
Jerusalem
91120
Israel

Richard (Rik) E. Musty, Ph.D.

Professor Emeritus of Psychology
Department of Psychology
College of Arts and Sciences
University of Vermont
Burlington, VT 05405
USA

Linda Parker, Ph.D.

Professor and Canada Research Chair
Department of Psychology
University of Guelph
Guelph, Ontario
N1G 2W1
Canada

Roger G. Pertwee, MA, D.Phil. D.Sc.

Professor of Neuropharmacology
Institute of Medical Sciences
University of Aberdeen
Aberdeen
AB25 2ZD
Scotland, United Kingdom

Keith Sharkey, Ph.D.

Professor
Department of Physiology and Biophysics and Medicine
University of Calgary
HSC 1745
3330 Hospital Drive NW
Calgary, AB
T2N 4N1
Canada

Cory Toth, B.Sc., M.D., C.S.C.N., F.R.C.P.C.
Assistant Professor of Neurosciences
Hotchkiss Brain Institute
Faculty of Medicine
University of Calgary
HMRB 155
3330 Hospital Drive NW
Calgary, AB
T2N 4N1
Canada

Mark Ware, M.D., M.R.C.P., M.Sc.
Associate Director
Allan Edwards Pain Management Unit, MUHC Pain Centre
E19.145 Montreal General Hospital
1650 Cedar Avenue
Montréal, Québec
H3G 1A4
Canada

IMPORTANT NOTE: For the sake of completeness and for contextual purposes, the content in the following document includes information on dried cannabis as well as selected cannabinoids. However, cannabis and cannabinoids should not be considered equivalent even though the information on both is presented together within the text. Cannabis is a highly complex material with hundreds of chemical constituents whereas cannabinoids are single molecules. Drawing direct comparisons between cannabis and cannabinoids must necessarily take into account differences in the route of administration, dosage, and the different pharmacokinetic and pharmacodynamic properties of these different substances.

1.0 The Endocannabinoid System

The endocannabinoid system (Figure 1) is an ancient, evolutionarily conserved, and ubiquitous lipid signaling system found in all vertebrates, and which appears to have important regulatory functions throughout the human body (1). The endocannabinoid system has been implicated in a very broad number of physiological as well as pathophysiological processes including neural development, immune function, inflammation, appetite, metabolism and energy homeostasis, cardiovascular function, digestion, bone development and bone density, synaptic plasticity and learning, pain, reproduction, psychiatric disease, psychomotor behaviour, memory, wake/sleep cycles, and the regulation of stress and emotional state (2,3,4).

Components of the endocannabinoid system

The system consists of the cannabinoid 1 and 2 (CB₁ and CB₂) receptors, the CB receptor ligands N-arachidonylethanolamine (i.e. "anandamide" or AEA) and 2-arachidonoylglycerol (2-AG) as well as the endocannabinoid-synthesizing and degrading enzymes fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) (Figure 1) (2). Anandamide and 2-AG are considered the primary endogenous mediators of cannabinoid signaling, but other endogenous molecules which exert "cannabinoid-like" effects have also been described. These other molecules include 2-arachidonoylglycerol ether (noladin ether), N-arachidonoyl dopamine (NADA), virodhamine, N-homo- γ -linolenylethanolamine (HEA) and N-docosatraenoylethanolamine (DEA) (2,5,6,7,8). Molecules such as palmitoylethanolamide (PEA) and oleoylethanolamide (OEA) do not appear to bind to cannabinoid receptors but rather to a specific isozyme belonging to a class of nuclear receptors/transcription factors known as peroxisome proliferator-activated receptors (PPARs) (8). These endocannabinoids may, however, potentiate the effect of anandamide by competitive inhibition of FAAH, and/or through direct allosteric effects on other receptors such as the transient receptor potential vanilloid (TRPV1) channel (9). These types of effects have been generally referred to as the so-called "entourage effect" (9,10).

Endocannabinoid synthesis

Endocannabinoids are arachidonic acid derivatives which are synthesized "on demand" from membrane phospholipid precursors in response to cellular requirements (2,11,12,13). Anandamide is principally produced by the transfer of arachidonic acid from phosphatidylcholine to phosphatidylethanolamine by N-acyltransferase (NAT) to yield N-arachidonoylphosphatidylethanolamine (NAPE). NAPE is then hydrolyzed to form anandamide by a NAPE-specific phospholipase D (2,14). In contrast, 2-AG is principally synthesized through phospholipase C- β -mediated hydrolysis of phosphatidylinositol-4,5-bisphosphate, with arachidonic acid on the *sn*-2 position, to yield diacylglycerol (DAG). DAG is then hydrolyzed to 2-AG by a DAG-lipase (2,14). While anandamide and 2-AG are both derivatives of arachidonic acid, they are synthesized by pathways distinct from those used to synthesize eicosanoids (15). Nevertheless, it appears that there may be a certain amount of cross-talk between the eicosanoid and endocannabinoid pathways (15).

Genetics and signaling through the cannabinoid receptors

Endocannabinoids such as anandamide and 2-AG, as well as the phytocannabinoids Δ^9 -tetrahydrocannabinol (Δ^9 -THC), Δ^8 -THC, cannabiol and others, bind to and activate (with differing affinities and efficacies) the CB₁ and CB₂ receptors which are G-protein coupled receptors that activate G_i/G_o-dependent signaling cascades (16,17). The receptors are encoded by separate genes located on separate chromosomes; in humans, the CB₁ receptor gene (*CNR1*) locus is found on chromosome 5q15 whereas the CB₂ receptor gene (*CNR2*) locus is located on chromosome 1p36 (18). The *CNR1* coding sequence consists of one exon encoding a protein of 472 amino acids (19). The CB₁ receptor protein shares 97-99% amino acid sequence identity across species (human, rat, mouse) (19). As with the *CNR1* coding sequence, the *CNR2* coding sequence consists of only one exon, but it encodes a shorter protein 360 amino-acids in length (19). The human CB₂ receptor shares 48% amino acid identity with the human CB₁ receptor; the mouse CB₂ receptor shares 82% amino acid sequence identity with the human CB₂ receptor (19).

Activation of the CB₁ or CB₂ G_{i/o}-protein coupled receptors results in inhibition of adenylyl cyclase activity, decreased formation of cyclic AMP with a corresponding decrease in protein kinase A activity, and inhibition of Ca²⁺ influx through various Ca²⁺ channels; it also results in stimulation of inwardly rectifying potassium (K⁺) channels and the mitogen-activated protein kinase signaling cascades (3,12). Anandamide is a partial agonist at CB receptors, and binds with slightly higher affinity at CB₁ compared to CB₂ receptors (2,20). 2-AG appears to bind equally well to both CB receptors (with slightly higher affinity to CB₁), but has greater potency and efficacy than anandamide at CB receptors (2,20).

In the central nervous system (CNS), the overall effect of CB₁ receptor activation is suppression of neurotransmitter release (5-hydroxytryptamine, glutamate, acetylcholine, GABA, noradrenaline, dopamine, D-aspartate, cholecystokinin) at both excitatory and inhibitory synapses with both short and long-term effects (2,16,21). Inhibition of neurotransmitter release occurs through a retrograde signaling mechanism whereby endocannabinoids synthesized and released from the post-synaptic neurons diffuse backwards across the synaptic cleft and bind to CB₁ receptors located on the pre-synaptic terminals (3). This retrograde signaling mechanism permits the regulation of neurotransmission in a precise spatio-temporal manner (3). In immune cells, activation of CB₂ receptors inhibits cytokine/chemokine release and neutrophil and macrophage migration, giving rise to complex modulatory effects on immune system function (17).

Cannabinoid receptor expression and receptor distribution

Most tissues contain a functional endocannabinoid system with the CB₁ and CB₂ receptors having distinct patterns of tissue expression. The CB₁ receptor is one of the most abundant G-protein coupled receptors in the central and peripheral nervous systems (17). It has been detected in the cerebral cortex, hippocampus, amygdala, basal ganglia, substantia nigra pars reticulata, internal and external segments of the globus pallidus and cerebellum (molecular layer), and at central and peripheral levels of the pain pathways including the periaqueductal gray matter, rostral ventrolateral medulla, the dorsal primary afferent spinal cord regions including the peripheral nociceptors, and the spinal interneurons (4,21,22). The CB₁ receptor is also expressed in many other organs and tissues including adipocytes, leukocytes, spleen, heart, lung, the gastrointestinal tract (liver, pancreas, stomach, and the small and large intestine), kidney, bladder, reproductive organs, skeletal muscle, bone, joints, and skin (23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41). CB₁ receptor expression appears to be relatively sparse in the brainstem region (4). CB₂ receptors are most highly concentrated in the tissues and cells of the immune system such as the leukocytes and the spleen, but can also be found in bone and to a lesser degree in liver and in nerve cells including astrocytes, oligodendrocytes and microglia, and even some neuronal sub-populations (reviewed in (42,43)).

Other molecular targets of cannabinoids

Besides the well-known CB₁ and CB₂ receptors, a number of different cannabinoids are believed to bind to a number of other molecular targets. Such targets include the third putative cannabinoid receptor GPR55, the transient receptor potential (TRP) cation channel family, and a class of nuclear receptors/transcription factors known as the peroxisome proliferator-activated receptors (PPARs). For additional details on this subject please consult the following resources (7,8,20,44). Modulation of these other cannabinoid targets adds additional layers of complexity to the known myriad effects of cannabinoids.

Signal termination

Endocannabinoid signaling is rapidly terminated by the action of two hydrolytic enzymes: fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) (3). FAAH is primarily localized post-synaptically (45,46) and preferentially degrades anandamide (13); MAGL is primarily localized pre-synaptically (45,46) and favors the catabolism of 2-AG (13).

Dysregulation of the endocannabinoid system and general therapeutic challenges of using cannabinoids

Dysregulation of the endocannabinoid system appears to be connected to a number of pathological conditions, with the changes in the functioning of the system being either protective or maladaptive (47). Modulation of the endocannabinoid system either through the targeted inhibition of specific metabolic pathways, and/or directed agonism or antagonism of its receptors may hold therapeutic promise (12). However, a major and consistent therapeutic challenge confronting the routine use of psychoactive cannabinoids (e.g. THC) in the clinic has remained that of achieving selective targeting of the site of disease and the sparing of other bodily regions such as the mood and cognitive centres of the brain (21,47,48,49,50).




Figure 1. The Endocannabinoid System in the Nervous System

(1) Endocannabinoids are manufactured "on-demand" in the post-synaptic terminals: anandamide (AEA) is generated from phospholipase-D (PLD)-mediated hydrolysis of the membrane lipid N-arachidonoylphosphatidylethanolamine (NAPE); 2-AG from the diacylglycerol lipase (DAGL)-mediated hydrolysis of the membrane lipid diacylglycerol (DAG); (2) These endocannabinoids (AEA and 2-AG) diffuse retrogradely towards the pre-synaptic terminals and like exogenous cannabinoids such as THC (from cannabis), dronabinol, and nabilone, they bind and activate the pre-synaptic G-protein-coupled CB₁ receptors; (3) Binding of phytocannabinoids and endocannabinoids to the CB₁ receptors triggers the activation and release of the G_i/G_o proteins from the CB receptors and inhibits adenylyl cyclase, thus decreasing the formation of cyclic AMP and the activity of protein kinase A; (4) Release of the G_i/G_o proteins also results in the opening of inwardly-rectifying K⁺ channels (depicted with a "+") causing a hyperpolarization of the pre-synaptic terminals, and the closing of Ca²⁺ channels (depicted with a "-"), arresting the release of stored excitatory and inhibitory neurotransmitters (e.g. glutamate, GABA, 5-hydroxytryptamine (5-HT), acetylcholine, noradrenaline, dopamine, D-aspartate and cholecystinin) which (5) once released, diffuse and bind to post-synaptic receptors; (6) Anandamide and 2-AG re-enter the post- or pre-synaptic nerve terminals (possibly through the actions of a specialized transporter depicted by a "dashed" line) where they are respectively catabolized by fatty acid amide hydrolase (FAAH) or monoacylglycerol lipase (MAGL) to yield either arachidonic acid (AA) and ethanolamine (ETA), or arachidonic acid and glycerol. See text for additional details. Figure adapted from (51,52,53).

1.1 Cannabis

1.1.1 Chemistry and composition

Marihuana (Marijuana) is the common name for *Cannabis sativa* (i.e. cannabis), a hemp plant that grows throughout temperate and tropical climates (54). The leaves and flowering tops of *Cannabis* plants contain at least 489 distinct compounds distributed among 18 different chemical classes, and harbor more than 70 different phytocannabinoids (55). The principal cannabinoids appear to be delta-9-tetrahydrocannabinol (i.e. Δ^9 -THC, THC), cannabinol (CBN), and cannabidiol (CBD) (56,57,58), although the relative abundance of these and other cannabinoids can vary depending on a number of factors such as the *Cannabis* strain, the soil and climate conditions, and the cultivation techniques (59,60). Other cannabinoids found in cannabis include cannabigerol (CBG), cannabichromene (CBC), tetrahydrocannabivarin (THCV) and many others (55). In the living plant, these phytocannabinoids exist as both inactive monocarboxylic acids (e.g. THCA) and as active decarboxylated forms (e.g. THC); however, heating (at temperatures above 120 °C) promotes decarboxylation (e.g. THCA to THC) and results in biological activation (61,62,63). Furthermore, pyrolysis transforms each of the hundreds of compounds in cannabis into a number of other compounds, many of which remain to be characterized both chemically and pharmacologically. Therefore, marihuana (cannabis) can be considered a very crude drug containing a very large number of chemical and pharmacological constituents, the properties of which are only slowly being understood.

Among all the chemical constituents of cannabis, and particularly among the cannabinoids, Δ^9 -THC is by far the best studied and is responsible for many, if not most, of the physical and psychotropic effects of cannabis (64). Other cannabinoids (such as CBD, CBC, CBG) are present in lesser amounts in the plant and have little, if any, psychotropic properties (64). It is reasonable to consider about 10% (range 1 - 30%) as an average for Δ^9 -THC content in cannabis found on the illicit market in Canada (internal communication). The dried marihuana currently provided by Health Canada is composed of the mature flowering heads of female plants and contains 12.5 ±2% total THC (Δ^9 -THC and Δ^9 -THCA), and less than 0.5% CBD, CBG, CBN, and CBC (65). The MS-17/338 production line has THC concentrations typically higher than 10%, with the mature flowering heads containing the highest concentration of THC (65). The plant is cultivated and harvested in compliance with Good Manufacturing Practices, by Prairie Plant Systems Inc. under contract to Health Canada (66). Furthermore, the product is irradiated to ensure that users whose immune systems may be compromised are not exposed to toxic spores which may contaminate the plant material, and the finished product lot release is based on the results of bacterial, fungal, and moisture testing (65). Irradiated pouches containing the dried cannabis are kept sterile over long-term cold storage, with measures of viable microbes being below detection (Health Canada internal communication).

1.1.2 Other constituents

The large number of compounds found in cannabis span many chemical classes including cannabinoids, nitrogenous compounds, amino acids, proteins, enzymes, glycoproteins, hydrocarbons, simple alcohols, aldehydes, ketones and acids, fatty acids, simple esters and lactones, steroids, terpenes, non-cannabinoid phenols, flavonoids, vitamins, and pigments (55). Furthermore, differences in the presence and the relative abundance of some of these various components have been investigated, and differences have been noted between cannabis extract, vapour, and smoke, and also between cannabis varieties (67). Of note, cannabis smoke contains many compounds not observed in either extracts or vapour, including a number which are known or suspected carcinogens or mutagens (67,68,69). Moreover, comparisons between cannabis smoke and tobacco smoke have shown that the former contains many of the same carcinogenic chemicals found in tobacco smoke (68,70).

Relatively little is known about the pharmacological actions of the various other compounds found within cannabis (e.g. terpenes, flavonoids). However, it is believed that some of these compounds (e.g. terpenes) may have a broad spectrum of action (e.g. anti-oxidant, anti-anxiety, anti-inflammatory, anti-bacterial, anti-neoplastic, anti-malarial), but this information comes from a few *in vitro* and *in vivo* studies and no clinical trials exist to support these claims. Terpenes vary widely among cannabis varieties and are thought to be primarily responsible for differences in fragrance among the different *Cannabis* strains (59). Furthermore, it is thought that terpenes may contribute to the distinctive smoking qualities and possibly to the character of the "high" associated with smoking cannabis (59), but again, this has not been studied in any detail. The concept that terpenes may somehow modify or enhance the physiological effects of the cannabinoids (71,72) is, for the moment, hypothetical as there is little, if any, pre-clinical evidence to support this hypothesis and no clinical trials on this subject have been carried out to date.

1.1.3 Stability and storage

Most of the information on the stability of marijuana/cannabis does not distinguish between Δ^9 -THC and its carboxylic acid (Δ^9 -THCA). The latter is transformed to Δ^9 -THC by heating during vapourization or cooking, or by pyrolysis during smoking or in the inlet of gas chromatographs used in forensic analysis (73). Heat, light, humidity, acidity and oxidation all affect the stability of cannabis and cannabinoids (74,75). The National Institute on Drug Abuse (NIDA) reports that retention samples of their carefully prepared and standardized cigarettes are stable for months, particularly when stored below 0 °C (-18 °C) in the dark, in tightly-closed containers (76). Even when stored at +18 °C, only a third of the THC content is lost over a five-year period with some increase in the concentration of CBN. Lower-potency cigarettes (1.15% THC) appear to lose more THC compared to higher potency cigarettes (2.87% THC) (76). Stability data for cannabis distributed by Health Canada indicate that, when stored in the refrigerator (4 °C \pm 1 °C) or freezer (-17 °C to -20 °C \pm 1 °C), the finished product is stable for over 2 years without significant conversion of Δ^9 -THCA to Δ^9 -THC or any alterations in colour or aroma (Health Canada internal communication). The moisture content of the sealed, finished product is constant at 11 - 12% over a period of 12 months. When stored at room temperature (20 °C \pm 2 °C), alterations in colour and aroma are detected in the finished product at 9 months, and conversion of Δ^9 -THCA to Δ^9 -THC is detected as early as 1.5 months, and increases to nearly 25% at 18 months (Health Canada internal communication). The ideal storage temperature for the finished dried cannabis product is 2 °C to 6 °C with a shelf-life of 12 months (Health Canada internal communication).

2.0 Clinical Pharmacology

2.1 Pharmacodynamics

Much of the pharmacodynamic information on cannabis refers to the effects of the major constituent Δ^9 -THC which acts as a partial agonist at both CB receptors (77), has activity at non-CB receptors and other targets (78), and is responsible for the psychoactive effects of cannabis through its actions at the CB₁ receptor (79). Δ^8 -THC (an isomer of Δ^9 -THC) is found in smaller amounts in the plant (64), but like Δ^9 -THC, it is a partial agonist at both CB receptors and shares relatively similar efficacy and potency with Δ^9 -THC in *in vitro* assays (77). An *in vivo* animal study and one clinical study suggest Δ^8 -THC to be a more potent anti-emetic than Δ^9 -THC (80,81).

Cannabinol (CBN) is a product of Δ^9 -THC oxidation and has 10% of the activity of Δ^9 -THC (82). Its effects are not well studied but it appeared to have some possible immunosuppressive properties in a small number of *in vitro* studies (83). Cannabigerol (CBG) is a partial CB_{1/2} receptor agonist and a small number of *in vitro* studies suggest it may have some anti-inflammatory and analgesic properties (44,82,84,85). It may also block 5-HT_{1A} receptors and act as an α_2 -adrenoceptor agonist (86).

Cannabidiol (CBD) lacks detectable psychoactivity and does not appear to bind to either CB₁ or CB₂ receptors at physiologically meaningful concentrations, but it affects the activity of a significant number of other targets including ion channels, receptors, and enzymes (reviewed in (16,82,87)). Results from pre-clinical studies suggest CBD has anti-inflammatory, analgesic, anti-nausea, anti-emetic, anti-psychotic, anti-ischemic, anxiolytic, and anti-epileptiform effects (reviewed in (82,88)).

Tetrahydrocannabivarin (THCV) acts as a CB₁ receptor antagonist and CB₂ receptor partial agonist *in vitro* and *in vivo* (89,90), and pre-clinical studies suggest it may have anti-epileptiform/anti-convulsant properties (91).

Much of what is known about the beneficial properties of the non-psychoactive cannabinoids (e.g. CBD, THCV) is derived from *in vitro* and animal studies and few, if any, clinical studies of these substances exist. However, the results from these *in vitro* and animal studies point to potential therapeutic indications such as psychosis, epilepsy, anxiety, sleep disturbances, neurodegeneration, cerebral and myocardial ischemia, inflammation, pain and immune responses, emesis, food intake, type-1 diabetes, liver disease, osteogenesis, and cancer (reviewed in (16,82,92)). For more in-depth information on the pharmacology of cannabinoids, the reader is invited to consult the following resources (20,82,93).

Phytocannabinoid-Phytocannabinoid Interaction and Phytocannabinoid Differences among Cannabis Strains

Despite anecdotal claims, there is limited reliable information regarding real or potential interactions, of biological or physiological significance, among phytocannabinoids, especially Δ^9 -THC and CBD. The limited information that exists is complex and requires further clarification through additional investigation. The following paragraphs summarize the available information on this subject.

Factors affecting the nature of the potential phytocannabinoid-phytocannabinoid interactions

Various studies have reported either potentiating, opposing, or neutral interactions between Δ^9 -THC and CBD (94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109). The discrepancies in the nature of the interactions between Δ^9 -THC and CBD reported in the literature may be explained by differences in the doses and ratios of THC and CBD used in the different studies, differences in the routes of administration, dose ordering effects (CBD pre-treatment vs. simultaneous co-administration), differences in the duration or chronicity of treatment (acute vs. chronic), differences in the animal species used, as well as the particular biological or physiological end-points being measured (110).

Pharmacokinetic vs. pharmacodynamic interactions

In general, there appear to be two types of mechanisms which could govern possible interactions between CBD and Δ^9 -THC: those of a *pharmacokinetic* origin (102,110), and those of a *pharmacodynamic* origin (95,97). Despite the limited and complex nature of the available information, it generally appears that pre-administration of CBD may potentiate some of the effects of THC (through a pharmacokinetic mechanism), whereas simultaneous co-administration of CBD and THC may result in the attenuation of some of the effects of THC (through a pharmacodynamic mechanism). Furthermore, the ratio between the two phytocannabinoids also appears to play a role in determining whether the overall effect will be of a potentiating or antagonistic nature. CBD-mediated attenuation of THC-induced effects may be observed when the ratio of CBD to THC is at least 8 : 1 (± 11.1) (96,109), whereas CBD appears to potentiate some of the effects associated with THC when the CBD to THC ratio is around 2 : 1 (± 1.4) (109). Potentiation of THC effects by CBD may be caused by inhibition of THC metabolism in the liver, resulting in higher plasma levels of THC (102,110). There is virtually no information in the peer-reviewed scientific or medical literature concerning the effects of varying CBD to THC ratios in the treatment of different medical disorders.

Psychological and physiological effects associated with varying phytocannabinoid concentrations

There are only a handful of studies examining the neurophysiological, cognitive, subjective, or behavioural effects of varying the concentrations of Δ^9 -THC, CBD, or other cannabinoids such as cannabichromene (CBC) in smoked cannabis (101,111). In one study, 24 healthy men and women who had reported using cannabis at least 10 times in their lifetime were subjected to a double-blind, placebo-controlled, mixed between- and within-subject clinical trial that showed that deliberate systematic variations in the levels of either CBD or CBC in smoked cannabis were not associated with any significant differences in any of the measured subjective, physiological, or performance tests (101). In another study, the subjective effects associated with the smoked or oral administration of cannabis plant material were directly compared to those associated with smoked or oral administration of Δ^9 -THC (using matched doses of Δ^9 -THC) to normal, healthy subjects (111). This double-blind, placebo-controlled, within-subject, crossover clinical study reported few reliable differences between the THC-only and whole-plant cannabis conditions (111). The authors further concluded that other cannabinoids present in the cannabis plant material did not alter the subjective effects of cannabis, but they speculated that cannabis samples with higher levels of cannabinoids or different ratios of the individual cannabinoids could conceivably produce different results, although no evidence to support this claim was provided in the study. They also hypothesized that whole-plant cannabis and THC alone could differ on other outcome measures more relevant to clinical entities (e.g. spasticity or neuropathic pain). With the possible exception of one study (112), (see section 4.6.2.3. Cancer Pain), which suggested differences between a whole-plant cannabis extract (i.e. nabiximols, marketed as Sativex®) and THC alone on cancer pain analgesia, no other clinical studies have examined this possibility. One study compared the subjective and physiological effects of oral THC to those of nabiximols in normal, healthy subjects (107). The authors reported the absence of any modulatory effect of CBD (or other components of cannabis) at low therapeutic cannabinoid doses, with the potential exception of the subjective "high" (107). An internet-based, cross-sectional study of 1 877 individuals with a consistent history of cannabis use reported that those individuals who had indicated using cannabis with a higher CBD to THC ratio had also reported experiencing fewer psychotic experiences (an effect typically associated with exposure to higher doses of THC) (113). However, the authors noted that the effects were subtle. The study was also hampered by a number of important methodological issues suggesting that the conclusions should be interpreted with caution. In summary, further careful study is required to elucidate the influence of CBD, and other phytocannabinoids or terpenoids, on the physiological or psychological effects associated with the use of Δ^9 -THC, as well as on any medical disorders. There is presently insufficient scientific and clinical evidence to lend support to the anecdotal claims that one strain of cannabis may be more beneficial than another one for a particular medical condition.

Table 1 (next page), adapted from a review (114), notes some of the pharmacological effects of cannabis in the therapeutic dosage range. Many of the effects are biphasic, with increased activity with acute or smaller doses, and decreased activity with larger doses or chronic use (115,116,117). Effects differ greatly among individuals and may be greater in those who are severely ill, elderly, or those taking other drugs.

Most of the available information regarding the acute effects of smoking cannabis comes from studies conducted on recreational users, with much less information available from clinical studies of patients using cannabis for medical purposes. The acute effects of smoking or eating cannabis include euphoria (the marijuana "high") as well as cardiovascular, bronchopulmonary, ocular, psychological and psychomotor effects. Maximum euphoria typically occurs within 15 min after smoking and generally takes longer with oral administration (64). However, some people can experience dysphoria and anxiety (118). The effects on the cardiovascular system (tachycardia, etc.) decline much faster as THC is distributed out of the circulatory system. Tachycardia is the most consistent of the acute physiological effects associated with the consumption of cannabis (117,119,120,121).

The short-term psychoactive effects associated with cannabis smoking in recreational users include the above-mentioned euphoria but also relaxation, time-distortion, intensification of ordinary sensory experiences (such as eating, watching films, and listening to music), and loss of inhibitions that may result in laughter (122). This is followed by a depressant period (123). While there is some inconsistency in reports regarding the acute effects of cannabis on memory and motor skills (124,125,126), most reviews note that cannabis use is associated with impaired function on a variety of cognitive and short-term memory tasks (83,123,127,128,129,130). The levels of Δ^9 -THC in the plasma after smoking appear to have a dose, time, and concentration-dependent effect on cognitive function (131,132,133). Driving and operation of intricate machinery, including aircraft, may be significantly impaired (134,135,136,137).

Table 1: Pharmacologic Actions of Cannabis (adapted from (114) with additional references)

Body System/Effect	Detail of Effects
Central Nervous System (CNS)	
Psychological	Euphoria ("high"), dysphoria, anxiety, depersonalization, precipitation or aggravation of psychosis (64,117,118,138,139,140,141,142,143,144,145,146,147,148,149,150,151,152,153,154,155,156,157,158).
Perception	Heightened sensory perception, distortion of space and time sense, hallucinations, misperceptions (151,156,159,160,161,162,163).
Sedative	Generalised CNS depression, drowsiness, somnolence; additive with other CNS depressants (opioids/alcohol) (117,142,157,158,164,165,166,167,168,169,170,171,172,173,174).
Cognition, psychomotor performance	Fragmentation of thoughts, mental clouding, memory impairment, global impairment of performance especially in complex and demanding tasks (101,129,134,135,136,137,157,174,175,176,177,178,179,180,181).
Motor function	Incoordination, ataxia, dysarthria, weakness (117,162,168,174,182,183).
Analgesic	Modest effect for chronic non-cancer pain (142,157,158,164,165,168,172,173,184,185,186,187,188,189).
Anti-nausea/anti-emetic; hyper-emetic	Observed with acute doses (88,190,191,192)-- Tolerance may occur with chronic use (193). Hyperemesis may be observed with larger doses or chronic use (194,195,196,197,198,199,200,201,202,203,204).
Appetite	Increased in normal, healthy subjects, but also in patients suffering from HIV/AIDS-associated anorexia/cachexia (166,167,174,205,206,207,208,209).
Tolerance	To most behavioural and somatic effects, including the "high" (with chronic use) (210,211,212,213,214,215,216,217,218) and (see section 2.4).
Dependence, withdrawal syndrome	Dependence has been produced experimentally, and observed clinically, following prolonged intoxication ((122,156,210,219,220,221) and see section 2.4). Abstinence leads to withdrawal symptoms which can include anger, anxiety, restlessness, irritability, depressed mood, disturbed sleep, strange dreams, decreased appetite, and weight loss ((156,210,222) and also see section 2.4).
Cardiovascular and Cerebrovascular System	
Heart rate/rhythm	Tachycardia with acute dosage; tolerance developing with chronic exposure (117,119,120,121,157,158,223,224,225,226). Premature ventricular contractions, atrial fibrillation, ventricular arrhythmia also seen with acute doses (121,174,227,228,229,230,231).
Peripheral circulation	Vasodilatation, conjunctival redness, supine hypertension, postural hypotension (170,174,225,227,232,233,234).
Cardiac output	Increased cardiac output (227) and myocardial oxygen demand (232).
Cerebral blood flow	Increased with acute dose, decreased with chronic use, region-dependent variations (225,235).
Myocardial infarction	Increased risk of acute myocardial infarction within 1 h after smoking cannabis especially in individuals with existing cardiovascular disease (121,232).
Stroke	Increased risk of experiencing stroke after an acute episode of smoking cannabis (227,236,237).
Respiratory System	
Carcinogenesis/mutagenesis	Cannabis smoke contains many of the same chemicals as tobacco smoke, and cannabis smoke condensates are more cytotoxic and mutagenic than condensates from tobacco smoke (68,70). Conflicting evidence linking cannabis smoking and cancer (238,239,240,241).
Histopathologic changes/inflammation	Chronic cannabis smoking associated with histopathologic changes in the lung (basal cell hyperplasia, stratification, goblet cell hyperplasia, cell disorganization, inflammation, basement membrane thickening, and squamous cell metaplasia) (242). Long-term smoking associated with

Body System/Effect	Detail of Effects
	cough, increased production of phlegm, and wheeze (243).
Bronchodilatation	Acute exposure causes dilatation; possibly reversed with chronic exposure (by smoking) (243).
Pulmonary function (FEV ₁ ; FVC)	Acute, low-level exposure possibly stimulatory; long-term, heavy smoking possibly associated with increased obstruction and decreased lung function (243,244,245,246,247).
Gastrointestinal System	
General pharmacologic actions	Decreased gastrointestinal motility, decreased secretion, decreased gastric/colonic emptying, anti-inflammatory actions (31,157,189,248).
Liver	Increased risk of hepatic steatosis/fibrosis, especially in patients with Hepatitis C (33,249,250,251). Increased Hepatitis C treatment adherence resulting in a potential sustained absence of detectable levels of Hepatitis C virus (252).
Pancreas	Acute risk of pancreatitis with chronic, heavy, daily use (253,254,255,256).
Musculoskeletal system	
General pharmacologic actions	Possible beneficial effect in chronic pain from rheumatoid arthritis (257,258,259) and fibromyalgia (158,260,261). May attenuate spasticity from multiple sclerosis (164,165,188,262). May negatively impact bone healing (263).
Eye	
General pharmacologic actions	Decreased intra-ocular pressure (264,265).
Immune System	
General pharmacologic actions	Complex immunomodulatory effects with suppressive and/or stimulatory effects (acute and chronic dosing) (24,266).
Reproductive System	
Males	With chronic administration: anti-androgenic, decreased sperm count and sperm motility, altered sperm morphology in animals (and possibly in humans) (267,268). Tolerance to these effects may develop. Possible inhibitory effects on sexual behaviour in men (269).
Females	Effects inconclusive in women (possibly due to tolerance) but changes in menstrual cycle, suppression of ovulation, and complex effects on prolactin secretion observed in female animals (268,270,271). Dose-dependent stimulatory or inhibitory effects on sexual behaviour in women (269).

2.2 Pharmacokinetics

This section is restricted to human pharmacokinetics of smoked and vapourized cannabis, oral preparations including prescription cannabinoid medicines such as dronabinol (Marinol[®]) and nabiximols (Sativex[®]), and other routes of administration (e.g. rectal, topical).

2.2.1 Absorption

2.2.1.1 Smoked cannabis

Smoking cannabis results in more rapid onset of action (within minutes), higher blood levels of cannabinoids, and a shorter duration of pharmacodynamic effects compared to oral administration (62). The amount of Δ^9 -THC delivered from cannabis cigarettes is not uniform and is a major variable in the assessment of absorption (62). Uncontrolled factors include the source of the plant material and the composition of the cigarette, together with the efficiency and method of smoking used by the subject (62,272). While it has been reported that smokers can titrate their Δ^9 -THC intake by adapting their smoking behaviour to obtain desired levels of Δ^9 -THC (273), other reasons may also explain the observed variation in smoking topography (274). Δ^9 -THC absorption by inhalation is extremely rapid but quite variable, with a bioavailability of 2 - 56% through the smoking route depending on depth of inhalation, puff duration, and breathhold (275,276). In practice, a maximum of 25 - 27% of the THC content in a cannabis cigarette is absorbed or delivered to the systemic circulation from the total available amount (117,277).

Standardized cannabis cigarettes have been developed by the National Institute on Drug Abuse (NIDA), and the relationships among cannabis Δ^9 -THC content, dose administered, and resultant plasma levels have been investigated. Mean plasma Δ^9 -THC concentrations were 7.0 ± 8.1 ng/mL and 18.1 ± 12.0 ng/mL upon a single inhalation of either a 1.75% "low-dose" Δ^9 -THC cannabis cigarette (total available dose ~16 mg Δ^9 -THC), or a 3.55% Δ^9 -THC "high-dose" cannabis cigarette (total available dose ~34 mg Δ^9 -THC) (62). Smoking cannabis containing 1.64% Δ^9 -THC (mean available dose 13.0 mg Δ^9 -THC) resulted in mean peak THC plasma levels of 77 ng/mL (278). Similarly, smoking cannabis joints containing 1.8% Δ^9 -THC (total available dose ~14 mg Δ^9 -THC) resulted in mean peak plasma THC levels of approximately 75 ng/mL, whereas with 3.6% Δ^9 -THC (total available dose ~28.8 mg Δ^9 -THC), mean peak plasma Δ^9 -THC levels of 100 ng/mL were attained (279). Smoking a 25 mg dose of cannabis containing 2.5, 6, or 9.4% Δ^9 -THC (total available doses of ~0.6, 1.5, or 2.4 mg Δ^9 -THC) was associated with mean peak plasma Δ^9 -THC concentrations of 10, 25, or 45 ng/mL Δ^9 -THC, respectively (172). Smoking one cannabis cigarette (mean weight 0.79 ± 0.16 g) containing 6.8% ± 0.2 THC, 0.25% ± 0.08 CBD, and 0.21% ± 0.02 CBN (w/w) yielding a total THC, CBD, and CBN content of 54, 2.0, and 1.7 mg of these cannabinoids per cigarette, respectively, was associated with a median whole blood THC concentration of approximately 60 ng/mL Δ^9 -THC (range 13 - 63 ng/mL) (280).

2.2.1.2 Vapourized cannabis

Vapourization of cannabis has been explored as an alternative to smoking. The potential advantages of vapourization include the formation of a smaller quantity of toxic by-products such as carbon monoxide, polycyclic aromatic hydrocarbons (PAHs), and tar, as well as a more efficient extraction of Δ^9 -THC from the cannabis material (273,281,282,283,284). The subjective effects and plasma concentrations of Δ^9 -THC obtained by vapourization of cannabis are comparable to those obtained by smoking cannabis, with absorption being somewhat faster with the vapourizer compared to smoking, according to one study (273). In addition, the study reported that the vapourizer was well tolerated with no reported adverse effects, and was preferred over smoking by the test subjects (273). While vapourization has been reported to be amenable to self-titration (as has been claimed for smoking) (273,283), the proper use of the vapourizer for optimal administration of cannabis for therapeutic purposes needs to be established in more detail (284). The amount and type of cannabis placed in the vapourizer, the vapourizing temperature and duration of vapourization, and the balloon volume are some of the parameters that can affect the delivery of Δ^9 -THC (283). Bioequivalence of vapourization compared to smoking has not been thoroughly established. Inhalation of vapourized cannabis (0.9 g of 3.56% Δ^9 -THC; total available dose of 32 mg of Δ^9 -THC) in a group of patients taking stable doses of sustained-release morphine or oxycodone resulted in mean plasma Δ^9 -THC levels of 126.1 ng/mL within 3 min after starting cannabis inhalation, rapidly declining to 33.7 ng/mL Δ^9 -THC at 10 min, and reaching 6.4 ng/mL Δ^9 -THC at 60 min (187). Peak Δ^9 -THC concentration was achieved at 3 min in all study participants (187). Maximal subjective "high" ratings occurred at 60 min following beginning of

inhalation, with a stronger and more sustained subjective "high" score for individuals taking oxycodone compared to those taking morphine (187). No statistically significant changes were reported for the AUC_{12} for either morphine or oxycodone, but there appeared to be a statistically significant decrease in the maximum concentration (C_{max}) of morphine sulfate, and a delay in the time needed to reach C_{max} for morphine during cannabis exposure (187).

2.2.1.3 Oral

Whereas the central nervous system and physiological effects occur within minutes by the smoking route or by vapourization (129,285), these effects proceed on a time scale of hours in the case of oral ingestion (285,286). Oral administration results in a slower onset of action, lower peak blood levels of cannabinoids, and a longer duration of pharmacodynamic effects compared to smoking (62). The psychotropic effect or "high" occurs much more quickly by the smoking than by the oral route, which is the reason why smoking appears to be the preferred route of administration by many, especially recreational users (287).

For orally administered prescription cannabinoid medicines such as synthetic Δ^9 -THC (dronabinol, marketed as Marinol[®]), only 10 - 20% of the administered dose enters the systemic circulation indicating extensive first-pass metabolism (174). Administration of a single 2.5 mg dose of dronabinol in healthy volunteers was associated with a mean plasma Δ^9 -THC C_{max} of 0.7 ng/mL (range: 0.3 - 1 ng/mL), and a mean time to peak plasma Δ^9 -THC concentration of 2 h (range: 30 min - 4 h) (174). A single 5 mg dose of dronabinol gave a reported mean plasma Δ^9 -THC C_{max} of 1.8 ng/mL (range: 0.4 - 3.3 ng/mL), whereas a single 10 mg dose yielded a mean plasma Δ^9 -THC C_{max} of 6.2 ng/mL (range: 3.5 - 9 ng/mL) (174). Again, the mean time to peak plasma Δ^9 -THC concentration ranged from 30 min - 3 h. Twice daily dosing of dronabinol (individual doses of 2.5 mg, 5 mg, 10 mg, b.i.d.) in healthy volunteers yielded plasma Δ^9 -THC C_{max} values of 1.3 ng/mL (range: 0.7 - 1.9 ng/mL), 2.9 ng/mL (range: 1.2 - 4.7 ng/mL), and 7.9 ng/mL (range: 3.3 - 12.4 ng/mL), respectively, with a time to peak plasma Δ^9 -THC concentration ranging between 30 min and 4 h after oral administration (174). Continuous dosing for seven days with 20 mg doses of dronabinol (total daily doses of 40 - 120 mg dronabinol) gave mean plasma Δ^9 -THC concentrations of ~20 ng/mL (288).

Δ^9 -THC can also be absorbed orally by ingestion of foods containing cannabis (e.g. butters, oils, brownies, cookies), and teas prepared from leaves and flowering tops. Absorption from an oral dose of 20 mg Δ^9 -THC in a chocolate cookie was described as slow and unreliable (272), with a systemic availability of only 4 - 12% (278). While most subjects displayed peak plasma Δ^9 -THC concentrations (6 ng/mL) between 1 - 2 h after ingestion, some of the 11 subjects in the study only peaked at 6 h, and many had more than one peak (62). Consumption of cannabis-laced brownies containing 2.8% Δ^9 -THC (44.8 mg total Δ^9 -THC) was associated with changes in behaviour, although the effects were slow to appear and variable (286). Peak effects occurred 2.5 - 3.5 h after dosing. Modest changes in pulse and blood pressure were also noted. Plasma concentrations of Δ^9 -THC were not measured in this study. In another study, ingestion of brownies containing a low dose of Δ^9 -THC (9 mg THC/brownie) was associated with mean peak plasma Δ^9 -THC levels of 5 ng/mL Δ^9 -THC (111). Ingestion of brownies containing a high dose of Δ^9 -THC (~13 mg Δ^9 -THC/brownie) was associated with mean peak plasma Δ^9 -THC levels of 6 or 9 ng/mL Δ^9 -THC depending on whether the THC in the brownie came from plant material or was added as pure THC (111). Using equivalent amounts of Δ^9 -THC, inhalation by smoking cannabis yielded peak plasma levels of Δ^9 -THC several-fold (five to six times or more) higher than when Δ^9 -THC was absorbed through the oral route (111). Tea made from dried cannabis flowering tops (19.1% Δ^9 -THCA (tetrahydrocannabinolic acid), 0.6% Δ^9 -THC) has been documented, but the bioavailability of Δ^9 -THC from such teas is likely to be smaller than that achieved by smoking because of the poor water solubility of Δ^9 -THC and the hepatic first-pass effect (289).

2.2.1.4 Oro-mucosal

Following a single oro-mucosal administration of nabiximols (Sativex[®]) (four sprays totalling 10.8 mg Δ^9 -THC and 10 mg CBD), mean peak plasma concentrations of both THC (~5.5 ng/mL) and CBD (~3 ng/mL) typically occur within 2 - 4 h, although there is wide inter-individual variation in the peak cannabinoid plasma concentrations and in the time to onset and peak of effects (290). When administered oro-mucosally, blood levels of Δ^9 -THC and other cannabinoids are lower than those achieved by inhalation of the same dose of smoked cannabis, but Δ^9 -THC blood levels were comparable to those seen with oral administration of dronabinol (108,290). Oro-mucosal administration of nabiximols is amenable to self-titration (107,259,291,292).

2.2.1.5 Rectal

While Δ^9 -THC itself is not absorbed through the rectal route, the pro-drug Δ^9 -THC-hemisuccinate is absorbed; this fact, combined with decreased first-pass metabolism through the rectal route, results in a higher bioavailability of Δ^9 -THC by the rectal route (52 - 61%) than by the oral route (293,294,295,296,297). Plasma concentrations of Δ^9 -THC are dose and vehicle-dependent, and also vary according to the chemical structure of the THC ester (296). In humans, rectal doses of 2.5 - 5.0 mg of the hemisuccinate ester of Δ^9 -THC were associated with peak plasma levels of Δ^9 -THC ranging between 1.1 and 4.1 ng/mL within 2 - 8 h, and peak plasma levels of carboxy- Δ^9 -THC ranging between 6.1 - 42.0 ng/mL within 1 - 8 h after administration (293).

2.2.1.6 Topical

Cannabinoids are highly hydrophobic, making transport across the aqueous layer of the skin the rate-limiting step in the diffusion process (62). No clinical studies exist regarding the percutaneous absorption of cannabis-containing ointments, creams, or lotions. However, some research has been carried out on transdermal delivery of synthetic and natural cannabinoids using a dermal patch (298,299). A patch containing 8 mg of Δ^8 -THC yielded a mean steady-state plasma concentration of 4.4 ng/mL Δ^8 -THC within 1.4 h in a guinea pig model, and this concentration was maintained for at least 48 h (298). Permeation of cannabidiol (CBD) and cannabinol (CBN) was found to be 10-fold higher than for Δ^8 -THC (300).

2.2.2 Distribution

Distribution of Δ^9 -THC is time-dependent and begins immediately after absorption. It is taken up primarily by fatty tissues and highly perfused organs such as the brain, heart, lung, and liver (62). Δ^9 -THC has a large apparent volume of distribution, approximately 10 L/kg, because of its high lipid solubility (301). The plasma protein binding of Δ^9 -THC and its metabolites is approximately 97% (302,303). Δ^9 -THC is mainly bound to low-density lipoproteins, with up to 10% present in red blood cells (304), while the metabolite, 11-hydroxy THC is strongly bound to albumin with only 1% found in the free-fraction (305).

The highest concentrations of Δ^9 -THC are found in the heart and in adipose tissue, with levels reaching 10 and 1000 times that of plasma, respectively (306). Despite the high perfusion level of the brain, the blood-brain barrier (BBB) appears to limit the access and accumulation of Δ^9 -THC in this organ (62,307,308), and the delay in correlating peak plasma concentration to psychoactive effects may be attributed to the time required for Δ^9 -THC to traverse this barrier (272).

Δ^9 -THC accumulates and is retained in fatty tissue, and its release from this storage site into the blood is slow (307). It is not certain if Δ^9 -THC persists in the brain in the long-term; however, the presence of residual cognitive deficits in abstinent heavy cannabis users raises the possibility that Δ^9 -THC may be retained in the brain at least in the short-term (179,309). One animal study suggested food deprivation or adrenocorticotrophic hormone (ACTH) administration in rats accelerates lipolysis and the release of Δ^9 -THC from fat stores, however further research is needed to determine if these effects are associated with intoxication or behavioural/cognitive changes (310).

2.2.3 Metabolism

Most cannabinoid metabolism occurs in the liver, and different metabolites predominate depending on the route of administration (62,272). The complex metabolism of Δ^9 -THC involves allylic oxidation, epoxidation, decarboxylation, and conjugation (272). Δ^9 -THC is oxidized by the xenobiotic-metabolizing cytochrome P450 (CYP) mixed-function oxidases 2C9, 2C19, and 3A4 (62). The major initial metabolites of Δ^9 -THC are the active 11-hydroxy Δ^9 -THC, and the non-active 11-nor-9-carboxy Δ^9 -THC (62). 11-hydroxy Δ^9 -THC is rapidly formed by the action of the above-mentioned hepatic microsomal oxidases, and plasma levels of this metabolite parallel the duration of observable drug action (311,312).

As would be expected, oral administration of Δ^9 -THC results in a greater metabolism of Δ^9 -THC to the 11-hydroxy metabolite compared to administration by smoking (or vapourization), resulting in similar plasma concentrations of Δ^9 -THC and 11-hydroxy Δ^9 -THC through the oral route vs. inhalation (276). Information from the dronabinol (Marinol[®]) product monograph suggests that single doses of 2.5 mg, 5 mg, and 10 mg of Δ^9 -THC in healthy volunteers result in mean plasma C_{max} values of 11-hydroxy Δ^9 -THC of 1.19 ng/mL (range: 0.4 - 1.9 ng/mL), 2.23 ng/mL (range: 0.7 - 3.7 ng/mL), and 7.51 ng/mL (range: 2.25 - 12.8 ng/mL), respectively (174).

Twice daily dosing of dronabinol (individual doses of 2.5 mg, 5 mg, 10 mg, b.i.d.) in healthy volunteers resulted in mean plasma C_{max} values of 1.65 ng/mL (range: 0.9 - 2.4 ng/mL), 3.84 ng/mL (range: 1.5 - 6.1 ng/mL), and 7.95 ng/mL (range: 4.8 - 11.1 ng/mL) of 11-hydroxy Δ^9 -THC, respectively (174). Time to reach C_{max} for 11-hydroxy Δ^9 -THC ranged from 30 min - 4 h, with a mean of approximately 2.5 h (174). Importantly, 11-hydroxy Δ^9 -THC has psychotomimetic properties equal to those of Δ^9 -THC (276,313,314). The psycho-inactive 11-nor-9-carboxy Δ^9 -THC is the primary acid metabolite of Δ^9 -THC excreted in urine (315), and it is the cannabinoid often screened for in forensic analysis of body fluids (316,317).

CYP isozyme polymorphisms may also affect the pharmacokinetics of THC (and 11-nor-9-carboxy Δ^9 -THC). For example, subjects homozygous for the *CYP2C9**3 allelic variant displayed significantly higher maximum plasma concentrations of Δ^9 -THC, significantly higher area under the curve (AUC), and significantly decreased clearance among other measures compared to the *CYP2C9**1 homozygote or the *1/*3 heterozygote (318).

Xenobiotics are not only metabolized by CYPs but they also modulate the expression level and activity of these enzymes; CYPs are therefore a focal point in drug-drug interactions and adverse drug reactions (319). Polyaromatic hydrocarbons found in tobacco and cannabis smoke induce the expression of CYP1A2 (320), while Δ^9 -THC, cannabidiol (CBD), and cannabinol (CBN) inhibit the activity of the CYP1A1, 1A2, and 1B1 enzymes (58). CBD has also been shown to inhibit the formation of Δ^9 -THC metabolites catalyzed by CYP3A4, with less effect on CYP2C9 (301), albeit sufficiently to decrease the formation of 11-hydroxy THC (102,321).

Results from *in vitro* experiments also suggest that Δ^9 -THC inhibits CYP3A4, CYP3A5, CYP2C9, and CYP2C19, while CBD inhibits CYP2C19, CYP3A4, and CYP3A5; however, higher concentrations than those seen clinically appear to be required for inhibition (58,290). While few clinical studies have specifically sought to evaluate cannabis-drug interactions *per se*, many, if not most, studies investigating the therapeutic effects of cannabis (e.g. smoked, vapourized, or orally ingested) and cannabinoid-based medicines (e.g. dronabinol, nabilone, nabiximols) have used patients that were concomitantly taking other medications (e.g. non-steroidal anti-inflammatory agents, opioids, anti-depressants, anti-convulsants, protease inhibitors) and, in general, did not report significantly increased incidences of severe adverse effects associated with the combination of cannabis or cannabinoids and these other medications. Nevertheless, clinicians should carefully monitor patients who are concomitantly consuming cannabis/cannabinoids and other medications that are metabolized by the above-mentioned enzymes.

The Sativex® product monograph cautions against combining Sativex® with amitriptyline or fentanyl (or related opioids) which are metabolized by CYP3A4 and 2C19 (290). Cannabis smoking, as well as orally administered dronabinol, may also affect the pharmacokinetics of anti-retroviral medications (322). In addition, and as seen with tobacco smoke, cannabis smoke has the potential to induce CYP1A2 thereby increasing the metabolism of xenobiotics biotransformed by this isozyme such as theophylline (323) or the anti-psychotic medications clozapine or olanzapine (324). Further information on drug-drug interactions can be found in section 6.2.

2.2.3.1 Inhalation

Plasma values of 11-hydroxy THC appear rapidly and peak shortly after Δ^9 -THC, at about 15 min after the start of smoking (325). Peak plasma concentrations of 11-hydroxy THC are approximately 5% - 10% of parent THC, and the area under the curve (AUC) profile of this metabolite averages 10 - 20% of the parent THC (312). Similar results were obtained with intravenous THC administration (326).

Peak plasma values of 11-nor-9-carboxy THC occur 1.5 - 2.5 h after smoking, and are about one third the concentration of parent THC (325). Following oxidation, the phase II metabolites of the free drug or hydroxy-THC appear to be glucuronide conjugates (272).

2.2.3.2 Oral

After oral doses of Δ^9 -THC, parent THC and its active metabolite 11-hydroxy- Δ^9 -THC (which is similar to or possibly greater in potency than Δ^9 -THC) are present in approximately equal concentrations in plasma (276,286,327). The plasma levels of active 11-hydroxy metabolite, achieved through oral administration, are about three times higher than those seen with smoking (312). Concentrations of both parent drug and metabolite peak between approximately 2 - 4 h after oral dosing, and decline over several days. Whole-body clearance of Δ^9 -THC and its hydroxy metabolite averages about 0.2 L/kg-h, but is highly variable due to the complexity of cannabinoid distribution (174).

2.2.4 Excretion

Δ^9 -THC levels in plasma decrease rapidly after cessation of smoking. Mean THC plasma concentrations are approximately 60% and 20% of peak plasma THC concentrations 15 and 30 min post-smoking (328), respectively, and are below 5 ng/mL THC 2 h after smoking (276). Elimination of THC and its metabolites occurs via the feces (65%) and the urine (20%) (62). After five days, 80% to 90% of the total dose is excreted (312). Nevertheless, THC from a single dose can be detected in plasma up to 13 days in chronic smokers probably due to extensive storage and release from body fat (329).

Following oral administration, THC and its metabolites are also excreted in both the feces and the urine (312,62). Biliary excretion is the major route of elimination, with about half of a radiolabelled THC oral dose being recovered from the feces within 72 h in contrast to the 10 to 15% recovered from urine (312).

The decline of Δ^9 -THC levels in plasma is multi-phasic, and the estimates of the terminal half-life of Δ^9 -THC in humans have progressively increased as analytical methods have become more sensitive (301). While figures for the terminal elimination half-life of Δ^9 -THC appear to vary, it is probably safe to say that it averages at least four days and could be considerably longer (62). The variability in terminal half-life measurements are related to the dependence of this measure on assay sensitivity, as well as on the duration and timing of blood measurements (330). Low levels of THC metabolites have been detected for more than five weeks in the urine and feces of cannabis users (301). The degree of Δ^9 -THC consumption does not appear to influence the plasma half-life of Δ^9 -THC (272,331).

2.3 Pharmacokinetic-pharmacodynamic relationships

Much of the information on cannabinoid pharmacokinetic-pharmacodynamic relationships (mostly on Δ^9 -THC) is derived from studies of recreational cannabis use rather than from studies looking at therapeutic use, but in either case, this relationship depends to some extent on the point in time at which observations are made following the administration of the cannabinoid. Furthermore, the temporal relationship between plasma concentrations of Δ^9 -THC and the associated clinical/therapeutic, psychotropic, cognitive and motor effects is not well established. These effects often lag behind the plasma concentrations of Δ^9 -THC, and tolerance is known to develop to some of the effects but not to others ((101,151,330) and also see (187) and section 2.4 (Tolerance and Dependence)).

As mentioned above, the relationship between dose (and plasma concentration) versus response for possible therapeutic applications are ill-defined, except for some information obtained for oral dosing with dronabinol (synthetic Δ^9 -THC, marketed as Marinol®), nabiximols (a botanical cannabis extract containing approximately equal concentrations of Δ^9 -THC and CBD as well as other cannabinoids, terpenoids and flavonoids, marketed as Sativex®), or nabilone (synthetic Δ^9 -THC, analog marketed as Cesamet®) for their limited indications (174,290,332). Interpretations of the pharmacokinetics of Δ^9 -THC are also complicated by the presence of active metabolites, particularly the psychoactive 11-hydroxy THC, which are found in higher concentrations after oral administration than after inhalation (286,327).

Target Δ^9 -THC plasma concentrations have been derived based on the subjective "high" response that may or may not be related to the potential therapeutic applications. Various pharmacodynamic models provide blood plasma concentration estimates in the range of 7 - 29 ng/mL Δ^9 -THC necessary for the production of a 50% maximal subjective "high" effect (330). Other studies suggest that Δ^9 -THC plasma concentrations associated with 50% of the maximum "high" effect range between 2 and 250 ng/mL Δ^9 -THC (median of 19 ng/mL; mean of 43 ng/mL Δ^9 -THC) for the smoked or i.v. routes, while for the oral route the values range between 1 and 8 ng/mL Δ^9 -THC (median and mean of 5 ng/mL Δ^9 -THC) (111,333). Serum concentrations between 7 and 10 ng/mL (whole blood, approximately 3 - 5 ng/mL) have been compared to a blood-alcohol concentration of 0.05% which is associated with driver impairment (133).

Smoked cannabis

Simulation of multiple dosing with a 1% THC cigarette containing 9 mg Δ^9 -THC yielded a maximal "high" lasting approximately 45 min after initial dosing, declining to 50% of peak at about 100 min following smoking (151). A dosing interval of 1 h with this dose would give a "continuous high", and the recovery time after the last dose would be 150 min (i.e. 2.5 h). The peak Δ^9 -THC plasma concentration during this dosage is estimated at about 70 ng/mL.

One clinical study reported a peak increase in heart rate and perceived "good drug effect" within 7 min after test subjects smoked a 1 g cannabis cigarette containing either 1.8% or 3.9% THC (mean doses of Δ^9 -THC being 18 mg or

39 mg, respectively) (129). Compared to the placebo, both doses yielded statistically significant differences in subjective and physiological measures; the higher dose was also significantly different from the lower dose for subjective effects, but not physiological effects such as heart rate. Pharmacokinetic-pharmacodynamic modelling of concentration-effect relationship of Δ^9 -THC on CNS parameters and heart rate suggests that THC-evoked effects typically lag behind THC plasma concentration, with the effects lasting significantly longer than Δ^9 -THC plasma concentrations (334). The equilibration half-life estimate for heart rate was approximately 7 min, but varied between 39 and 85 min for various CNS parameters (334). According to this model, the effects on the CNS developed more slowly and lasted longer than the effect on heart rate.

The psychomotor performance, subjective, and physiological effects associated with whole-blood Δ^9 -THC concentrations in heavy, chronic, cannabis smokers following an acute episode of cannabis smoking has been studied (280). Subjects reported smoking a mean of one joint per day in the previous 14 days prior to the initiation of the study (range 0.7 - 12 joints per day) (280). During the study, subjects smoked one cannabis cigarette (mean weight 0.79 \pm 0.16 g) containing 6.8 \pm 0.2% THC, 0.25 \pm 0.08% CBD, and 0.21 \pm 0.02% CBN (w/w) yielding a total THC, CBD, and CBN content of 54, 2.0, and 1.7 mg of these cannabinoids per cigarette (280). Mean peak THC blood concentrations and peak visual analog scale scores for different subjective measures occurred 15 min after starting smoking (280). According to the authors of the study, the pharmacodynamic-pharmacokinetic relationship described a counter-clockwise hysteresis (i.e. where for the same plasma concentration of a drug (e.g. THC), the pharmacological effect is greater at a later time point than at an earlier one) for all measured subjective effects (e.g. "good drug effect", "high", "stoned", "stimulated", "sedated", "anxious", and "restless"). This particular kind of relationship demonstrates a lack of correlation between blood concentrations of THC and observed effects, beginning immediately after the end of smoking and continuing during the initial distribution and elimination phases (280). All participants reported a peak subjective "high" between 66 and 85 on the visual analog scale, with peak whole blood THC concentrations at the time of these responses ranging from 13 - 63 ng/mL (280). Following the start of cannabis smoking, heart rate increased significantly at the 30 min time point, diastolic blood pressure decreased significantly only from the 30 min to 1 h time point, and systolic blood pressure and respiratory rate were unaffected at any time (280).

Oral and oro-mucosal cannabinoids

The subjective and physiological effects after controlled administration of nabiximols (Sativex®) or oral THC have also been compared (107). Increases in systolic blood pressure occurred with low (5 mg) and high (15 mg) oral doses of THC, as well as low (5.4 mg Δ^9 -THC and 5 mg CBD) and high (16.2 mg Δ^9 -THC and 15 mg CBD) dose nabiximols, with the effect peaking at around 3 h after administration (107). In contrast, diastolic blood pressure decreased between 4 and 8 h after dosing. Heart rate increased after all active treatments. A statistically significant increase in heart rate relative to placebo was observed after high-dose oral THC (15 mg Δ^9 -THC) and high-dose nabiximols (16.2 mg Δ^9 -THC and 15 mg CBD), but the authors indicated that the increases appeared to be less clinically significant than those typically seen with smoked cannabis (107). High-dose oral THC (15 mg Δ^9 -THC) and high-dose nabiximols (16.2 mg Δ^9 -THC and 15 mg CBD) were associated with significantly greater "good drug effects" compared to placebo, whereas low-dose nabiximols (5.4 mg Δ^9 -THC and 5 mg CBD) was associated with significantly higher "good drug effects" compared to 5 mg THC (107). A subjective feeling of a "high" was reported to be significantly greater after 15 mg oral THC compared to placebo and to 5 mg oral THC. In contrast, neither the high nor the low doses of nabiximols were reported to produce a statistically significant subjective "high" feeling. Study subjects reported being most "anxious" approximately 4 h after administration of 5 mg oral THC, 3 h after 15 mg oral THC, 5.5 h after low-dose nabiximols, and 4.5 h after high-dose nabiximols (107). All active drug treatments induced significantly more anxiety compared to placebo. After 15 mg oral THC, the concentration of THC in plasma was observed to have a weak, but statistically significant, positive correlation with systolic and diastolic blood pressure, "good drug effect", and "high" (107). After high-dose nabiximols, positive correlations were also observed between plasma THC concentrations and "anxious", "good drug effect", "high", "stimulated", and M-scale (marihuana-scale) scores (107). Consistent with other studies, the authors of this study reported that linear correlations between plasma THC concentrations and physiological or subjective effects were weak. Lastly, although cannabidiol did not appear to significantly modulate the effects of THC, the authors suggested it may have attenuated the degree of the subjective "high" (107).

2.4. Tolerance, dependence, and withdrawal symptoms

Tolerance

Tolerance, as defined by the Liaison Committee on Pain and Addiction (a joint committee with representatives from the American Pain Society, the American Academy of Pain Medicine, and the American Society of Addiction Medicine) is a state of adaptation in which exposure to the drug causes changes that result in a diminution of one or more of the drug's effects over time (335).

Tolerance to the effects of cannabis or cannabinoids appears to result mostly from pharmacodynamic rather than pharmacokinetic mechanisms (211). Pre-clinical studies indicate that *pharmacodynamic* tolerance is mainly linked to changes in the availability of the cannabinoid receptors, principally the CB₁ receptor, to signal. There are two independent but interrelated molecular mechanisms producing these changes: receptor desensitization (or uncoupling of the receptor from intra-cellular downstream signal transduction events), and receptor downregulation (resulting from the internalization and/or degradation of the receptor) (336). Furthermore, within the brain, tolerance appears to vary across different regions suggesting cellular and tissue-specific mechanisms regulating desensitization/downregulation (see review by Gonzalez et al. (211)). This may also hold true for other tissues or organs, explaining why tolerance develops to some of the effects of cannabis and cannabinoids but not to other effects. In animal models, the degree and time-course of tolerance appear to depend on the species used, the type of cannabinoid ligand, the dosage and duration of the treatment, and the measures employed to determine tolerance (211). *Pharmacokinetic* tolerance (including changes in absorption, distribution, biotransformation and excretion) has also been documented, but apparently occurs to a lesser degree than pharmacodynamic tolerance (337). In the clinical setting, tolerance to the effects of cannabis or cannabinoids can potentially be minimized by combining lower doses of cannabis or cannabinoids along with one or more additional therapeutic drugs (338).

Tolerance to most of the effects of cannabis and cannabinoids can develop after a few doses, and it also disappears rapidly following cessation of administration (118). In normal subjects, tolerance develops to the effects of cannabis on mood, intra-ocular pressure, EEG, psychomotor performance, nausea, as well as on the cardiovascular system (212,213). There is also some evidence to suggest that tolerance can develop to the effects of cannabis on sleep (reviewed in (161)). As mentioned above, the dynamics of tolerance vary with respect to the different effects; tolerance to some of the effects develops more readily and rapidly than to others (214,215). A positron emission tomography imaging study of chronic daily cannabis smokers reported reversible and regionally selective downregulation of brain cannabinoid CB₁ receptors (339). This finding could help explain the results obtained from a previously published double-blind, randomized, placebo-controlled study which showed that subjects who reported frequently using cannabis (*frequently* being defined in this study as a positive toxicological test result for cannabis at screening, at least 10 exposures to cannabis immediately prior to study initiation, and meeting DSM-IV criteria for cannabis use disorder) displayed blunted responses to the psychotomimetic, perceptual altering, cognitive impairing, anxiogenic, and cortisol-increasing effects of THC compared to controls, but notably not to its euphoric effects (216). Another study reported that tolerance to some of the effects of cannabis, including tolerance to the "high", developed both when THC was administered orally (30 mg; four times per day; total daily dose 120 mg) (207) and when a roughly equivalent dose was given by smoking (3.1% THC cigarette; four times per day) (340). Interestingly, there was no diminution of the appetite-stimulating effect from either route of administration.

An uncontrolled, open-label extension study of an initial five-week randomized trial of nabiximols in patients with multiple sclerosis and central neuropathic pain reported the *absence* of pharmacological tolerance (measured by a change in the mean daily dosage of nabiximols), even after an almost two-year treatment period in a group of select patients (217). Another long-term, open-label extension study of nabiximols in patients with spasticity caused by multiple sclerosis echoed these findings, also reporting the *absence* of pharmacological tolerance (measured by a change in the mean daily dosage of nabiximols) after almost one year of treatment (218).

Dependence and withdrawal

Dependence can be divided into two independent, but in certain situations interrelated concepts: physical dependence and psychological dependence (i.e. addiction) (335). Physical dependence, as defined by the Liaison Committee on Pain and Addiction, is a state of adaptation manifested by a drug-class specific withdrawal syndrome that can be produced by abrupt cessation, rapid dose reduction, decreasing blood level of the drug, and/or administration of an antagonist (190). Psychological dependence (i.e. addiction) is a primary, chronic, neurobiological disease, with genetic, psychosocial, and environmental factors influencing its development and manifestations, and is characterized by behaviours that include one or more of the following: impaired control over drug use, compulsive use, continued use

despite harm, and craving (335). In the DSM-IV-TR, the term 'dependence' is closely related to the concept of addiction which may or may not include physical dependence, and is characterized by use despite harm, and loss of control over use (341).

There is evidence that cannabis dependence (physical and psychological) occurs especially with chronic, heavy use (122,156,210). The endocannabinoid system has been implicated in the acquisition and maintenance of drug taking behaviour, and in various physiological and behavioural processes associated with psychological dependence or addiction (2). Physical dependence is most often manifested in the appearance of withdrawal symptoms when use is abruptly halted or discontinued. Withdrawal symptoms associated with cessation of cannabis use (oral or smoked) appear within the first one to two days following discontinuation; peak effects typically occur between days 2 and 6 and most symptoms resolve within 1 - 2 weeks (342). The most common symptoms include anger or aggression, irritability, anxiety, nightmares/strange dreams, insomnia/sleep difficulties, craving, headache, restlessness, and decreased appetite or weight loss (156,210,222). Other symptoms appear to include depressed mood, chills, stomach pain, shakiness and sweating (156,210,222).

3.0 Dosing

General remarks

Cannabis has many variables that do not fit well with the typical medical model for drug prescribing (277). The complex pharmacology of cannabinoids, interindividual (genetic) differences in cannabinoid receptor structure and function, interindividual (genetic) differences in cannabinoid metabolism affecting cannabinoid bioavailability, prior exposure to and experience with cannabis/cannabinoids, pharmacological tolerance to cannabinoids, changes to cannabinoid receptor distribution/density and/or function as a consequence of a medical disorder, the variable potency of the cannabis plant material, and the different dosing regimens and routes of administration used in different research studies all contribute to the difficulty in reporting precise doses or establishing uniform dosing schedules for cannabis (and/or cannabinoids) (277,328).

While precise dosages have not been established, some "rough" dosing guidelines for smoked or vapourized cannabis have been published (see below). Besides smoking and vapourization, cannabis is known to be consumed in baked goods such as cookies or brownies, or drunk as teas or infusions. However, absorption of these products by the oral route is slow and erratic, and the onset of effects is delayed with the effects lasting much longer compared to smoking (see section 2.2); furthermore, dosages for orally administered products are even less well established than for smoking/vapourization (111,286,289,343). Other forms of preparation reported in the lay literature include cannabis-based butters, oils, compresses, creams, ointments, and tinctures (64,344,345,346,347) but again, no dosing information exists here and much of the information is anecdotal in nature.

Dosing remains highly individualized and relies to a great extent on titration (277). Patients with no prior experience with cannabis and initiating cannabis therapy for the first time are cautioned to begin at a very low dose and to stop therapy if unacceptable or undesirable side effects occur. Consumption of smoked/inhaled or oral cannabis should proceed slowly, waiting between puffs for a few minutes and waiting 30 - 60 min between bites of cannabis-based oral products (e.g. cookies, baked goods) to gauge for strength of effects or for possible overdosing.

Minimal therapeutic dose and dosing ranges

Information obtained from the monograph for Marinol® (dronabinol) indicates that a **daily oral dose as low as 2.5 mg Δ^9 -THC is associated with a therapeutic effect (e.g. treatment of AIDS-related anorexia/cachexia)**. Naturally, dosing will vary according to the underlying disorder and the many other variables mentioned above. Dosing ranges for Marinol® (dronabinol) vary from 2.5 mg - 40 mg Δ^9 -THC/day (174). Dosing ranges for Cesamet® (nabilone) vary from 0.2 mg - 6 mg/day (332,348). Dosing ranges for Sativex® (nabiximols) vary from one spray (2.7 mg Δ^9 -THC and 2.5 mg CBD) to 16 sprays (43.2 mg Δ^9 -THC to 40 mg CBD) per day (290,349).

Various surveys published in the peer-reviewed literature have suggested that the majority of people using smoked or orally ingested cannabis for medical purposes reported using between 10 - 20 g of cannabis per week or approximately 1 - 3 g of cannabis per day (165,277,350).

Monitoring

Currently, there are no clinical guidelines on monitoring patients who are taking cannabis for medical purposes.

3.1 Smoking

According to the World Health Organization (WHO) (351), a typical joint contains between 0.5 and 1.0 g of cannabis plant matter (average weight = 750 mg) which may vary in Δ^9 -THC content between 7.5 and 225 mg (i.e. typically between 1 and 30%; see Table 2). The amount of other cannabinoids present, mainly cannabitol (CBN) and cannabidiol (CBD), is usually much lower. The actual amount of Δ^9 -THC delivered in the smoke varies widely and has been estimated at 20 - 70%, the remainder being lost through combustion or side-stream smoke (277). Furthermore, the bioavailability of Δ^9 -THC (the fraction of Δ^9 -THC in the cigarette which reaches the bloodstream) from the smoking route is variable (2 - 56%) and influenced by the smoking topography (the number, duration, and spacing of puffs, hold time and inhalation volume) (276). In addition, expectation of drug reward can also influence smoking dynamics (352). Thus, the actual dose of Δ^9 -THC absorbed systemically when smoked is not easily quantified but has been approximated to be around 25% of the total available amount of Δ^9 -THC in a cigarette (117,277).

Relationship between a smoked dose and an oral dose

Little information exists regarding conversion of a "smoked dose" of THC to an equivalent oral dose, however multiplication of a "smoked dose" of Δ^9 -THC by a conversion factor of 2.5 (to correct for differences between the bioavailability of Δ^9 -THC through the smoked route (~25%) vs. the oral route (~10%)) can yield an approximately equivalent oral dose of Δ^9 -THC (117). The "smoked dose" can be defined as the dose, in mg, of Δ^9 -THC that is available in the *cigarette*. As an example, smoking a cigarette containing 75 mg Δ^9 -THC by weight (see Row 4 in Table 2 [10% Δ^9 -THC, 750 mg dried plant material]) would yield an estimated oral dose of 187.5 mg Δ^9 -THC (75 mg Δ^9 -THC X 2.5 = 187.5 mg Δ^9 -THC). Please consult Tables 3, 4 and 5 for further information regarding converting between smoked and oral doses of Δ^9 -THC.

Table 2: Relationship between THC Percent in Plant Material and the Available Dose (in mg THC) in an Average Joint

% THC	mg THC per 750 mg dried plant material* ("average joint")
1	7.5
2.5	18.75
5	37.5
10†	75†
15	112.5
20	150
30	225

* WHO average weight

† see text in section 3.1 for additional details

Table 3: Approximate Conversion Factors Smoked/Oral Δ^9 -THC

	To Smoked Dose†	To Oral Dose‡
From Smoked Dose†		<p>Multiply the dose of Δ^9-THC (in mg) in the dried plant material to be smoked by a factor of 2.5 to obtain the estimated dose of Δ^9-THC (in mg) to be ingested orally.</p> <p>(Smoked dose in mg X 2.5 = Oral dose in mg)</p>
From Oral Dose‡	<p>Divide the dose of Δ^9-THC (in mg) to be ingested orally by a factor of 2.5 to obtain the estimated dose of Δ^9-THC (in mg) to be smoked.</p> <p>(Oral dose in mg ÷ 2.5 = Smoked dose in mg)</p>	

† A "smoked dose" can be defined as the total available amount of Δ^9 -THC in a cannabis cigarette (calculated by multiplying the percentage of Δ^9 -THC by the total gram amount of cannabis in the cigarette).

‡ An oral dose is defined as the total amount of Δ^9 -THC that is ingested orally.

Table 4: Quick Reference of Smoked to Estimated Oral Doses of Δ^9 -THC

"Smoked Dose" [†] % THC in a 750 mg cannabis cigarette (Total available mg Δ^9 -THC)	Estimated Oral Dose (mg Δ^9 -THC) [‡]
1 % THC (7.5 mg)	18.8 mg
2 % THC (15 mg)	37.5 mg
2.5 % THC (18.8 mg)	46.8 mg
3 % THC (22.5 mg)	56.3 mg
5 % THC (37.5 mg)	93.8 mg
7.5 % THC (56.3 mg)	140.6 mg
10 % THC (75 mg)	187.5 mg
12.5% THC (93.8 mg)	234.4 mg
15 % THC (112.5 mg)	281.3 mg
20 % THC (150 mg)	375 mg

[†] A "smoked dose" is defined as the total available amount (in mg) of Δ^9 -THC in a standard cannabis cigarette (750 mg joint)

[‡] An oral dose is defined as the total amount (in mg) of orally ingested Δ^9 -THC

Numbers in the table are rounded to the nearest decimal place

Table 5: Quick Reference of Oral to Estimated Smoked Doses of Δ^9 -THC

Oral Dose† (mg Δ^9 -THC)	Estimated "Smoked Dose" ‡ (Total available mg Δ^9 -THC in the dried plant material in the cigarette)
0.25	0.1
0.5	0.2
0.75	0.3
1	0.4
1.25	0.5
1.5	0.6
1.75	0.7
2	0.8
2.25	0.9
2.5	1
2.75	1.1
3	1.2
3.25	1.3
3.5	1.4
3.75	1.5
4	1.6
4.25	1.7
4.5	1.8
4.75	1.9
5	2
6	2.4
7	2.8
8	3.2
9	3.6
10	4
15	6
20	8
25	10
30	12
40	16
50	20
75	30
100	40

† An oral dose is defined as the total amount (in mg) of orally ingested Δ^9 -THC

‡ A "smoked dose" is defined as the total available amount (in mg) of Δ^9 -THC in a standard cannabis cigarette (750 mg joint)

Numbers in the table are rounded to the nearest decimal place

Table 6: Comparison between Cannabis and Prescription Cannabinoid Medications

Rx cannabinoids	Cannabinoid (Generic name)	Registered name	Principal constituents/ Source	Official status in Canada	Approved indications	Onset (O)/ Duration of action (D)	Route of admin.	Availability on provincial/ territorial formulary
	Dronabinol†	Marinol®†	Synthetic Δ^9 -THC	Approved†	AIDS-related anorexia associated with weight loss; Severe nausea and vomiting associated with cancer chemotherapy	O: 30 - 60 min D: 4 - 6 h	Oral	MB†; NB†; NS†; ON†; PE†; QC†; YT†
	Nabilone	Cesamet®	Synthetic Δ^9 -THC analogue	Approved	Severe nausea and vomiting associated with cancer chemotherapy	O: 60 - 90 min D: 8 - 12 h	Oral	AB; BC; MB; NB; NL; NS; NT; NU; ON; PE; QC; SK; YT.
	Nabiximols (THC+CBD and other minor cannabinoids, terpenoids, and flavonoids)	Sativex®	Botanical extract from established and well-characterized <i>C. sativa</i> strains	Approved *	*	O: 15 - 40 min D: 2 - 4 h	Oro-mucosal spray	NS.
Plant product	Cannabis (smoked)	N/A	<i>C. sativa</i> (various)	Not an approved product	N/A	O: 5 min D: 2 - 4 h	Smoking	N/A
	Cannabis (vaporized)	N/A	<i>C. sativa</i> (various)	Not an approved product	N/A	O: 5 min D: 2 - 4 h	Inhalation by vaporizer	N/A
	Cannabis (oral edible)	N/A	<i>C. sativa</i> (various)	Not an approved product	N/A	O: 30 - 60 min D: 8 - 12 h	Oral	N/A
	Cannabis (topical)	N/A	<i>C. sativa</i> (various)	Not an approved product	N/A	N/A	Topical	N/A

† Product has been discontinued by the manufacturer (post-market; as of February 2012; not for safety reasons)

* For Sativex®, the following marketing authorizations apply:

Standard marketing authorization: Adjunctive treatment for symptomatic relief of spasticity in adult patients with multiple sclerosis who have not responded adequately to other therapy and who demonstrate meaningful improvement during an initial trial of therapy.

Marketing authorization with conditions: Adjunctive treatment for symptomatic relief of neuropathic pain in adult patients with multiple sclerosis; and adjunctive analgesic treatment in adult patients with advanced cancer who experience moderate to severe pain during the highest tolerated dose of strong opioid therapy for persistent background pain.

Plasma concentrations of Δ^9 -THC following smoking

Using a paced smoking protocol, the mean plasma concentration of Δ^9 -THC after a first inhalation of a cannabis cigarette containing 3.55% Δ^9 -THC has been reported to be 18.1 ng/mL (range: 1.8 - 37.0 ng/mL), with the mean peak plasma concentration of Δ^9 -THC reaching 162 ng/mL (range: 76 - 267 ng/mL) after seven puffs or almost complete smoking of the cigarette (276,328). Peak plasma concentrations of Δ^9 -THC in the range of 50 - 100 ng/mL are associated with a subjective "high" ((279) and section 2.3) and can be easily attained by smoking a single 3.55% Δ^9 -THC cannabis cigarette (900 mg plant material, 32 mg total available Δ^9 -THC) (328). If the current average "street" marijuana contains 10% THC, joints from such a source might have an available 75 mg dose of Δ^9 -THC and could result in rapid attainment of elevated plasma Δ^9 -THC concentrations (> 100 ng/mL Δ^9 -THC). More potent strains of cannabis could yield even higher plasma concentrations of THC.

Plasma concentrations of Δ^9 -THC following smoking, and therapeutic efficacy

There are a small number of efficacy studies on the amounts of cannabis required for therapeutic effects (see Table 7 for a quick overview, and information throughout this document for more detailed information). A Canadian dose-ranging study showed that a single inhalation of a 25 mg dose of smoked cannabis (Δ^9 -THC content 9.4%; total available dose of Δ^9 -THC = 2.35 mg) yielded a mean plasma Δ^9 -THC concentration of 45 ng/mL within 2 min after initiating smoking (172). The study reported improvements in sleep and pain relief in patients suffering from chronic neuropathic pain (172). Using the above-mentioned conversion formula to translate smoked to estimated oral doses of Δ^9 -THC, 2.35 mg Δ^9 -THC in the dried plant material would correspond to an estimated oral dose of 5.9 mg Δ^9 -THC.

Please consult Tables 3, 4 and 5 for further information regarding converting between smoked and oral doses of Δ^9 -THC. Please consult Table 7 for a list of clinical trials of smoked cannabis and general details regarding those trials.

3.2 Oral

The pharmacokinetic information described in section 2.2.1.3 reports the erratic and slow absorption of Δ^9 -THC from the oral route, and oral doses are estimated from the information in the monograph for Marinol® (dronabinol). A 10 mg b.i.d. dose of Marinol® (20 mg total Δ^9 -THC per day) yielded a mean peak plasma Δ^9 -THC concentration of 7.88 ng/mL (range: 3.33 - 12.42 ng/mL), with a bioavailability ranging between 10 and 20% (174). By comparison, consumption of a chocolate cookie containing 20 mg Δ^9 -THC resulted in a mean peak plasma Δ^9 -THC concentration of 7.5 ng/mL (range: 4.4 - 11 ng/mL), with a bioavailability of 6% (278). Tea prepared from *Cannabis* flowering tops and leaves has been documented, but no data are available regarding efficacy (289). To convert an oral dose to an estimated "smoked dose", the oral dose is divided by a conversion factor of 2.5 (117). Thus, an oral dose of 20 mg Δ^9 -THC would be approximately equivalent to a "smoked dose" of 8 mg of Δ^9 -THC. Please consult Tables 3, 4 and 5 for further information regarding converting oral to smoked doses of Δ^9 -THC.

Marinol

The Marinol® (dronabinol) product monograph suggests a mean of 5 mg Δ^9 -THC/day (range: 2.5 - 20 mg Δ^9 -THC/day) for AIDS-related anorexia associated with weight loss (174). A 2.5 mg dose may be administered before lunch, followed by a second 2.5 mg dose before supper. On the other hand, to reduce or prevent cancer chemotherapy-induced nausea or vomiting, a dosage of 5 mg t.i.d. or q.i.d. is suggested (174). In either case, the dose should be carefully titrated to avoid the manifestation of adverse effects. Please consult the drug product monograph for more detailed instructions.

Cesamet

The Cesamet® (nabilone) product monograph suggests administration of 1 - 2 mg of the drug, twice a day, with the first dose given the night before administration of the chemotherapeutic medication (332). A 2 mg dose of nabilone gave a mean plasma concentration of 10 ng/mL nabilone, 1 - 2 h after administration (332). The second dose is usually administered 1 - 3 h before chemotherapy. If required, the administration of nabilone can be continued up to 24 h after the chemotherapeutic agent is given. The maximum recommended daily dose is 6 mg in divided doses. Dose adjustment (titration) may be required in order to attain the desired response, or to improve tolerability. More recent clinical trials report starting doses of nabilone of 0.5 mg at night for pain or insomnia in fibromyalgia, and for insomnia in post-traumatic stress disorder (348,353,354). Please consult the drug product monograph for more detailed instructions.

3.3 Oro-mucosal

Dosing with nabiximols (Sativex[®]) is described in the product monograph along with a titration method for proper treatment initiation (290). Briefly, dosing indications in the drug product monograph suggest that on the first day of treatment patients take one spray during the morning (anytime between waking and noon), and another in the afternoon/evening (anytime between 4 pm and bedtime). On subsequent days, the number of sprays can be increased by one spray per day, as needed and tolerated. A fifteen minute time gap should be allowed between sprays. During the initial titration, sprays should be evenly spread out over the day. If at any time unacceptable adverse reactions such as dizziness or other CNS-type reactions develop, dosing should be suspended or reduced or the dosing schedule changed to increase the time intervals between doses. According to the product monograph, the average dose of nabiximols is five sprays per day (i.e. 13 mg Δ^9 -THC and 12.5 mg CBD) for patients with multiple sclerosis, whereas those patients with cancer pain tend to use an average of eight sprays per day (i.e. 21.6 mg Δ^9 -THC and 20 mg CBD) (290). The majority of patients appear to require 12 sprays or less; dosage should be adjusted as needed and tolerated (290). Administration of four sprays to healthy volunteers (total 10.8 mg Δ^9 -THC and 10 mg CBD) was associated with a mean maximum plasma concentration varying between 4.90 - 6.14 ng/mL Δ^9 -THC and 2.50 - 3.02 ng/mL CBD depending whether the drug was administered under the tongue or inside the cheek. Please consult the product monograph for more detailed information.

3.4 Vapourization

The Dutch Office of Medicinal Cannabis has published "rough" guidelines on the use of vapourizers (289). Although the amount of cannabis used per day needs to be determined on an individual basis, the initial dosage should be low and may be increased slowly as symptoms indicate. The amount of cannabis to be placed in the vapourizer may vary depending on the type of vapourizer used. Studies using the Volcano[®] vapourizer have reported using up to 1 g of dried cannabis in the chamber, but 50 to 500 mg of plant material is typically used (284); Δ^9 -THC concentrations up to 6.8% have been tested (273,284). Subjects appeared to self-titrate their intake in accordance with the Δ^9 -THC content of the cannabis (273). Peak plasma Δ^9 -THC levels varied between 70 - 190 ng/mL depending on the strength of Δ^9 -THC. The levels of cannabinoids released into the vapour phase increased with the temperature of vapourization (284). Vapourization temperature is typically between 180 - 195°C (289); higher temperatures (e.g. 230°C) greatly increase the amounts of cannabinoids released, but also increase the amounts of by-products (284).

4.0 Potential Therapeutic Uses

While there are many anecdotal reports concerning the therapeutic value of cannabis, clinical studies supporting the safety and efficacy of smoked cannabis for therapeutic purposes in a variety of disorders are limited, but slowly increasing in number. There are no clinical studies on the use of cannabis edibles (e.g. cookies, baked goods) or topicals for therapeutic purposes. It has been repeatedly noted that the psychotropic side effects associated with the use of cannabinoids have been found to limit their therapeutic utility (21,48,50,185,355). Table 7 summarizes the information on published clinical trials that have been carried out thus far using smoked/vapourized cannabis.

Dronabinol is the generic name for the oral form of synthetic Δ^9 -THC and is marketed in the U.S. and Canada as Marinol[®]. It is sold in capsules containing 2.5, 5, or 10 mg of the drug dissolved in sesame oil. It is indicated for the treatment of severe nausea and vomiting associated with cancer chemotherapy, and for AIDS-related anorexia associated with weight loss (174). The drug appears to no longer be sold in Canada (post-market discontinuation of the drug product as of February 2012; not for safety reasons).

Nabilone is the generic name for an orally administered synthetic structural analogue of Δ^9 -THC which is marketed in Canada as Cesamet[®]. It is sold as capsules (0.25, 0.5, 1 mg) and is indicated for severe nausea and vomiting associated with cancer chemotherapy (332).

Nabiximols is the generic name for a whole-plant extract of two different, but standardized, strains of *Cannabis sativa* giving an oro-mucosal spray product containing approximately equivalent amounts of Δ^9 -THC (27 mg/mL) and CBD (25 mg/mL), and other cannabinoids, terpenoids, and flavonoids per 100 μ l of dispensed spray. Nabiximols is marketed as Sativex[®] in Canada and has received a notice of compliance for use as an adjunctive treatment for the symptomatic relief of spasticity in adult patients with multiple sclerosis who have not responded adequately to other therapy, and who demonstrate meaningful improvement during an initial trial of therapy. It is also marketed (with conditions) as an adjunctive treatment for the symptomatic relief of neuropathic pain in adults with multiple sclerosis and (with conditions) as an adjunctive analgesic in adult patients with advanced

cancer who experience moderate to severe pain during the highest tolerated dose of strong opioid therapy for persistent background pain (290).

The existing scientific and clinical evidence for cannabis and certain cannabinoids in treating various symptoms associated with various medical conditions is summarized in the following sections beginning on the next page.

Table 7: Published Clinical Trials on Smoked/Vapourized Cannabis and Associated Therapeutic Benefits

Primary medical conditions and associated secondary end-points (if any) for which benefits were observed	Percent and dose of Δ^9 -THC (if known)	Trial duration; and number of patients/participants	Reference
HIV/AIDS-associated weight loss	1 cannabis cigarette (~800 mg) containing 1.8% or 3.9% THC by weight, smoked once daily (i.e. one dose per day) (~14-31 mg Δ^9 -THC /day)	8 sessions total (3 sessions per week); 30 participants	(166)
HIV/AIDS-associated weight loss; disease-associated mood and insomnia	1 cannabis cigarette (~800 mg) containing 2.0% or 3.9% THC by weight, smoked four times per day (i.e. 4 doses per day) (~64-125 mg of Δ^9 -THC /day)	4 days total; 10 participants	(167)
Multiple sclerosis-associated pain and spasticity	1 cannabis cigarette (~800 mg) containing 4% THC by weight, smoked once per day (i.e. one dose per day) (~32 mg Δ^9 -THC /day)	3 days total; 30 patients	(188)
Central and peripheral chronic neuropathic pain (various etiologies)	1 cannabis cigarette (~800 mg) containing either 3.5% or 7% THC by weight, smoked in bouts over a 3 h period (i.e. one dose per day)	1 day total; 38 patients	(168)
Chronic neuropathic pain from HIV-associated sensory neuropathy	1 cannabis cigarette (~900 mg) containing 3.56% THC by weight, smoked three times daily (i.e. 3 doses per day) (~96 mg Δ^9 -THC /day)	5 days total; 25 patients	(142)
HIV-associated chronic neuropathic pain refractory to other medications	1 cannabis cigarette (~800 mg) containing between 1 and 8% THC by weight, smoked four times daily (i.e. 4 doses per day)	5 days total; 28 patients	(186)
Chronic post-traumatic or post-surgical neuropathic pain refractory to other medications and associated insomnia	One 25 mg dose of cannabis containing 9.4% THC by weight, smoked three times daily (i.e. three doses per day) (~7 mg Δ^9 -THC /day)	5 days total; 21 patients	(172)
Chronic pain of various etiologies (musculoskeletal, post-traumatic, arthritic, peripheral neuropathy, cancer, fibromyalgia, migraine, multiple sclerosis, sickle cell disease, thoracic outlet syndrome)	One 0.9 g dose of vapourized cannabis containing 3.56% THC by weight administered three times per day (one dose the first day, three doses per day for next three days, one dose the last day) (~96 mg Δ^9 -THC /day)	5 days total; 21 patients	(187)

4.1 Palliative Care

Among the goals of palliative care described by the World Health Organization (WHO) are relief from pain and other distressing symptoms, and the enhancement of quality of life (356). While integration of cannabis into mainstream medical use can be characterized as extremely cautious, its use appears to be gaining some ground in palliative care settings where the focus is on individual choice, patient autonomy, empowerment, comfort and especially quality of life (357). Nevertheless, establishing the effectiveness of cannabis as a viable treatment option in a palliative care context requires a careful assessment of its effects in a wide range of conditions; such evidence is not yet abundant and further research is needed (358). Furthermore, while prescription cannabinoids demonstrate an acceptable safety profile according to some studies for certain medical conditions, the use of cannabis and cannabinoids in the clinic is known to be limited by their psychotropic effects (21,209,359). Certain patient populations (e.g. the elderly or those suffering from pre-existing psychiatric disease) may be also be more sensitive or susceptible to experiencing adverse psychotropic, cognitive, psychiatric or other effects (359,360).

The evidence thus far suggests that cannabis and prescription cannabinoids (e.g. dronabinol, nabilone, or nabiximols) may be useful in alleviating a wide variety of single or co-occurring symptoms often encountered in the palliative care setting; these symptoms include intractable nausea and vomiting associated with chemotherapy or radiotherapy, anorexia/cachexia, severe intractable pain, severe depressed mood, and insomnia (208,209). The use of cannabinoids for palliative care may also result in a decrease in the number of medications used by this patient population (208).

For information on the use of cannabis/cannabinoids for the **control of nausea and vomiting** please consult section 4.2 of this document. For additional information on the use of cannabis/cannabinoids for **anorexia/cachexia associated with HIV/AIDS infection or cancer** please consult sections 4.3.1 and 4.3.2, respectively. For further information on the use of cannabis/cannabinoids for **chronic pain syndromes** (including cancer pain) please consult sections 4.6.2.2 and 4.6.2.3. For further information on the use of cannabis/cannabinoids in the treatment of **sleep disorders associated with chronic diseases** please see section 4.8.5.2, and please consult section 4.8.9 for information on the use of cannabis/cannabinoids in **oncology**.

Quality of Life

A handful of clinical studies have used standardized quality-of-life (QoL) instruments to measure whether the use of cannabis or prescription cannabinoids (e.g. nabilone, dronabinol, or nabiximols) is associated with improvements in QoL. The available studies report mixed effects of cannabis and cannabinoids on measures of QoL for a variety of different disorders. The evidence from these studies is summarized below.

Clinical studies with dronabinol

A randomized, double-blind, placebo-controlled, crossover trial of dronabinol (maximum dose of 10 mg Δ^9 -THC per day, for a total of three weeks) for the treatment of central neuropathic pain in patients suffering from multiple sclerosis reported statistically significant improvements in measures of QoL (SF-36 quality of life questionnaire; measures for bodily pain and mental health) (361).

A two-centre, phase II, randomized, double-blind, placebo-controlled 22-day pilot study carried out in adult patients suffering from chemosensory alterations (i.e. changes in olfaction and gustation) and poor appetite associated with advanced cancer of various etiologies reported improved and enhanced chemosensory perception among patients treated with dronabinol (2.5 mg b.i.d.) compared to those receiving placebo (362). The majority (73%) of dronabinol-treated patients self-reported an increased overall appreciation of food compared to those receiving placebo (30%). While global scores on the Functional Assessment of Anorexia-Cachexia Therapy (FAACT) QoL instrument improved to a similar extent for dronabinol and placebo-treated groups, the FAACT sub-domain for anorexia-cachexia-related nutritional well-being improved with dronabinol compared to placebo (362). Statistically significant improvements were also noted for quality of sleep and relaxation with dronabinol treatment compared to placebo (362). According to the study authors, negative psychoactive effects were minimized by starting patients at a low dose (2.5 mg once a day for three days) followed by gradual dose escalation (up to a maximum of 7.5 mg dronabinol per day) (362).

Clinical studies with cannabis extract

A multi-centre, phase III, randomized, double-blind, placebo-controlled, three-arm, parallel study in adult patients with advanced incurable cancer and suffering from cancer-related anorexia-cachexia syndrome concluded that neither cannabis extract (2.5 mg Δ^9 -THC, 1 mg CBD, for six weeks) nor THC (2.5 mg Δ^9 -THC b.i.d., for six weeks) provided any statistically significant benefit compared to placebo on measures of QoL (EORTC QLQ-C30) (363).

Clinical studies with nabilone

A randomized, double-blind, placebo-controlled trial of nabilone in patients suffering from fibromyalgia reported that adjuvant nabilone therapy (four weeks; maximum dose in the final week of treatment: 1 mg b.i.d.) was associated with a significant improvement in measures of QoL (Visual Analogue Scale for pain, and the Fibromyalgia Impact Questionnaire) (353). An enriched-enrolment, randomized withdrawal, flexible-dose, double-blind, placebo-controlled, parallel-assignment efficacy study of nabilone as an adjuvant in the treatment of long-standing diabetic peripheral neuropathic pain reported statistically significant improvements in measures of QoL (Composite EQ-5D Index Score) and overall patient status compared to placebo (364). Doses of nabilone ranged from 1 - 4 mg/day; treatment duration was five weeks (364).

Clinical studies with nabiximols

A ten-week, prospective, randomized, double-blind, placebo-controlled trial assessing the safety and efficacy of nabiximols (Sativex®) as an adjunctive medication in the treatment of intractable diabetic peripheral neuropathy concluded that nabiximols failed to show statistically significant improvements in measures of QoL (EuroQOL, SF-36, and the McGill Pain and QOL Questionnaire) (365). A twelve-week, double-blind, randomized, placebo-controlled, parallel-group, enriched enrolment study of nabiximols as add-on therapy for patients with refractory spasticity concluded that there was no significant difference between active treatment and placebo on measures of QoL (EQ-5D Health State Index, EQ-5D Health Status VAS, SF-36) (366). A five-week, multi-centre, randomized, double-blind, placebo-controlled, parallel-group, graded-dose study evaluated the analgesic efficacy and safety of nabiximols in three dose ranges in opioid-treated cancer patients with poorly-controlled chronic pain (349). The study reported the lack of any positive treatment effects on overall QoL in this study population even at the highest doses of nabiximols (11 - 16 sprays per day) (349).

Clinical studies with smoked cannabis

A randomized, double-blind, placebo-controlled, four-period, cross-over trial of smoked cannabis in the treatment of chronic neuropathic pain (chronic post-traumatic or post-surgical etiology) concluded that inhalation of smoked cannabis (25 mg of cannabis containing 2.5, 6.0, or 9.4% Δ^9 -THC, t.i.d. for five days) was not associated with a statistically significant difference compared to placebo on measures of QoL (EQ-5D Health Outcomes Quality of Life instrument) (172). In contrast, a cross-sectional survey examining the benefits associated with cannabis use in patients with fibromyalgia reported a statistically significant benefit in the mental health component summary score of the SF-36 Quality of Life questionnaire in patients who used cannabis compared to non-users (158). However, no significant differences between cannabis and non-cannabis users were found in the other SF-36 domains, in the Fibromyalgia Impact Questionnaire, or the Pittsburgh Sleep Quality Index (158).

A preliminary observational, open-label, prospective, single-arm trial in a group of 13 patients suffering from Crohn's disease or ulcerative colitis reported that treatment with inhaled cannabis over a three-month period improved subjects' quality of life, caused a statistically significant increase in subjects' weight, and improved the clinical disease activity index in patients with Crohn's disease (189). Patients reported a statistically significant improvement in their perception of their general health status, their ability to perform daily activities, and their ability to maintain a social life (189). Patients also reported a statistically significant reduction in physical pain as well as improvement in mental distress (189).

4.2 Nausea and vomiting

Chemotherapy-induced nausea and vomiting (CINV) is one of the most distressing and common adverse events associated with cancer treatment (367). While chemotherapy-induced vomiting generally appears to be well-controlled with current first-line therapies, the associated acute, delayed, or anticipatory nausea remain more poorly controlled and the use of cannabis/cannabinoids may provide some measure of benefit in certain cases (88,192). It is important to note that excessive use of cannabis has been reported to paradoxically trigger a chronic cyclic vomiting syndrome (i.e. hyperemesis) (see section 7.6.1 for further details on this syndrome).

Pre-clinical studies

Patient claims that smoked cannabis relieves CINV are widely recognized, and increasing evidence suggests a role for the endocannabinoid system in the regulation of nausea and vomiting (88). Cannabinoid CB₁ and CB₂ receptors have been found in areas of the brainstem associated with emetogenic control (368,369), and results from animal studies suggest the anti-nausea and anti-emetic properties of cannabinoids (e.g. Δ^9 -THC, dronabinol, nabilone) are most likely related to their agonistic actions at CB₁ receptors (80,88,370). An *in vivo* animal study and one small clinical study

have also suggested Δ^8 -THC to be a more potent anti-emetic than Δ^9 -THC (80,81). In addition to its actions at CB₁ receptors, an *in vitro* study has also shown that Δ^9 -THC antagonizes the 5-HT₃ receptor (371), a target of standard anti-emetic drugs, raising the possibility that cannabinoids may exert their anti-emetic action through more than one mechanism. More recently, studies carried out in animal models of nausea and vomiting have shown that cannabidiol (5 mg/kg, s.c.) suppressed nicotine, lithium chloride, and cisplatin-induced vomiting in the shrew; lithium chloride-induced conditioned gaping was suppressed in rats through a yet-to-be identified, but probably indirect, activation of somatodendritic 5-HT_{1A} autoreceptors located in the dorsal raphe nucleus (372). Another study showed that the anti-nausea/vomiting effects of cannabidiol could be reversed by pre-treatment with cannabigerol (5 mg/kg, i.p.) (373).

Clinical studies

The evidence for cannabinoids such as nabilone (Cesamet[®]), dronabinol (Marinol[®]), and levonantradol in treating CINV has been reviewed (159,374). While cannabinoids present clear advantages over placebo in the control of CINV, the evidence from randomized clinical trials shows cannabinoids to be clinically only slightly better than conventional dopamine D₂-receptor antagonist anti-emetics (159,374). In some cases, patients appeared to prefer the cannabinoids over these conventional therapies despite the increased incidence of adverse effects such as drowsiness, dizziness, dysphoria, depression, hallucinations, paranoia, and arterial hypotension. This may be explained in part by the notion that for certain patients a degree of sedation and euphoria may be perceived as beneficial during chemotherapy.

While no peer-reviewed clinical trials of smoked cannabis for the treatment of CINV exist, Musty and Rossi have published a review of U.S. state clinical trials on the subject (191). Patients who smoked cannabis showed a 70 - 100% relief from nausea and vomiting, while those who used a Δ^9 -THC capsule experienced 76 - 88% relief (191). Plasma levels of > 10 ng/mL Δ^9 -THC were associated with the greatest suppression of nausea and vomiting, although levels ranging between 5 and 10 ng/mL were also effective (191). In all cases, patients were admitted only after they failed treatment with standard phenothiazine anti-emetics. A small clinical trial comparing smoked cannabis (2.11% Δ^9 -THC, in doses of 8.4 mg or 16.9 mg Δ^9 -THC; 0.30% cannabiniol; 0.05% cannabidiol) to ondansetron (8 mg) in ipecac-induced nausea and vomiting in healthy volunteers showed that both doses of Δ^9 -THC reduced subjective ratings of queasiness and objective measures of vomiting; however, the effects were very modest compared to ondansetron (192). Furthermore, only cannabis produced changes in mood and subjective state.

Few, if any, clinical trials directly comparing cannabinoids to newer anti-emetics such as 5-HT₃ (Ondansetron, Granisetron) or NK-1 receptor antagonists have been reported to date (367,374). In one clinical study with a small sample size, ondansetron and dronabinol (2.5 mg Δ^9 -THC first day, 10 mg second day, 10 - 20 mg thereafter) provided equal relief of delayed CINV, and the combination of dronabinol and ondansetron did not provide added benefit beyond that observed with either agent alone (375). However, two animal studies showed that low doses of Δ^9 -THC, when combined with low doses of the 5-HT₃ receptor antagonists ondansetron or tropisetron, were more efficacious in reducing nausea and emesis frequency than when administered individually (376,377). More research is required to determine if combination therapy provides added benefits above those observed with newer standard treatments.

The use of cannabinoids (whether administered orally or by smoking cannabis) is currently considered a fourth-line adjunctive therapy in CINV when conventional anti-emetic therapies have failed (285,378,379,380,381,382). Nabilone (Cesamet[®]) and dronabinol (Marinol[®]) are indicated for the management of severe nausea and vomiting associated with cancer chemotherapy (174,332). Nabilone may be administered orally every 12 h at dosages ranging from 1 - 2 mg, whereas dronabinol may be administered every 6 - 8 h orally, rectally, or sub-lingually at doses ranging from 5 - 10 mg (208,383).

The current Marihuana Medical Access Regulations (MMAR) allow the use of dried marihuana in the context of cancer chemotherapy-associated nausea and vomiting as well as nausea and vomiting associated with HIV/AIDS infection in patients who have either not benefited from, or would not be considered to benefit from, conventional treatments (384).

4.3 Wasting syndrome (cachexia, e.g., from tissue injury by infection or tumour) and loss of appetite (anorexia) in AIDS and cancer patients, and anorexia nervosa

The ability of cannabis to increase appetite has been recognized anecdotally for many years (206). In addition, results from epidemiological studies suggest that people actively using cannabis have higher intakes of energy and nutrients than non-users (385). Controlled laboratory studies with healthy subjects suggest exposure to cannabis, whether by inhalation or oral ingestion of Δ^9 -THC-containing capsules, correlates positively with an increase in food consumption, caloric intake, and body weight (205,206). Studies showing a high concentration of CB₁ receptors in brain areas associated with control of food intake and satiety lend further support to the link between cannabis consumption and appetite regulation (386,387,388). Furthermore, increasing evidence suggests a role for the endocannabinoid system not only in modulating appetite, food palatability, and intake, but also in energy metabolism and the modulation of both lipid and glucose metabolism (reviewed in (17,387,388,389)).

4.3.1 To stimulate appetite and produce weight gain in AIDS patients

The ability of cannabis to stimulate appetite and food intake has been applied to clinical situations where weight gain is deemed beneficial such as in HIV-associated muscle wasting and weight loss. One study (166) showed that experienced HIV+ cannabis smokers with clinically significant muscle mass loss benefited from both dronabinol (four to eight times the standard 2.5 mg Δ^9 -THC b.i.d dose, or 10 - 20 mg Δ^9 -THC daily, three times per week for a total of eight sessions) and smoked cannabis (three puffs at 40 sec intervals; ~800 mg cigarettes containing 1.8 - 3.9% THC giving an estimated total daily amount of 14.4 mg - 31.2 mg THC *in the cigarette*, three times per week, for a total of eight study sessions). A subsequent study employed even higher doses of dronabinol (20 - 40 mg total Δ^9 -THC daily, for a total of four days) and smoked cannabis (~800 mg cannabis cigarettes containing 2 and 3.0% THC, administered four times per day, giving an estimated 64 - 125 mg total Δ^9 -THC daily *in the cigarette*, for a total of four days) (167). Both drugs produced substantial and comparable increases in food intake and body weight, as well as improvements in mood and sleep (166,167). The cannabis-associated increase in body weight appeared to result from an increase in body fat rather than lean muscle mass (390,391). On the other hand, a randomized, open-label, multi-center study to assess the safety and pharmacokinetics of dronabinol and megestrol acetate (an orexigenic), alone or in combination, found that only the high-dose megestrol acetate treatment alone (750 mg/day), but not dronabinol (2.5 mg b.i.d, 5 mg total Δ^9 -THC/day) alone or the combination of low-dose megestrol acetate (250 mg/day) and dronabinol (2.5 mg b.i.d, 5 mg total Δ^9 -THC/day), produced a significant increase in mean weight over 12 weeks of treatment in patients diagnosed with HIV-associated wasting syndrome (392). The lack of an observed clinical effect in this study could have been caused by too low a dose of dronabinol.

AIDS-related anorexia associated with weight loss is an approved indication in Canada for dronabinol (Marinol[®]). The Marinol[®] product monograph summarizes a six-week, randomized, double-blind, placebo controlled-trial in 139 patients, with the 72 patients in the treatment group initially receiving 2.5 mg dronabinol twice a day, then reducing the dose to 2.5 mg at bedtime due to side effects (feeling high, dizziness, confusion and somnolence) (393). Over the treatment period, dronabinol significantly increased appetite, with a trend towards improved body-weight and mood and a decrease in nausea. At the end of the six-week period, patients were allowed to continue receiving dronabinol, during which appetite continued to improve (394). This secondary, open-label, 12 month follow-up study suggested that dronabinol was safe and effective for long-term use for the treatment of anorexia associated with weight loss in patients with AIDS (394). The use of higher doses of dronabinol (20 mg - 40 mg per day) has been reported both in the Marinol[®] product monograph (174) as well as in the literature (166,167). However, caution should be exercised in escalating dosage because of the increased frequency of dose-related adverse effects.

The current Marihuana Medical Access Regulations (MMAR) allow the use of dried marihuana in the context of HIV/AIDS-associated anorexia, cachexia, and weight loss in patients who have either not benefited from, or would not be considered to benefit from, conventional treatments (384).

4.3.2 To stimulate appetite and produce weight gain in cancer patients

Anorexia is ranked as one of the more troublesome symptoms associated with cancer, with more than half of patients with advanced cancer experiencing a lack of appetite and/or weight loss (395,396). While it is anecdotally known that smoking cannabis can stimulate appetite, the effects of smoking cannabis on appetite and weight gain in patients with cancer cachexia have not been studied. The results from trials with oral Δ^9 -THC (dronabinol) or

oral cannabis extract are mixed and the effects, if any, appear to be modest. In two early studies, oral THC (dronabinol) improved appetite and food intake in some patients undergoing cancer chemotherapy (397,398). An open-label study of dronabinol (2.5 mg Δ^9 -THC, two to three times daily, four to six weeks) in patients with unresectable or advanced cancer reported increases in appetite and food intake, but weight gain was only achieved in a few patients (399,400). Modest weight gain was obtained with a larger dosing regimen of dronabinol (5 mg t.i.d.), but the CNS side effects including dizziness and somnolence were limiting factors (401). In contrast, a randomized, double-blind, placebo-controlled study involving cancer patients with related anorexia-cachexia syndrome failed to demonstrate any differences in patients' appetite across treatment categories (oral cannabis extract, Δ^9 -THC, or placebo) (363). Furthermore, when compared to megestrol acetate, an orexigenic medication, dronabinol was significantly less efficacious in reported appetite improvement and weight gain (402). According to a recent review of the medical management of cancer cachexia, the current level of evidence for cannabinoids (e.g. dronabinol) in the treatment of this condition is low (403).

A two-centre, phase II, randomized, double-blind, placebo-controlled, 22-day pilot study carried out in adult patients suffering from advanced cancer reported improved and enhanced chemosensory perception among patients treated with dronabinol (2.5 mg Δ^9 -THC b.i.d.) compared to those receiving placebo (362). The majority (73%) of dronabinol-treated patients self-reported an increased overall appreciation of food compared to those receiving placebo (30%). Similarly, the majority of dronabinol-treated patients (64%) reported increased appetite, whereas the majority of patients receiving placebo reported either decreased appetite (50%) or no change (20%). Total caloric intake per kilogram body weight did not differ significantly between treatment groups but did increase in both groups compared to baseline. Furthermore, compared to placebo, dronabinol-treated patients reported an increase in their protein intake as a proportion of total energy. According to the study authors, negative psychoactive effects were minimized by starting patients at a low dose (2.5 mg Δ^9 -THC once a day, for three days) followed by gradual dose escalation (up to a maximum of 7.5 mg dronabinol per day) (362).

Cancer cachexia is not an approved indication for dronabinol either in Canada or the U.S. The current Marihuana Medical Access Regulations (MMAR) allow the use of dried marihuana in the context of anorexia, cachexia and weight loss associated with cancer in patients who have either not benefited from, or would not be considered to benefit from, conventional treatments (384).

4.3.3 Anorexia nervosa

The endocannabinoid system has been implicated in appetite regulation and is suspected to play a role in eating disorders such as anorexia nervosa (387,404). However, genetic studies have thus far failed to agree on an association between genes coding for endocannabinoid system proteins and the manifestation of anorexia nervosa, in spite of epidemiological and familial studies which suggest a genetic basis for this disorder (405,406).

Little information exists on the use of cannabinoids to treat anorexia nervosa. Inter- and intra-species differences in animals with respect to anorexia nervosa-like behaviour have to some extent hampered research on the effects of Δ^9 -THC in this disorder. One study in a mouse model of anorexia nervosa reported conflicting results (407), while another study in a rat model reported a significant attenuation in weight loss only at high doses of Δ^9 -THC (2.0 mg/kg/day Δ^9 -THC) (408). A small, randomized, crossover trial of oral THC in female anorexic patients suggested that Δ^9 -THC produced a weight gain equivalent to the active placebo (diazepam) (409). Δ^9 -THC was administered in daily doses increasing from 7.5 mg (2.5 mg, t.i.d.) to a maximum of 30 mg (10 mg, t.i.d.), 90 min before meals, for a period of two weeks. Three of the eleven patients administered Δ^9 -THC also reported severe dysphoric reactions, withdrawing from the study. Another small clinical study of 15 patients with dementia of the Alzheimer-type reported increases in body weight, but no change in caloric intake with dronabinol (2.5 mg Δ^9 -THC, b.i.d.) compared to placebo (410). However, the study suffered from a number of limitations and the results should be interpreted with caution. No studies have examined the effects of smoking cannabis on anorexia nervosa. Both the British Medical Association (115) and the Institute of Medicine (378) concluded that cannabis was unlikely to be effective in patients with anorexia nervosa; however, further research may be warranted.

4.4 Multiple sclerosis, amyotrophic lateral sclerosis, spinal cord injury

Anecdotal reports suggest cannabis can ameliorate spasticity in patients suffering from multiple sclerosis or spinal cord injury when other drugs fail or produce unacceptable side effects (115,378,411,412,413).

4.4.1 Multiple sclerosis

A number of studies, both in patients suffering from multiple sclerosis (MS) and in animal models of the disease, suggest the disorder is associated with changes in endocannabinoid levels, although the findings are conflicting (414,415,416,417).

Pre-clinical studies

Pre-clinical studies across different animal species suggest cannabinoids improve the signs of motor dysfunction in experimental models of MS (reviewed in (418)). Lyman was one of the first to report the effects of Δ^9 -THC in one such model (419). In that study, affected animals treated with Δ^9 -THC either had no clinical signs of the disorder or showed mild clinical signs with delayed onset (419). The treated animals also typically had a marked reduction in central nervous system tissue inflammation compared to untreated animals (419). Subsequent studies in murine models of MS have supported and extended these findings demonstrating that Δ^9 -THC, but not cannabidiol, ameliorated both tremor and spasticity and reduced the overall clinical severity of the disease (414,420). Further work highlighted the importance of the CB₁ receptor in controlling tremor, spasticity, and the neuroinflammatory response. In contrast, the exact function of the CB₂ receptor in MS remains somewhat unclear, although it is believed to play a role in regulating the neuroinflammatory response (420,421,422). Although a large body of evidence suggests cannabinoids exert immunosuppressive effects, which could be beneficial in diseases such as MS, much of this information comes from pre-clinical studies where the levels of exogenous cannabinoids given to animals would likely exceed those typically administered to patients (422). Therefore it is believed that the beneficial effects of cannabinoids are more likely to come from their neuroprotective properties rather than their immunosuppressive characteristics (422,423,424).

Historical and survey data

In humans, published reports spanning 100 years suggest that people with spasticity (one of the symptoms associated with MS) may experience relief with cannabis (425). In the UK, 43% of patients with MS reported having experimented with cannabis at some point, and 68% of this population used it to alleviate the symptoms of MS (426). In Canada, the prevalence of medicinal use of cannabis among patients seeking treatment for MS, in the year 2000, was reported to be 16% in Alberta, with 43% of study respondents stating they had used cannabis at some point in their lives (164). Fourteen percent of people with MS surveyed in the year 2002 in Nova Scotia reported using cannabis for medical purposes, with 36% reporting ever having used cannabis for any purpose (165). MS patients reported using cannabis to manage symptoms such as spasticity and chronic pain as well as anxiety and/or depression (164,165). MS patients also reported improvements in sleep. Reported dosages of smoked cannabis by these patients varied from a few puffs to 1 g or more at a time (165).

Clinical studies with orally administered cannabinoid medications (cannabis extract, oral THC, nabiximols)

The results of randomized, placebo-controlled trials with orally administered cannabinoids for the treatment of muscle spasticity in MS are encouraging, but modest.

The large, multi-centre, randomized, placebo-controlled CAMS (CAnnabis in Multiple Sclerosis) study researching the effect of cannabinoids for the treatment of spasticity and other symptoms related to MS enrolled over 600 patients (262). The primary outcome was change in overall spasticity scores measured using the Ashworth scale. The study did not show any statistically significant improvement in the Ashworth score in patients taking either an oral cannabis extract ("Cannador") containing 2.5 mg Δ^9 -THC, 1.25 mg CBD, and < 5% other cannabinoids), or oral Δ^9 -THC, for 15 weeks. However, there was evidence of a significant treatment effect on *subjective, patient-reported* spasticity and pain, with improvement in spasticity using either orally administered cannabis extract (61%) (Dosing: 5 - 25 mg Δ^9 -THC; 5 - 15 mg CBD/day; and < 5% other cannabinoids, adjusted to body weight and titrated according to side effects) or oral Δ^9 -THC (60%) (Dosing: 10 - 25 mg Δ^9 -THC/day, adjusted to body weight and titrated according to side effects) compared to placebo (46%). Patients were concomitantly taking other medications to manage MS-associated symptoms. In contrast, a long-term (12 months), double-blind, follow-up to the CAMS study showed evidence of a small treatment effect of oral Δ^9 -THC (Dosing: 5 - 25 mg Δ^9 -THC/day, adjusted to body weight and titrated according to side effects) on

muscle spasticity measured by *objective* methods, whereas a *subjective* treatment effect on muscle spasticity was observed for both oral Δ^9 -THC and oral cannabis extract ("Cannador") (427).

Other randomized clinical trials using standardized cannabis extract capsules (containing 2.5 mg Δ^9 -THC and 0.9 mg CBD per capsule) (428) or nabiximols (Sativex[®]) (291,429,430) reported similar results, in that improvements were only seen in patient *self-reports* of symptoms but not with *objective* measures (e.g. Ashworth scale). The reasons behind the apparent discrepancies between subjective and objective measures are not clear; however, a number of possible explanations may be found to account for the differences. For example, it is known that spasticity is a complex phenomenon (431) and is affected by patient symptoms, physical functioning, and psychological disposition (427). Spasticity is also inherently difficult to measure, and has no single defining feature (430). In addition, the reliability and sensitivity of the Ashworth scale (for objectively measuring spasticity) has been called into question (262,430).

The efficacy, safety, and tolerability of a whole-plant cannabis extract administered in capsules (2.5 mg THC and 0.9 mg CBD/capsule) were studied in a fourteen-day, prospective, randomized, double-blind, placebo-controlled crossover trial in patients with clinically stable MS-associated spasticity and an Ashworth score greater than 2 (428). Slightly more than half of the study subjects had a maintenance dose of 20 mg/day of THC or more (maximum of 30 mg THC/day). Patients were concomitantly taking anti-spasticity medications. Many study subjects had had previous experience with cannabis; a significant number of those who withdrew from the study upon starting treatment with the cannabis extract did not have previous experience with cannabis. While there were no statistically significant differences between active treatment with the cannabis extract and placebo, trends in favour of active treatment were observed for mobility, *self-reported* spasm frequency, and ability in getting to sleep (428). The cannabis extract was generally well tolerated with no serious adverse events during the study period. However, adverse events were slightly more frequent and more severe during the active treatment period.

A six-week, multi-centre, randomized, double-blind, placebo-controlled, parallel-group study of nabiximols (Sativex[®]) for the treatment of five primary symptoms associated with MS (spasticity, spasm frequency, bladder problems, tremor, and pain) reported mixed results (291). Patients had clinically confirmed, stable MS of any type, and were on a stable medication regimen. Approximately half of the study subjects in either the active or placebo groups had previous experience with cannabis, either recreationally or for medical purposes. While the global primary symptom score (PSS), which combined the scores for all five symptoms, was not significantly different between the active treatment group and the placebo group, patients taking cannabis extract showed statistically significant differences compared to placebo in *subjective*, but not objective measures of spasticity (i.e. Ashworth Score), in Guy's Neurological Disability Score (GNDS), and in quality of sleep, but not in spasm frequency, pain, tremor, or bladder problems among other outcome measures (291). Patients self-titrated to an average daily maintenance dose of nabiximols of 40.5 mg THC and 37.5 mg CBD (i.e. ~15 sprays/day). Adverse effects associated with active treatment included dizziness, disturbance in attention, fatigue, disorientation, feeling drunk, and vertigo (291).

A long-term, open-label, follow-up study of nabiximols (Sativex[®]) concluded that the beneficial effect observed in the study by Wade et al. 2004 (291) was maintained in patients who had initially benefited from the drug (429). The mean duration of study participation in subjects who entered the follow-up study was 434 days (range: 21 - 814 days). The average number of daily doses taken by the subjects remained constant or was slightly reduced over time. The average number of daily doses of nabiximols was 11, corresponding to a dose of 30 mg THC and 28 mg CBD/day (429). Long-term use of nabiximols in this patient population was associated with reductions in *subjective* measures of spasticity, spasm frequency, pain, and bladder problems (429). Dizziness, diarrhea, nausea, fatigue, headache, and somnolence were among the most frequently reported adverse effects associated with chronic nabiximols use in this study. A two-week withdrawal study, incorporated into the long-term follow-up study, suggested that cessation of nabiximols use was not associated with a consistent withdrawal syndrome but it was associated with withdrawal-type symptoms (e.g. interrupted sleep, hot/cold flushes, fatigue, low mood, decreased appetite, emotional lability, vivid dreams, intoxication) as well as re-emergence/worsening of some MS symptoms (429).

The efficacy, safety and tolerability of nabiximols in MS were investigated in a six-week, multi-centre, phase III, double-blind, randomized, parallel-group clinical study in patients with stable MS who had failed to gain adequate relief using standard therapeutic approaches (430). Patients had to have significant spasticity in at least two muscle groups, and an Ashworth score of 2 or more. A significant number of patients had previous experience with cannabis. Forty percent of subjects assigned treatment with nabiximols showed a $\geq 30\%$ reduction in self-

reported spasticity using an 11-point *subjective* numerical rating spasticity scale (NRS) compared to subjects assigned to placebo (21.9%) (difference in favour of nabiximols = 18%; 95% Confidence Interval = 4.73, 31.52; $p = 0.014$). Mean number of sprays per day was 9.4 ± 6.4 (~25 mg THC and ~24 mg CBD) (430). Subjects on placebo or nabiximols exhibited similar incidences of adverse effects, but adverse CNS effects were more common with the nabiximols group (430). The majority of adverse events were of mild or moderate severity (e.g. dizziness, fatigue, depressed mood, disorientation, dysgeusia, disturbance in attention, blurred vision).

Nabiximols (Sativex[®]), an oro-mucosal spray containing 27 mg/mL of Δ^9 -THC and 25 mg/mL CBD, is currently marketed in Canada as an adjunctive treatment for the symptomatic relief of spasticity in adult patients with MS who have not responded adequately to other therapy and who demonstrate meaningful improvement during an initial trial of therapy. It is also marketed (with conditions) as an adjunctive treatment for the symptomatic relief of neuropathic pain in adults with MS.

CUPID and MUSEC clinical studies

The CUPID (Cannabinoid Use in Progressive Inflammatory Brain Disease) study was a randomized, double-blind, clinical investigation designed to measure whether orally administered Δ^9 -THC was able to slow the progression of MS (<http://sites.pcmd.ac.uk/cnrg/cupid.php>). This three-year publicly-funded trial took place at the Peninsula Medical School in the U.K. and followed the earlier, one-year long, CAMS study. A total of 493 subjects with primary or secondary progressive, but not relapse-remitting, MS had been recruited from across the U.K. in 2006 and preliminary results were recently made public (http://sites.pcmd.ac.uk/cnrg/files/cupid/CUPID_results_press_release_web.pdf). The CUPID trial found no evidence to support an effect of Δ^9 -THC on MS progression, as measured by using either the Expanded Disability Status Scale or the Multiple Sclerosis Impact Scale 29 (MSIS-29). However, the authors concluded that there was some evidence to suggest a beneficial effect in participants who were at the *lower end* of the disability scale at the time of patient enrolment. Since the observed benefit only occurred in a small sub-group of patients, further studies would be required to more closely examine the reasons for this selective effect.

A double-blind, placebo-controlled, phase III study (the Multiple Sclerosis and Extract of Cannabis trial—i.e. “MUSEC”) published by the same group of researchers that conducted the CUPID trial, reported that a twelve-week treatment with an oral cannabis extract (“Cannador”) (2.5 mg Δ^9 -THC and 0.9 mg CBD/capsule) was associated with a statistically significant relief in *patient-reported* muscle stiffness, muscle spasms, and body pain as well as a statistically significant improvement in sleep compared to placebo, in patients with stable MS (432). There were no statistically significant differences between cannabis extract and placebo on functional measures such as those examining the effect of spasticity on activities of daily living, ability to walk, or on social functioning (432). The majority of the patients using cannabis extract used total daily doses of 10, 15, or 25 mg of Δ^9 -THC with corresponding doses of 3.6, 5.4, and 9 mg of CBD. The majority of the study subjects were concomitantly using analgesics and anti-spasticity medications, but were excluded if they were using immunomodulatory medications (e.g. interferons). Active treatment with the extract was associated with an increase in the number of adverse events, but the majority of these were considered to be mild to moderate and did not persist beyond the study period (432). The highest number of adverse events were observed during the initial two-week titration period and appeared to decrease progressively over the course of the remaining treatment sessions (432). The most commonly observed adverse events were those associated with disturbances in CNS function (e.g. dizziness, disturbance in attention, balance disorder, somnolence, feeling abnormal, disorientation, confusion, and falls). Disturbances in gastrointestinal function were the second most commonly occurring adverse events (e.g. nausea, dry mouth).

Clinical studies with smoked cannabis

There has only been one clinical study so far using smoked cannabis for symptoms associated with MS (188). The study, a double-blind, placebo-controlled, crossover trial reported a statistically significant reduction in patient scores on the modified Ashworth scale for measuring spasticity after patients smoked cannabis once daily for three days (each cigarette contained 800 mg of 4% Δ^9 -THC; total available Δ^9 -THC dose of 32 mg per cigarette) (188). Smoking cannabis was also associated with a statistically significant reduction in patient scores on the visual analog scale for pain, although patients reportedly had low levels of pain to begin with (188). No differences between placebo and cannabis were observed in the timed-walk task, a measure of physical performance (188). Cognitive function, as assessed by the Paced Auditory Serial Addition Test (PASAT), appeared to be significantly decreased immediately following administration of cannabis; however, the long-term clinical significance of this finding was not examined in this study (188). The majority of patients (70%) were on disease-modifying therapy (e.g. interferon β -1a, interferon β -1b, or glatiramer), and 60% were taking anti-

spasticity agents (e.g. baclofen or tizanidine). Cannabis treatment was associated with a number of different, but commonly observed adverse effects including dizziness, headache, fatigue, nausea, feeling "too high", and throat irritation (188). Study limitations included the fact that the majority of patients had prior experience with cannabis, and that the study was unblinded since most of the patients were able to tell apart the placebo from the active treatment with cannabis (188).

The current Marijuana Medical Access Regulations (MMAR) allow the use of dried marijuana in the context of severe pain and persistent muscle spasms associated with MS in patients who have either not benefited from, or would not be considered to benefit from, conventional treatments (384).

Generally speaking, orally administered prescription cannabinoids (e.g. dronabinol, nabilone, nabiximols) are reported to be well tolerated in patients with MS (428,433,434). Clinical trials to date do not indicate serious adverse effects associated with the use of these prescription cannabinoid medications. However, there appears to be an increase in the number of non-serious adverse effects associated with the short-term use of cannabinoids (4). The most commonly reported short-term physical adverse effects are dizziness, drowsiness, and dry mouth (262,434). Prolonged use of ingested or inhaled cannabis was associated with poorer performance on various cognitive domains (information processing speed, working memory, executive function, and visuospatial perception) in patients with MS according to one cross-sectional study (178). In contrast, another study concluded that nabiximols (Sativex[®]) treatment, in cannabis-naïve MS patients, was not associated with cognitive impairment (434). However, the study did raise the possibility that higher dosages could precipitate changes in psychological disposition, especially in those patients with a prior history of psychosis. In any case, important information is generally lacking regarding the long-term adverse effects of chronic cannabinoid use for therapeutic purposes.

Bladder dysfunction associated with multiple sclerosis or spinal cord injury

Bladder dysfunction occurs in most patients suffering from multiple sclerosis (MS) or spinal cord injury (435). The most common complaints are increased urinary frequency, urgency, urge, and reflex incontinence (436). Cannabinoid receptors are expressed in human bladder detrusor and urothelium (35,36), and may help regulate detrusor tone and bladder contraction as well as affecting bladder nociceptive response pathways (reviewed in (36)).

A survey of MS patients regularly using cannabis for symptomatic relief of urinary problems reported that over half of these patients claimed improvement in urinary urgency (437). A sixteen-week, open-label, pilot study of cannabis-based extracts (a course of Sativex[®] treatment followed by maintenance with 2.5 mg Δ^9 -THC only) for bladder dysfunction, in 15 patients with advanced MS, reported significant decreases in urinary urgency, number and volume of incontinence episodes, frequency, and nocturia (438). Improvements were also noted in patient self-assessments of pain and quality of sleep. A subsequent randomized controlled trial of 250 MS patients suggested a clinical effect of orally administered cannabinoids (2.5 mg Δ^9 -THC or 1.25 mg cannabidiol (CBD) with < 5% other cannabinoids per capsule, up to a maximum 25 mg/day) on incontinence episodes (435).

4.4.2 Amyotrophic lateral sclerosis

There is some pre-clinical evidence implicating the endocannabinoid system in the progression of an amyotrophic lateral sclerosis (ALS)-like disease in mouse models of the disorder, and under certain conditions cannabinoids have been reported to modestly delay disease progression and prolong survival in these animal models (reviewed in (439) and in (440)). Anecdotal reports suggest decreased muscle cramps and fasciculations in ALS patients who smoked herbal cannabis or drank cannabis tea, with up to 10% of these patients using cannabis for symptom control (441,442). Only two clinical trials of cannabis for the treatment of symptoms associated with ALS exist, and the results of the studies are mixed. In one four-week, randomized, double-blind, crossover pilot study of 19 ALS patients, doses of 2.5 - 10 mg per day of dronabinol (Δ^9 -THC) were associated with improvements in sleep and appetite, but not cramps or fasciculations (443). In contrast, a shorter two-week study reported no improvement in these measures in ALS patients taking 10 mg of dronabinol per day (442). In either case, dronabinol was well tolerated with few reported side effects in this patient population at the tested dosages.

4.4.3 Spinal cord injury (or spinal cord disease)

Pre-clinical animal studies suggest that spinal cord injury triggers changes in the activity of the endocannabinoid system, and that cannabinoid receptor agonists may alleviate neuropathic pain associated with spinal cord injury (444,445,446). However, limited clinical information exists regarding the use of cannabinoids to treat symptoms associated with spinal cord injury such as pain, spasticity, muscle spasms, urinary incontinence, and difficulties

sleeping. No clinical trials of smoked cannabis for the treatment of these symptoms have been documented, but subjective improvements have been anecdotally reported by patients smoking cannabis (378,447). Double-blind, crossover, placebo-controlled studies of oral Δ^9 -THC and/or Δ^9 -THC : CBD extract (Sativex[®]) suggested modest improvements in pain, spasticity, muscle spasms, and sleep quality in patients with spinal cord injury (378,448,449). A randomized, double-blind, placebo-controlled parallel study using a minimum of 15 - 20 mg Δ^9 -THC/day (mean daily doses of 31 mg Δ^9 -THC orally, or 43 mg Δ^9 -THC-hemisuccinate rectally) showed a statistically significant improvement in spasticity scores in patients with spinal cord injury (450). A more recent double-blind, placebo-controlled, crossover study using nabilone (0.5 mg b.i.d.) also showed an improvement in spasticity compared to placebo in patients with spinal cord injury (451).

The current Marihuana Medical Access Regulations (MMAR) allow the use of dried marihuana in the context of severe pain and persistent muscle spasms associated with spinal cord injury or spinal cord disease in patients who have either not benefited from, or would not be considered to benefit from, conventional treatments (384).

4.5 Epilepsy

Increasing evidence points to a role for the endocannabinoid system in the modulation of neuronal tone and excitability, and possibly in epilepsy. Human and animal studies suggest epileptic activity is associated with changes in the levels and distribution of CB₁ receptors in the hippocampus (452,453,454). Reduced levels of the endocannabinoid anandamide have been detected in the cerebrospinal fluid of patients with untreated, newly diagnosed, temporal lobe epilepsy (455).

Pre-clinical studies

In vitro studies, as well as those carried out in animals, generally suggest an anti-convulsant role for cannabinoids (91,456,457,458,459). However, a pro-convulsant role has also been described (91,460). CB₁ receptors are located mainly pre-synaptically where they typically inhibit the release of classical neurotransmitters (461). The purported anti-epileptic effect of cannabinoids is thought to be mediated by CB₁-receptor dependent pre-synaptic inhibition of glutamate release (453,462); on the other hand, epileptogenic effects may be triggered by pre-synaptic inhibition of GABA release (456,457,459,463,464). CB₁ receptor agonists therefore have the potential to trigger or suppress epileptiform activity depending upon which cannabinoid-sensitive pre-synaptic terminals are preferentially affected (i.e. glutamatergic or GABAergic) (91,462).

Clinical studies

A review of the literature describing the effects of cannabis on epileptic symptoms in humans concluded that although cannabis use can reduce seizure frequency in some cases and provoke seizures in others, in the majority of cases it probably has no effect (465). This may be caused by the rather unspecific actions of exogenously administered cannabinoids, such as Δ^9 -THC, which would target both excitatory and inhibitory neurons (91). Cannabidiol (CBD) has also been examined as a potential anti-epileptic in humans (see (466) for full review) but these early studies have not been followed up with larger and more convincing clinical trials. A recent Cochrane Collaboration review aimed at assessing the efficacy and safety of cannabinoids as monotherapy or add-on treatment for patients with epilepsy concluded that the available evidence is not sufficient to be able to draw reliable conclusions regarding the efficacy of cannabinoids as a treatment for epilepsy (467). While a dose of 200 - 300 mg of CBD could be safely administered to a small number of patients for a short period of time, the safety of long-term cannabidiol treatment could not be reliably assessed (467).

The current Marihuana Medical Access Regulations (MMAR) allow the use of dried marihuana in the context of epilepsy in patients who experience seizures and who have either not benefited from, or would not be considered to benefit from, conventional treatments (384).

4.6 Pain

It is now well established that the endocannabinoid system plays an important role in the modulation of pain states and that elements of the endocannabinoid system can be found at supraspinal, spinal, and peripheral levels of pain pathways (22,468). The particular distribution of cannabinoid receptors provides an anatomical basis to explain some of the analgesic effects of cannabinoids, and a number of pre-clinical studies suggest a functional role for endocannabinoids (such as anandamide and 2-arachidonoylglycerol (i.e. 2-AG)) in suppressing pain under physiological conditions (22).

Considerations and caveats

Animal vs. human studies

Pre-clinical studies in animals predict that cannabinoids should relieve both acute and chronic pain. However, results from both experimental models of pain in human volunteers and from clinical trials of patients suffering from pain instead suggest cannabinoids may be more effective for chronic rather than acute pain (469,470,471). A number of possible explanations can exist to account for discrepancies between animal studies and human clinical trials. Such explanations include interspecies differences, differences in experimental stimuli and protocols used in the studies, and differences in the outcomes measured in the studies. Data from animal pain models are mostly based on observations of behavioural changes and cannabinoid doses sufficient to produce relevant anti-nociception in rodents are similar to those which cause other behavioural effects such as hypomotility and catatonia (21,472). This pharmacological overlap can make it difficult to distinguish between cannabinoid-associated anti-nociceptive effects and behavioural effects (21,472).

Experimental models of pain vs. chronic pain

Translation of research findings from human experimental models of pain (i.e. acute pain) to clinical pain is also complex and not straightforward (185). In contrast to acute pain, chronic pain is a complex condition which involves interaction between sensory, affective, and cognitive components (185). Unlike acute pain, chronic pain is considered a disease and generally originates from prolonged acute pain which is not managed in a timely or effective manner (473). Chronic pain also appears to involve distinct spatiotemporal neuronal mechanisms which differ from those recruited during acute, experimental pain (474). Chronic pain involves altered neural transmission and long-term plasticity changes in the peripheral and central nervous systems which generate and maintain the chronic pain state (473,474). As such, it is difficult to compare studies of interventions for chronic pain with studies of experimentally-induced pain because of fundamental differences in the physiological state of the subjects, differences in the stimulus conditions and experimental protocols employed in the studies, and differences in the outcomes which are measured (185).

Placebo effect

The placebo effect is another consideration to keep in mind when considering studies of cannabis/cannabinoids for the treatment of pain. The placebo effect, a psychobiological phenomenon, is perhaps more salient in disorders which have a more significant subjective or psychological component (e.g. pain, anxiety/depression), and may be somewhat less salient in diseases which have a more objective pathophysiological component (e.g. infectious diseases, cancer) (475,476).

Patient/study subject population

Many, if not most, of the clinical trials of cannabinoids for the treatment of pain (and even other disorders such as multiple sclerosis) have recruited patients or volunteers who have had prior exposure or experience with cannabis or cannabinoids. This has raised the issue of unblinding because any study subjects having prior experience with cannabis or cannabinoids would be more likely to be able to distinguish active treatment with these drugs from the placebo control (364). Furthermore, a number of clinical trials of cannabis/cannabinoids for the treatment of pain (or other disorders) have also used an "open-phase" period which eliminated subjects who would have either responded poorly to cannabinoids or who would have had greater chances of experiencing adverse effects (48). The use of individuals with prior experience with cannabis or cannabinoids or the use of an "open-phase" period would increase the proportion of patients yielding results tending to overestimate some of the potential therapeutic benefits of cannabis/cannabinoids, while also tending to underestimate the extent or degree of adverse effects among the general patient population (48,364).

Other considerations

It is also perhaps worth mentioning that a number of clinical studies suggest the presence of a relatively narrow therapeutic window for cannabis and prescription cannabinoids in the treatment of pain (21,48,50,472). The well-known psychotropic and somatic side effects associated with the use of cannabis and cannabinoids (e.g.

dronabinol, nabilone, nabiximols) are known to limit the general therapeutic utility of these drugs; it has therefore been suggested that it may be preferable to pursue therapies which focus on manipulation of the endocannabinoid system (e.g. by inhibiting the endocannabinoid-degrading enzymes FAAH or MAGL), or to combine low doses of cannabinoids with low doses of other analgesics in order to achieve the desired therapeutic effects while minimizing the incidence, frequency, and severity of the adverse effects (21,50).

With the above considerations and caveats in mind, the sections below summarize the results of studies examining the analgesic potential of cannabis or cannabinoids in pre-clinical and clinical models of experimentally-induced acute pain, as well as in clinical studies of chronic pain.

4.6.1. Acute Pain

4.6.1.1 Experimentally-induced acute pain

Pre-clinical studies

A number of pre-clinical studies suggest that anandamide, THC, and certain synthetic cannabinoids block pain responses in different animal models of acute pain (reviewed in (21,472)). Cannabinergic modulation of neuronal circuits in the brain and spinal cord can inhibit nociceptive processing (477,478,479,480). However, despite the results obtained in pre-clinical studies, the results of studies using cannabis or cannabinoids (e.g. nabilone) to alleviate experimentally-induced acute pain in humans are mixed.

Clinical studies with smoked cannabis

An early study by Hill of 26 healthy male cannabis smokers failed to demonstrate an analgesic effect of smoked cannabis (1.4% Δ^9 -THC, 12 mg available Δ^9 -THC) in response to transcutaneous electrical stimulation (481). The study did, however, report an *increase* in sensory and pain sensitivity to the applied stimulus. In contrast, Milstein showed that smoked cannabis (1.3% Δ^9 -THC, 7.5 mg total available Δ^9 -THC) increased pain tolerance to a pressure stimulus in both healthy cannabis-naïve and cannabis-experienced subjects compared to placebo (482). Another study employing healthy cannabis smokers reported that smoking cannabis cigarettes (containing 3.55% Δ^9 -THC, or approximately 62 mg available Δ^9 -THC) was associated with a mild, dose-dependent, anti-nociceptive effect to a thermal heat stimulus (184). A more recent randomized, double-blind, placebo-controlled, crossover trial examined the effects of three different doses of smoked cannabis on intra-dermal capsaicin-induced pain and hyperalgesia in 15 healthy volunteers (185). Capsaicin was administered either 5 min or 45 min after smoking cannabis. Effects appeared to be dose and time dependent. No effect was observed 5 min after smoking, but analgesia was observed 45 min after smoking, and only with the medium dose of smoked cannabis (4% Δ^9 -THC by weight). A low dose (2% Δ^9 -THC by weight) had no effect. In contrast, a high dose (8% Δ^9 -THC by weight) was associated with significant *hyperalgesia*. This study identified a so-called "narrow therapeutic window"; a medium dose provided analgesic benefit, a high dose worsened the pain and was associated with additional adverse effects, and a low dose had no effect.

Clinical studies with oral THC and cannabis extract

A randomized, placebo-controlled, double-blind, crossover study of 12 healthy cannabis-naïve volunteers administered a single oral dose of 20 mg Δ^9 -THC reported a lack of a significant analgesic effect following exposure to a multi-model pain test battery (pressure, heat, cold, and transcutaneous electrical stimulation) (483). In addition, significant hyperalgesia was observed in the heat pain test. Psychotropic and somatic side effects were common and included anxiety, perceptual changes, hallucinations, strange thoughts, ideas and mood, confusion and disorientation, euphoria, nausea, headache, and dizziness. Another randomized, double-blind, active placebo-controlled, crossover study in 18 healthy female volunteers reported a lack of analgesia or anti-hyperalgesia with an oral cannabis extract containing 20 mg THC and 10 mg CBD (other plant cannabinoids were less than 5%) in two different experimental pain models (intra-dermal capsaicin or sunburn) (484). Side effects (sedation, nausea, and dizziness) were frequently observed. Hyperalgesia was also observed at the highest dose as in the study conducted by Wallace (above) (185).

Clinical studies with nabilone

A randomized, double-blind, placebo-controlled, crossover study of single oral doses of nabilone (0.5 mg or 1 mg) failed to show any analgesic effects during a tonic heat pain stimulus (485). However, an anti-hyperalgesic effect was observed at the highest administered dose, but only in female subjects. The authors noted a significant placebo effect and also suggested that the lack of an analgesic effect could have been

attributed to the single-dose administration of the cannabinoid; a gradual dose escalation could have potentially revealed an effect (485). Similarly, a randomized, double-blind, placebo-controlled, crossover study in subjects receiving single oral doses of nabilone (1, 2, or 3 mg) failed to show any analgesic, or primary or secondary anti-hyperalgesic effects in response to capsaicin-induced pain in healthy male volunteers (355). Adverse effects of mild to moderate intensity were noted in the majority of subjects. Severe adverse reactions (e.g. dizziness, sedation, anxiety, agitation, euphoria, and perceptual and cognitive disturbances) were reported only at the highest administered dose (3 mg) in four subjects leading to their withdrawal from the study. Dose-dependent CNS effects were observed 1.5 - 6 h after dosing, reaching a maximum between 4 and 6 h after administration. A recent review suggests that there is little convincing evidence of a significant reduction in acute pain in human experimental or clinical studies of cannabinoids (21).

4.6.1.2 Post-operative pain

Despite the introduction of new standards, guidelines, and educational efforts, data indicate that post-operative pain continues to be under or poorly managed and many of the drugs commonly used in this setting either lack sufficient efficacy or cause unacceptable side effects (486,487). To date, there are only four published reports on the use of cannabinoids in post-operative pain (486,488,489,490). The conclusions from these studies were that cannabinoids (THC, nabilone, or an oral cannabis extract containing a 2 : 1 ratio of THC to CBD) are not ideally suited to manage post-operative pain, being either moderately effective (486,488), not different from placebo (489), or even anti-analgesic at high doses (490). However, a definitive conclusion on the role of these cannabinoids in the post-operative setting cannot yet be made because of the different drugs, dosages, routes of administration, and protocols that were used in these studies (491).

4.6.2 Chronic Pain

Acute pain that is poorly managed can lead to chronic pain (492,493). In contrast to acute pain, chronic pain is typically considered a far more complex condition which involves physical, psychological, and psychosocial factors, and which contributes to a reduced quality of life (494). The information below summarizes pre-clinical studies carried out in animal models of chronic pain, clinical studies in human subjects suffering from chronic pain of various etiologies, as well as some studies of experimentally-induced pain performed on patients.

4.6.2.1 Experimentally-induced pain

The anti-nociceptive efficacy of cannabinoids has been unequivocally demonstrated in several different animal models of inflammatory and neuropathic pain (reviewed in (495) and in (496)). In addition, the findings from these studies suggest that modulation of the endocannabinoid system through administration of specific cannabinoid receptor agonists, or by elevation of endocannabinoid levels, suppresses hyperalgesia and allodynia induced by diverse neuropathic states (reviewed in (496)). As such, similar to the situation with acute pain, pre-clinical studies of chronic pain in animal models suggest that endocannabinoids (anandamide and 2-AG), THC, and several synthetic cannabinoids have beneficial effects (reviewed in (21,472,496)).

With respect to cannabidiol (CBD), while chronic oral administration of cannabidiol effectively decreased hyperalgesia in a rat model of inflammatory pain (497), no such parallels have been found to date in humans. A more recent study suggested that a medium or a high dose of CBD attenuates tactile allodynia and thermal hypersensitivity in a mouse model of diabetic neuropathy, when administered early in the course of the disease; on the other hand there is little, if any, restorative effect if CBD is administered at a later time point (498). In contrast, nabilone was not as efficacious as CBD if administered early on, but appeared to have a small beneficial effect when administered later in the course of the disease (498). CBD also appeared to attenuate microgliosis in the ventral lumbar spinal cord, but only if administered early in the course of the disease, whereas nabilone had no effect (498).

There are no studies of experimentally-induced chronic pain in humans. However, in contrast to the mixed findings in human subjects exposed to acute painful stimuli, cannabinoids appear to have a more consistent beneficial profile for patients already suffering from chronic pain.

4.6.2.2 Neuropathic pain or chronic non-cancer pain

Short-term clinical studies suggest prescription cannabinoid medications (e.g. nabiximols, dronabinol, nabilone) are moderately effective in reducing intractable central or peripheral neuropathic pain of various etiologies in individuals already receiving analgesic drugs (499). Side effects appear to be comparable to

existing treatments and typically include dizziness/lightheadedness, sedation, confusion, ataxia, a feeling of intoxication, euphoria ("high"), xerostomia, dysgeusia, and hunger (499,500). These effects may be minimized by employing low doses of cannabinoids that are gradually escalated, as required. The following summarizes the existing clinical information on the use of cannabis and cannabinoids (THC, nabilone, dronabinol and nabiximols) to treat neuropathic and chronic non-cancer pain.

Clinical studies with smoked or vapourized cannabis

A randomized, double-blind, placebo-controlled, cross-over study of cannabis-experienced patients suffering from chronic neuropathic pain of various etiologies (complex regional pain syndrome, central neuropathic pain from spinal cord injury or multiple sclerosis, or peripheral neuropathic pain from diabetes or nerve injury) reported that administration of either a low dose or a high dose of smoked cannabis (3.5% Δ^9 -THC, 19 mg total available Δ^9 -THC; or 7% Δ^9 -THC, 34 mg total available Δ^9 -THC) was associated with significant equianalgesic decreases in central and peripheral neuropathic pain (168). No analgesic effect was observed in tests of experimentally-induced pain (tactile or heat stimuli). Patients were taking other pain control medications during the trial such as opioids, anti-depressants, non-steroidal anti-inflammatory drugs, or anti-convulsants. Adverse effects associated with the use of cannabis appeared to be dose-dependent and included feeling "high", sedation, confusion, and neurocognitive impairment. Cognitive changes appeared to be more pronounced with higher doses of Δ^9 -THC (168).

In another randomized, placebo-controlled study a greater than 30% decrease in HIV-associated sensory neuropathic pain was reported in 52% of cannabis-experienced patients smoking cannabis cigarettes containing 3.56% Δ^9 -THC (32 mg total available Δ^9 -THC per cigarette), three times per day (96 mg total daily amount of Δ^9 -THC) for five days, compared to a 24% decrease in pain in the placebo group (142). The number of patients that needed to be treated (NNT) to observe a 30% reduction in pain compared to controls was 3.6 and was comparable to that reported for other analgesics in the treatment of chronic neuropathic pain. In the "experimentally-induced pain" portion of the study, smoked cannabis was not associated with a statistically significant difference in acute heat pain threshold compared to placebo. However, it did appear to reduce the area of heat and capsaicin-induced acute secondary hyperalgesia (142). Patients were taking other pain control medications during the trial such as opioids, gabapentin or other drugs. Adverse effects of smoked cannabis in this study included sedation, dizziness, confusion, anxiety, and disorientation.

A phase II, double-blind, placebo-controlled, crossover clinical trial of smoked cannabis for HIV-associated refractory neuropathic pain reported a 30% decrease in HIV-associated, distal sensory predominant, polyneuropathic pain in 46% of patients smoking cannabis for five days (1 - 8% Δ^9 -THC, four times daily), compared to a decrease of 18% in the placebo group (186). The NNT in this study was 3.5. Almost all of the subjects had prior experience with cannabis and were concomitantly taking other analgesics such as opioids, non-steroidal anti-inflammatory drugs, anti-depressants or anti-convulsants. Adverse effects associated with the use of cannabis were reported to be frequent, with a trend for moderate or severe adverse effects during the active treatment phase compared to the placebo phase.

A randomized, double-blind, placebo-controlled, four period, crossover clinical study of smoked cannabis for chronic neuropathic pain caused by trauma or surgery and refractory to conventional therapies reported that compared to placebo, a single smoked inhalation of 25 mg of cannabis containing 9.4% Δ^9 -THC (2.35 mg total available Δ^9 -THC per cigarette), three times per day (7.05 mg total Δ^9 -THC per day) for five days, was associated with a modest but statistically significant decrease in average daily pain intensity (172). In addition, there were statistically significant improvements in measures of sleep quality and anxiety with cannabis. The majority of subjects had previous experience with cannabis and most were concomitantly taking other analgesics such as opioids, anti-depressants, anti-convulsants, or non-steroidal anti-inflammatory drugs. Adverse effects associated with the use of cannabis included headache, dry eyes, burning sensation in the upper airways (throat), dizziness, numbness, and cough.

A clinical study of patients suffering from chronic pain (musculoskeletal, post-traumatic, arthritic, peripheral neuropathy, cancer, fibromyalgia, multiple sclerosis, sickle cell disease, and thoracic outlet syndrome) reported that inhalation of vapourized cannabis (0.9 g, 3.56% Δ^9 -THC), three times per day for five days, was associated with a statistically significant decrease in pain (-27%, Confidence Interval = 9 - 46) (187). Subjects were on stable doses of sustained-release morphine sulfate or oxycodone, and had prior experience with smoking cannabis (187). There was a statistically significant decrease in the maximum concentration (C_{max}) of morphine sulfate, but not oxycodone, during cannabis exposure. No clinically significant adverse

effects were noted, but all subjects reported experiencing a "high". The study design carried a number of important limitations including small sample size, short duration, a non-randomized subject population, and the lack of a placebo.

A double-blind, placebo-controlled, crossover study of patients suffering from neuropathic pain of various etiologies (spinal cord injury, CRPS type I, causalgia-CRPS type II, diabetic neuropathy, multiple sclerosis, post-herpetic neuralgia, idiopathic peripheral neuropathy, brachial plexopathy, lumbosacral radiculopathy, and post-stroke neuropathy) reported that inhalation of vapourized cannabis (0.8 g containing either a low dose of Δ^9 -THC (1.29% Δ^9 -THC; total available amount of Δ^9 -THC 10.3 mg) or a medium dose of Δ^9 -THC (3.53% Δ^9 -THC; total available amount of Δ^9 -THC 28.2 mg)) during three separate 6 h sessions was associated with a statistically significant reduction in pain intensity (501). Inhalation proceeded using a standardized protocol (i.e. the "Foltin procedure"); participants were verbally signaled to hold the vapourizer bag with one hand, put the vapourizer mouthpiece in their mouth, get ready, inhale (5 s), hold vapour in their lungs (10 s), and finally exhale and wait before repeating the inhalation cycle (40 s) (501). Non-significant differences were observed between placebo and active treatments with respect to pain ratings at the 60 min time point following study session initiation. Following four cued inhalations of either dose of THC at the 60 min time point, a significant treatment effect was recorded 60 min later (i.e. at the 120 min time point following trial initiation). A second cued inhalation of vapourized cannabis, at the 180 min time point following trial initiation (4 - 8 puffs, flexible dosing, 2 h after first inhalation), was associated with continued analgesia lasting another 2 h (501). Both the 1.29% and 3.53% Δ^9 -THC doses were equianalgesic and significantly better in achieving analgesia than placebo. The NNT to achieve a 30% pain reduction was 3.2 for the placebo vs. the low-dose, 2.9 for the placebo vs. the medium-dose, and 29 for the medium- vs. the low-dose (501). The authors suggested that the NNT for active vs. placebo conditions is in the range of two commonly used anti-convulsants used to treat neuropathic pain (pregabalin, 3.9; gabapentin, 3.8). Using a Global Impression of Change rating scale, pain relief appeared to be maximal after the second dosing at 180 min, and dropped off between 1 and 2 h later. Both active doses had equal effects on ratings of pain "sharpness", while the low-dose was more effective than either the placebo or medium-dose for pain described as "burning" or "aching". All patients had prior experience with cannabis and were concomitantly taking other medications (opioids, anti-convulsants, anti-depressants, and non-steroidal anti-inflammatory drugs) (501). Cannabis treatment was associated with a small impairment of certain cognitive functions, with the greatest effects seen in domains of learning and memory (501). The study suffered from a number of drawbacks including a relatively small number of patients, a short study period, and the possibility of treatment unblinding.

Clinical studies with orally administered prescription cannabinoids

Nabilone

An off-label, retrospective, descriptive study of 20 adult patients suffering from chronic non-cancer pain of various etiologies (post-operative or traumatic pain, reflex sympathetic dystrophy, arthritis, Crohn's disease, neuropathic pain, interstitial cystitis, HIV-associated myopathy, post-polio syndrome, idiopathic inguinal pain, and chronic headaches) reported subjective overall improvement and reduced pain intensity with nabilone as an adjunctive pain-relief therapy (494). Furthermore, beneficial effects on sleep and nausea were the main reasons for continuing use. Patients used between 1 and 2 mg of nabilone per day. Higher doses (3 - 4 mg/day) were associated with an increased incidence of adverse effects. These included dry mouth, headaches, nausea and vomiting, fatigue, cognitive impairment, dizziness, and drowsiness. Many patients were concomitantly taking other drugs such as non-steroidal anti-inflammatory drugs, opioids, and various types of anti-depressants. Many of the subjects also reported having used cannabis in the past to manage symptoms. Limitations in study design included the lack of an appropriate control group and the small number of patients.

An enriched-enrolment, randomized-withdrawal, flexible-dose, double-blind, placebo-controlled, parallel-assignment efficacy study of nabilone as an adjuvant in the treatment of diabetic peripheral neuropathic pain reported a statistically significant decrease in pain compared to placebo, with 85% of the subjects in the nabilone group reporting a $\geq 30\%$ reduction in pain from baseline to end point, and 31% of subjects in the nabilone group reporting a $\geq 50\%$ reduction in pain from baseline to end point (364). Subjects taking nabilone also reported statistically significant improvements in anxiety, sleep, quality of life, and overall patient status (364). Doses of nabilone ranged from 1 - 4 mg/day (364). Most subjects were concomitantly taking a variety

of pain medications including non-steroidal anti-inflammatory drugs, opioids, anti-depressants, and anxiolytics. Adverse events associated with the nabilone intervention included dizziness, dry mouth, drowsiness, confusion, impaired memory, lethargy, euphoria, headache, and increased appetite although weight gain was not observed (364).

Dronabinol

A randomized, double-blind, placebo-controlled, crossover trial of patients suffering from multiple sclerosis-associated central neuropathic pain reported a decrease in central pain with 10 mg maximum daily doses of dronabinol (361). Dosing started with 2.5 mg dronabinol/day and employed gradual dose-escalation every other day; total trial duration was three weeks (range: 18 - 21 days). Pain medications, other than paracetamol, were not permitted during the trial. The NNT for 50% pain reduction was 3.5 (95% Confidence Interval = 1.9 to 24.8). Fifty-four percent of patients had a $\geq 33\%$ reduction in pain during dronabinol treatment compared with 21% of patients during placebo. The degree of pain reduction in this study was comparable to that seen with other drugs commonly used in the treatment of neuropathic pain conditions (361). There were no significant differences reported between the treatment group and placebo in thermal sensibility, tactile and pain detection, vibration sense, temporal summation, or mechanical or cold allodynia (361). However, there was a statistically significant increase in the pain pressure threshold in dronabinol-treated subjects. Self-reported adverse effects were common, especially during the first week of active treatment. These included lightheadedness, dizziness, drowsiness, headache, myalgia, muscle weakness, dry mouth, palpitations, and euphoria (361).

A phase I, randomized, single-dose, double-blind, placebo-controlled, crossover trial of 30 patients taking short- or long-acting opioids (68 mg oral morphine equivalents/day; range 7.5 - 228 mg) for intractable, chronic non-cancer pain (of various etiologies) reported that both a 10 mg and 20 mg dose of dronabinol was associated with significant pain relief compared to placebo, although no difference in pain relief was observed between the two active treatments (502). Pain intensity and evoked pain were also significantly reduced in subjects who received the active treatments compared to placebo. Significant pain relief compared to baseline was also reported in an open-label, phase II extension to the initial phase I trial. Subjects were instructed in a stepwise dosage schedule beginning with a 5 mg/day dose, and titrating upwards to a maximum of 20 mg t.i.d. Significant side effects were observed in the majority of patients in the single-dose trial, were consistent with those observed in other clinical trials, and occurred more frequently in subjects receiving the highest dosage of the study medication (502). The authors reported that compared to the single-dose phase I trial, the frequency of self-reported side effects in the phase II open-label study decreased with continued use of dronabinol. Limitations in the design of the study included the small number of study subjects, the large number of subjects with a history of cannabis use, the lack of appropriate comparison groups, and the lack of an active placebo. Other limitations specific to the open-label phase-II trial included the lack of a control group or crossover arm (502).

Nabiximols

A number of randomized, placebo-controlled, double-blind crossover and parallel studies have shown a significant reduction in central or peripheral neuropathic pain of various etiologies (e.g. brachial plexus avulsion, multiple sclerosis-related) following treatment with nabiximols (Sativex[®]) (292,503,504). In all three studies, patients were concomitantly using other drugs to manage their pain (anti-epileptics, tricyclic anti-depressants, opioids, non-steroidal anti-inflammatory drugs, selective serotonin reuptake inhibitors, benzodiazepines, skeletal muscle relaxants). The NNT for 30% pain reduction (deemed clinically significant) varied between 8 and 9, whereas the NNT for 50% pain reduction for central neuropathic pain was 3.7, and 8.5 for peripheral pain. In two of the three studies, the majority of subjects had prior experience with cannabis for therapeutic or recreational purposes (503,504). Furthermore, the majority of subjects allocated to the active treatment experienced minor to moderate adverse effects compared to the placebo group. These included nausea, vomiting, constipation, dizziness, intoxication, fatigue, and dry mouth among other effects.

According to the consensus statement and clinical guidelines on the pharmacological management of chronic neuropathic pain published by the Canadian Pain Society in 2007, the Society considered cannabinoid-based therapies (e.g. dronabinol and nabiximols) to be fourth-line treatments for neuropathic pain, mostly as adjuvant analgesics for pain conditions refractory to standard drugs (505) (but also see section 4.7.3 and reference (506) for updated clinical guidelines on the use of cannabinoids for the treatment of symptoms associated with fibromyalgia). Health Canada has approved Sativex[®] (with conditions) as an adjunct treatment for the symptomatic relief of neuropathic pain in multiple sclerosis (290).

A Canadian systematic review of randomized clinical trials of cannabinoids (cannabis, nabilone, dronabinol and nabiximols) for the treatment of chronic non-cancer pain (neuropathic pain, mixed chronic pain, rheumatoid arthritis, fibromyalgia) concluded that cannabinoids are modestly effective for neuropathic pain, with preliminary evidence of efficacy in rheumatoid arthritis (see section 4.7.2) and fibromyalgia (see section 4.7.3) (173). Major limitations identified in the review were short trial duration, small sample sizes, and modest effect sizes, with a need for larger trials of longer duration to better establish efficacy and safety as well as potential for abuse.

4.6.2.3 Cancer pain

Clinical studies with dronabinol

Two randomized, double-blind, placebo-controlled studies suggested oral Δ^9 -THC (dronabinol) provided an analgesic benefit in patients suffering from moderate to severe continuous pain due to advanced cancer. The first study was a dose-ranging study of 5, 10, 15, and 20 mg Δ^9 -THC, given in successive days, to 10 cancer patients (507). Significant pain relief was found at the 15 and 20 mg dose levels, but at these higher doses patients were heavily sedated and mental clouding was common. A second, placebo-controlled study compared 10 and 20 mg oral Δ^9 -THC with 60 and 120 mg codeine in 36 patients with cancer pain (508). While the lower and higher doses of THC were equianalgesic to the lower and higher doses of codeine, respectively, statistically significant differences in analgesia were only obtained between placebo and 20 mg Δ^9 -THC, and between placebo and 120 mg codeine. The 10 mg Δ^9 -THC dose was well tolerated, and despite its sedative effect appeared to have mild analgesic potential. The 20 mg Δ^9 -THC dose induced somnolence, dizziness, ataxia, and blurred vision. Extreme anxiety was also observed at the 20 mg dose in a number of patients.

Clinical studies with nabiximols

A more recent randomized, double-blind, placebo-controlled, parallel-group trial of patients suffering from intractable cancer-related pain (mixed, bone, neuropathic, visceral, somatic/incident) suggested that an orally administered THC : CBD extract (nabiximols), containing 2.7 mg of Δ^9 -THC and 2.5 mg CBD per dose, is an efficacious adjunctive treatment for such cancer-related pain which is not fully relieved by strong opioids (112). Baseline median morphine equivalents/day ranged from 80 - 120 mg. Forty-three percent of patients (n = 60) taking the extract achieved a $\geq 30\%$ improvement in their pain score, which was twice the number of patients who achieved this response in the THC (n = 58) and placebo (n = 59) groups. Both the nabiximols and the THC medications were reported to be well tolerated in this patient population, and adverse events were reported to be similar to those seen in other clinical trials of nabiximols (e.g. somnolence, dizziness, and nausea). This study was followed-up by an open-label extension study which evaluated the long-term safety and tolerability of nabiximols (as well as oro-mucosal THC spray) as an adjuvant pain treatment in patients with terminal cancer-related pain refractory to strong opioid analgesics (509). Patients who had taken part in, fully complied with the study requirements of, had not experienced an unacceptable adverse event in the initial parent study (112), and that were expected to receive clinical benefit from nabiximols (with acceptable tolerability) were enrolled in the extension study. The most commonly reported (50%) pain type was mixed pain (nociceptive and neuropathic), followed by neuropathic pain (37%), and bone pain (28%) (509). The median duration of treatment with nabiximols (n = 39 patients) was 25 days (range: 2 - 579 days) while the mean duration of treatment with oro-mucosal THC spray (n = 4 patients) was 151.5 days (range: 4 - 657 days). The average number of sprays/day for nabiximols during the last seven days of dosing was 5.4 ± 3.28 vs. 14.5 ± 16.84 for THC only. No dose escalation was noted in patients taking nabiximols beyond six months and up to one year following treatment initiation (509). Although the study was a non-comparative, open-label study with no formal hypothesis testing and mostly used descriptive statistics, a decrease from baseline in mean score on the BPI-SF (Brief Pain Inventory Short-Form) was observed for both "pain severity" and "worst pain" over the five weeks of treatment (509). However, the authors noted that the clinical investigators considered that their patients' pain control was sub-optimal. A negative change from baseline (i.e. indicating a worsening) was also reported in the physical functioning score on the EORTC QLQ-30 (an assessment tool to measure the quality of life of patients with cancer), although some improvements in scores for sleep and pain, between baseline and week 5 of treatment, were reported (509). Eight percent of the patients on nabiximols developed a serious nabiximols-associated adverse event. The most commonly reported adverse events for nabiximols were nausea/vomiting, dry mouth, dizziness, somnolence, and confusion (509).

In contrast to the above-mentioned studies using nabiximols, a randomized, double-blind, placebo-controlled, parallel group clinical trial of opioid-treated cancer patients with intractable chronic cancer pain (e.g. bone, mixed, neuropathic, somatic, visceral) reported no statistically significant difference between placebo and the nabiximols treatment group in the primary endpoint of 30% relief from baseline pain at study end (349). However, when using a continuous responder rate analysis as a secondary endpoint (i.e. comparing the proportion of active drug vs. placebo responders across the full spectrum of response from 0 to 100%), the study was able to report a statistically significant treatment effect in favour of nabiximols. Patients were taking median opioid equivalent doses ranging between 120 and 180 mg/day. Adverse events were dose-related, with only the highest dose group comparing unfavourably to placebo. The authors noted that the trial was a dose-ranging study, and that confirmatory studies are strongly warranted. The study design also did not permit the evaluation of a therapeutic index.

In Canada, nabiximols (Sativex®) is approved (with conditions) as an adjunctive analgesic in adults with advanced cancer who experience moderate to severe pain during the highest tolerated dose of strong opioid therapy for persistent background pain (290). Current dosing recommendations for nabiximols suggest a maximum daily dose of 12 sprays (32.4 mg THC and 30 mg CBD) over a 24 h period (107,112,290), although higher numbers of sprays/day have been used or documented in clinical studies (290,349). It should be noted that increases in the number of sprays/day were accompanied by increases in the incidence of adverse effects.

While there are no clinical trials of smoked marijuana for the treatment of cancer pain, the current Marijuana Medical Access Regulations (MMAR) allow the use of dried marijuana in cancer patients who experience severe pain and who have either not benefited from, or would not be considered to benefit from, conventional treatments (384).

“Opioid-sparing” effects and cannabinoid-opioid synergy

The “opioid-sparing” effect refers to the ability of a non-opioid medication to confer adjunctive analgesia with the use of a lower dose of the opioid thereby decreasing opioid-associated side effects. While there are some pre-clinical data supporting such an effect for cannabinoids, this is less well-established in published clinical studies. The following information summarizes the results from pre-clinical and clinical studies investigating cannabinoid-opioid interactions and the potential “opioid-sparing effect” of cannabinoids.

Pre-clinical data

There is a fair amount of evidence to suggest a functional interaction between the cannabinoid and the opioid systems, although much additional research is needed to understand precisely how the two systems communicate with one another. The evidence supporting a putative interaction between the cannabinoid and opioid systems comes from a number of observations. First, it is known that cannabinoids and opioids produce similar biological effects such as hypothermia, sedation, hypotension, inhibition of gastrointestinal motility, inhibition of locomotor activity, and anti-nociception (510,511,512). Furthermore, neuroanatomical studies in animals have demonstrated overlapping tissue distribution of the cannabinoid and opioid receptors, with both receptor types found in nervous system tissues associated with the processing of painful stimuli, namely the periaqueductal gray, raphe nuclei, and central-medial thalamic nuclei (510,511,512). There is also some evidence that the CB₁ and mu-opioid receptors can co-localize in some of the same neuronal sub-populations such as those located in the superficial dorsal horn of the spinal cord (510). This co-localization may play an important role in spinal-level modulation of peripheral nociceptive inputs (510). Both receptors also share similar signal transduction molecules and pathways, the activation of which generally results in the inhibition of neurotransmitter release (510,512). The role of these receptors in inhibiting neurotransmitter release is further supported by their strategic localization on pre-synaptic membranes (510). Evidence from some pre-clinical studies also suggests that acute administration of cannabinoid receptor agonists can lead to endogenous opioid peptide release, and that chronic THC administration increases endogenous opioid precursor gene expression (e.g. preproenkephalin, prodynorphin, and proopioidmelanocortin) in different spinal and supraspinal structures involved in the perception of pain (510). A few studies have even demonstrated the existence of cannabinoid-opioid receptor heteromers, although the exact biological significance of such receptor heteromerization remains to be fully elucidated (513,514). Taken together, these findings suggest the existence of cross-talk between the cannabinoid and opioid systems. Furthermore, pre-clinical studies using a combination of different opioids (morphine, codeine) and cannabinoids (THC), at acute or sub-effective doses, have reported additive and even synergistic analgesic effects (515,516,517,518,519,520).

Clinical data

A limited number of clinical trials have been carried out to date with mixed results. One double-blind, placebo-controlled, crossover study of healthy human volunteers given low doses of THC, morphine, or a combination of the two drugs failed to find any differences between subjects' ratings of *sensory* responses to a painful thermal stimulus (521). However, the study did report that the combination of morphine and THC was associated with a decrease in the subjects' *affective* response to the painful thermal stimulus (521). The authors suggested that morphine and THC could combine to yield a synergistic analgesic response to the *affective* aspect of an experimentally-evoked pain stimulus. One clinical study (502) reported that patients suffering from chronic non-cancer pain and not responding to opioids experienced increased analgesia, decreased pain intensity, and decreased evoked pain when given either 10 or 20 mg dronabinol (for additional details see section 4.6.2.2, under "Clinical Studies With Orally Administered Prescription Cannabinoids"). More recently it was reported that patients suffering from chronic pain of various etiologies, unrelieved by stable doses of opioids (extended release morphine or oxycodone), experienced a statistically significant improvement in pain relief (27%, Confidence Interval = 9 - 46) following inhalation of vaporized cannabis (0.9 g, 3.56% THC, three times per day for five days) (187) (for additional details see section 4.6.2.2, under "Clinical Studies With Smoked or Vaporized Cannabis"). The findings from this study suggest that addition of cannabinoids (in this case inhaled vapourized cannabis) to existing opioid therapy for pain may serve to enhance opioid-associated analgesia (187).

In contrast, another study did not note a statistically significant decrease in the amounts of background or breakthrough opioid medications consumed by the majority of patients suffering from intractable cancer-related pain and taking either nabiximols or THC (112). Similarly, no statistically significant changes were observed in the amounts of background or breakthrough opioid doses taken by patients suffering from intractable cancer-related pain who were administered nabiximols (349). However, the design of the latter study did not allow proper assessment of an "opioid-sparing effect" of nabiximols.

In summary, while "cannabinoid-opioid synergy" has been proposed as a way to significantly increase the analgesic effects of opioids while avoiding, or minimizing, tolerance to the effects of opioid analgesics and circumventing, or attenuating, the well-known undesirable side effects associated with the use of either cannabinoids or opioids, the clinical results are mixed and further study is required on this topic (510,512).

4.6.2.4 Headache and Migraine

While historical and anecdotal evidence suggest a role for cannabis in the treatment of headache and migraine (522), no controlled clinical studies of cannabis or prescription cannabinoids to treat headache or migraine have been carried out to date (523,524).

With regard to migraine, an endocannabinoid deficiency has been postulated to underlie the pathophysiology of this disorder (525); however, the evidence supporting this hypothesis is limited. Clinical studies suggest that the concentrations of anandamide are decreased in the cerebrospinal fluid of migraineurs, while the levels of calcitonin-gene-related-peptide and nitric oxide (normally inhibited by anandamide and implicated in triggering migraine) are increased (526,527). In addition, the activity of the anandamide-degrading enzyme FAAH is significantly decreased in chronic migraineurs compared to controls (528).

In one case-report, a patient suffering from pseudotumour cerebri and chronic headache reported significant pain relief after smoking cannabis (529). In another case-report, a patient complaining of cluster headaches refractory to multiple acute and preventive medications reported improvement with smoked cannabis or dronabinol (5 mg) (530). However, these single-patient case-studies should be interpreted with caution. A recent report indicated that cannabis use was very frequent among a population of French patients with episodic or chronic cluster headache, and of those patients who used cannabis to treat their headache, the majority reported variable, uncertain, or even negative effects of cannabis smoking on cluster headache (531). It should also be noted that cannabis use has been associated with reversible cerebral vasoconstriction syndrome and severe headache (532). In addition, headache is an observed adverse effect associated with the use of cannabis or prescription cannabinoid medications (172,174,290,332,430,449), and headache is also one of the most frequently reported physical symptoms associated with cannabis withdrawal (533). It is therefore possible that using cannabis simply relieves headache caused by cannabis withdrawal.

4.7. Arthritides and Musculoskeletal Disorders

The arthritides include a broad spectrum of different disorders (e.g. osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, gout, and many others) all of which have in common the fact that they target or involve the joints. Among these, osteoarthritis is by far the most common type of arthritis and is the leading cause of disability in those over the age of 65 years in developed countries (534). Rheumatoid arthritis is a destructive, auto-immune disease that affects a smaller, but not insignificant, proportion of the adult population (534). Also covered in this section are musculoskeletal disorders such as fibromyalgia and osteoporosis.

While scientific studies have demonstrated that joints, bone, and muscle all contain a working endocannabinoid system (38,39,40), there is relatively little scientific or medical information on the use of cannabis or cannabinoids to treat either the arthritides or musculoskeletal disorders. The available information is summarized below.

4.7.1 Osteoarthritis

Pre-clinical studies

Very little information is available regarding the use of cannabis or cannabinoids to treat osteoarthritis. One study reported elevated levels of the endocannabinoids anandamide and 2-arachidonoylglycerol (i.e. 2-AG), and the "entourage" compounds PEA and OEA in the spinal cords of rats with experimentally-induced knee joint osteoarthritis (535). While no changes were observed in the levels or the activities of the endocannabinoid catabolic enzymes FAAH or MAGL in the spinal cords of the affected rats, protein levels of the major enzymes responsible for endocannabinoid synthesis were reported to be significantly elevated in these animals (535). Another study in rats reported that intra-articular injection of the CB₁ receptor agonist arachidonyl-2-chloroethylamide (ACEA) in control animals was associated with a reduction in firing rate and suppression of nociceptive activity from pain fibers innervating the joints when the joints were subjected to either normal or noxious joint rotation (536). Similar results were obtained in animals with osteoarthritic joints. The anti-nociceptive effect was blocked by co-administration of a CB₁ receptor antagonist in osteoarthritic joints, but not control joints (536). Lastly, local administration of URB597 (a FAAH inhibitor) by intra-arterial injection proximal to an osteoarthritic joint was associated with decreased mechanosensitivity of joint afferent fibers in two different rodent models of osteoarthritis (537). Behavioural experiments carried out in these rats suggested that treatment with the inhibitor also decreased joint pain measured by a decrease in hindlimb incapitance (537).

Clinical studies

To date there have been no clinical studies of cannabis or cannabinoids to treat osteoarthritis. Nevertheless, the current Marihuana Medical Access Regulations (MMAR) allow the use of dried marihuana for those patients experiencing severe pain associated with severe arthritis who have either not benefited from, or would not be considered to benefit from, conventional treatments (384).

4.7.2 Rheumatoid Arthritis

Rheumatoid arthritis is a systemic, auto-immune, inflammatory arthritis characterized by progressive synovitis with resultant joint destruction, functional disability, significant pain, and systemic complications (e.g. cardiovascular, pulmonary, psychological, and skeletal disorders such as osteoporosis) (538,539).

Pre-clinical studies

A pre-clinical study in a rat model of rheumatoid arthritis reported that treatment with either THC or anandamide was associated with significant anti-nociception in the paw-pressure test (258). Another study using the same animal model demonstrated a synergistic anti-nociceptive interaction between THC and morphine in both arthritic and non-arthritic rats in the paw-pressure test (257).

Clinical studies

In humans, one study found that the levels of the endocannabinoids anandamide (AEA) and 2-arachidonoylglycerol (2-AG) in the synovial fluid of patients with osteoarthritis and rheumatoid arthritis were increased compared to non-inflamed normal controls, although the significance of these findings remains unclear (40).

A preliminary clinical study assessing the effectiveness of nabiximols (Sativex[®]) for pain caused by rheumatoid arthritis reported a modest but statistically significant analgesic effect on movement and at rest, as well as

improvement in quality of sleep (259). Administration of nabiximols was well tolerated and no significant toxicity was observed. The mean daily dose in the final treatment week was 5.4 pump actuations (equivalent to 14.6 mg THC and 13.5 mg CBD/day, treatment duration was three weeks) (259). The differences observed were small and variable across the participants.

A recent Cochrane Collaboration review concluded that the evidence in support of the use of oro-mucosal cannabis (e.g. nabiximols) for the treatment of pain associated with rheumatoid arthritis is weak and given the significant side effect profile typically associated with the use of cannabinoids, the potential harms seem to outweigh any modest benefit achieved (538).

Nevertheless, the current Marijuana Medical Access Regulations (MMAR) allow the use of dried marijuana for those patients experiencing severe pain associated with severe arthritis who have either not benefited from, or would not be considered to benefit from, conventional treatments (384).

4.7.3 Fibromyalgia

Fibromyalgia is a disorder characterized by widespread pain (allodynia and hyperalgesia) and a constellation of other symptoms including sleep disorders, fatigue, and emotional or cognitive disturbances (540). While the underlying pathophysiology of fibromyalgia remains unclear, disturbances in the recruitment or functioning of peripheral and central pain processing pathways and in the levels of several important neurotransmitters (serotonin, noradrenaline, dopamine, opioids, glutamate and substance P) have been noted in patients suffering from fibromyalgia (541,542,543,544). Co-morbid depressive symptoms have also been associated with a more pronounced deficit in pain inhibition, as well as increased pain in fibromyalgia patients (545).

Clinical studies with smoked or orally ingested cannabis

There are no clinical trials of smoked or ingested cannabis for the treatment of fibromyalgia. However, a cross-sectional survey of patients suffering from fibromyalgia found that the patients reported using cannabis (by smoking and/or eating) to alleviate pain, sleep disturbance, stiffness, mood disorders, anxiety, headaches, tiredness, morning tiredness, and digestive disturbances associated with fibromyalgia (158). Subjects (mostly middle-aged women who did not respond to current treatment) reported statistically significant decreases in pain and stiffness, and statistically significant increases in relaxation, somnolence, and well-being 2 h after cannabis self-administration (158). Side effects included somnolence, dry mouth, sedation, dizziness, high, tachycardia, conjunctival irritation, and hypotension (158). The study suffered from a number of limitations including the study design, small sample size, variability in frequency and duration of cannabis use, and a biased subject population.

Clinical studies with prescription cannabinoid medications

There are relatively few properly controlled clinical studies examining the role of cannabinoids in the treatment of fibromyalgia. The available evidence is summarized below.

Dronabinol

A non-placebo controlled pilot study examining the effect of dronabinol monotherapy (2.5 - 15 mg Δ^9 -THC/day; with weekly increases of 2.5 mg Δ^9 -THC, up to a maximum of 15 mg THC/day) on experimentally-induced pain, axon reflex flare, and pain relief in patients suffering from fibromyalgia reported that a sub-population of such patients experienced significant pain relief (reduced pain perception) with 10 and 15 mg/day Δ^9 -THC, but no changes were observed in axon reflex flare (260). Touch-evoked allodynia and pinprick-induced hyperalgesia were also not significantly affected by Δ^9 -THC. Subjects who completed a three-month course of therapy (15 mg/day Δ^9 -THC) reported a > 50% decrease in pain (260). The study, however suffered from low power due to the high rate of patient drop-out caused by intolerable side effects of the treatment. A multi-center, retrospective study of patients suffering from fibromyalgia who were prescribed an average daily dose of 7.5 mg Δ^9 -THC, over an average treatment period of seven months, reported a significant decrease in pain score, a significant decrease in depression, and a reduction in the intake of concomitant pain-relief medications such as opioids, antidepressants, anti-convulsants, and non-steroidal anti-inflammatory drugs following treatment with Δ^9 -THC (261). It is important to note that the study had a number of considerable limitations (method of data collection, heterogeneous patient selection criteria, and high subject drop-out rate) and as such, the results should be interpreted with caution.

Nabilone

A randomized, double-blind, placebo-controlled trial of nabilone (1 mg b.i.d.) for the treatment of fibromyalgia showed statistically significant improvements in a subjective measure of pain relief and anxiety, as well as on scores on the fibromyalgia impact questionnaire, after four weeks of treatment (353). However, no significant changes in the number of tender points or tender point pain thresholds were observed (note: the use of the "tender point" as a diagnostic criterion for fibromyalgia is no longer an absolute requirement) (546). Patients were taking concomitant pain medications such as non-steroidal anti-inflammatory drugs, opioids, anti-depressants, and muscle relaxants. Nabilone did not have any lasting benefit in subjects when treatment was discontinued. A two-week randomized, double-blind, active-control, crossover study of 29 patients suffering from fibromyalgia reported that nabilone (0.5 - 1.0 mg before bedtime) improved sleep in this patient population (354).

The recently published Canadian Clinical Guidelines for the Diagnosis and Management of Fibromyalgia Syndrome (endorsed by the Canadian Pain Society and the Canadian Rheumatology Association) indicate that with regards to possible treatments, a trial of a prescribed pharmacologic cannabinoid may be considered in a patient with fibromyalgia, particularly in the setting of important sleep disturbance (this recommendation was based on Level 3, Grade C evidence) (506). For additional information regarding the use of cannabis/cannabinoids to alleviate sleep disorders or disturbances, please consult section 4.8.5.2.

4.7.4 Osteoporosis

Osteoporosis is a disease characterized by reduced bone mineral density and an increased risk of fragility fractures (547). It occurs when the normal cycle of bone remodelling is perturbed, leading to a net decrease in bone deposition and a net increase in bone resorption (548). While increasing evidence suggests a role for the endocannabinoid system in bone homeostasis, the role of cannabinoids in the treatment of osteoporosis has only been studied pre-clinically and the information remains unclear due to the complex and conflicting results among the various pre-clinical studies.

Pre-clinical studies

CB₁ and CB₂ receptors have been detected in mouse osteoblasts and osteoclasts, although CB₁ is expressed at very low levels compared to CB₂ (18,549,550). In fact, it appears that CB₁ receptors are expressed more abundantly in skeletal sympathetic nerve terminals in close proximity to osteoblasts (551). Besides the receptors, the endocannabinoids 2-arachidonoylglycerol (2-AG) and anandamide have been detected in mouse trabecular bone and in cultures of mouse osteoblasts and human osteoclasts (550,552,553). Taken together, these findings suggest the existence of a functional endocannabinoid system in bone.

The role of the endocannabinoid system in bone physiology has been investigated using mice carrying genetic deletions of either the CB₁ (*CNR1*) or CB₂ (*CNR2*) receptor genes. The skeletal phenotypes of CB₁ receptor knockout mice appear to vary depending on the gene targeting strategy used, the mouse strain, gender, time points at which the phenotypes were assessed, and the different experimental methodologies used to measure bone density (18). In one CB₁-deficient mouse strain, young female mice had normal trabecular bone with slight cortical expansion whereas young male mice had high bone mass (549,551). Loss of CB₁ receptor function was associated with protection from ovariectomy-induced bone loss (549). In addition, antagonism of CB₁ and CB₂ receptors prevented ovariectomy-induced bone loss *in vivo* (549). A subsequent study by the same group reported that CB₁ knockout mice had increased peak bone mass but eventually developed age-related osteoporosis (547). The increased peak bone mass was attributed to a reduction in osteoclast formation and activity, with preservation of normal osteoblast activity. In contrast, age-related bone loss in the knockout mice appeared to be caused by preferential formation and accumulation of adipocytes at the expense of osteoblasts within the bone-marrow space as well as decreased bone formation (547). In contrast to these studies, another study using a different gene targeting strategy and mouse strain reported that both male and female CB₁ knockout mice exhibited low bone mass, increased numbers of osteoclasts, and a decrease in the rate of bone formation (551). The effects of ovariectomy in this mouse line were not examined, most likely because the baseline bone mass was too small to properly measure differences between mice subjected to ovariectomy and controls.

The skeletal phenotypes of CB₂ receptor knockout mice have also been investigated. Ofek reported that CB₂-deficient mice display a low bone mass phenotype as well as age-related trabecular bone loss (554). These deficits were associated with increased numbers of osteoclasts and decreased numbers of osteoblast precursors (554). Furthermore, a selective CB₂ receptor agonist was reported to increase osteoblast proliferation and activity and to decrease the formation of osteoclast-like cells *in vitro*, and administration of this agonist attenuated ovariectomy-induced bone loss *in vivo* (554). While a more recent study supported the finding of age-related bone

loss, it failed to find any significant differences in peak bone mass between wild-type and knockout mice (555). Furthermore, and in contrast to the study by Ofek (554), selective stimulation of the CB₂ receptor was associated with an increase in osteoblast differentiation and function rather than proliferation. Another study reported no differences in peak bone mass between CB₂ receptor knockout mice and wild-type mice under normal conditions (556). Age-related bone loss was not measured in this study. Genetic ablation of the CB₂ receptor appeared to protect against ovariectomy-induced bone loss, an effect mimicked by administration of a CB₂-selective antagonist (556). Conversely, results from *in vitro* studies suggested that CB₂-selective agonists significantly increased osteoclast formation and osteoclast size (556). It may be relevant to note here that single nucleotide polymorphisms (SNPs) and SNP haplotypes located in the coding region of the CB₂ receptor gene have also been associated with osteoporosis in humans (557,558,559).

A pre-clinical study in rats measuring the impact of cannabis smoke on bone healing around titanium implants reported that chronic exposure to cannabis smoke reduced cancellous bone healing around the implants by reducing bone filling and bone-to-implant contact inside the implant threads (263). No such effect was observed for cortical bone (263).

4.8 Other diseases and symptoms

4.8.1 Movement disorders

The individual components of the endocannabinoid system are particularly abundant in areas of the brain which control movement, such as the basal ganglia (560). Motor effects generally arise as a consequence of changes in endocannabinoid system activity, with activation of the CB₁ receptor typically resulting in inhibition of movement (560). A number of studies have reported changes in CB₁ receptor levels and CB₁ receptor activity in motor diseases such as Parkinson's and Huntington's disease (561,562,563,564), and the findings from such studies suggest a role for the endocannabinoid system in the pathophysiology of these and other neurological diseases.

4.8.1.1 Dystonia

Pre-clinical data

A pre-clinical study in a hamster model of primary generalized dystonia reported a dose-dependent decrease in disease severity with administration of the synthetic CB₁ and CB₂ cannabinoid receptor agonist WIN 55,212-2 (565). However, anti-dystonic doses of the agonist were associated with severe side effects including depression of spontaneous locomotor activity and catalepsy. In addition, this CB receptor agonist increased the anti-dystonic effect of diazepam (565). A follow-up study by the same group confirmed the anti-dystonic efficacy of WIN 55,212-2 and also showed that cannabidiol delayed the progression of dystonia, but only at a very high dose (566). A pre-clinical study of anti-psychotic-induced acute dystonia and tardive dyskinesia in monkeys showed that oral dyskinesia, but not dystonia, was dose-dependently reduced by the synthetic CB₁ receptor agonist CP 55,940 (567).

Clinical data

While anecdotal reports suggest cannabis may alleviate symptoms associated with dystonia in humans (568), no properly controlled clinical studies of cannabis to treat dystonia have been published. A placebo-controlled, single-dose trial with 5 mg of Δ^9 -THC administered to a musician with focal dystonia ("Musician's Dystonia") reported an improvement in motor control in the subject's affected hand, with tiredness and poor concentration cited as side effects associated with the use of Δ^9 -THC (569). The therapeutic effect persisted until 2 h after intake, with a progressive return to baseline values after 5 h (569). A six-week, open-label, pilot trial of five patients taking 100 - 600 mg/day of cannabidiol reported modest dose-related improvements in all study subjects, but a worsening of tremor and hypokinesia in two patients with co-existing Parkinson's disease (570). Results of a double-blind, randomized, placebo-controlled study of 15 patients taking a single 0.03 mg/kg dose of nabilone and not taking any other anti-dystonia medication showed no significant reduction in dystonia (571).

4.8.1.2 Huntington's disease

Pre-clinical and human experimental data

Results from studies carried out in animal models of Huntington's disease (HD) as well as post-mortem studies carried out in HD patients suggest that brain CB₁ receptors, especially those found in the basal ganglia, are downregulated and/or desensitized as a result of the expression of the mutant Huntingtin protein, and that this occurs early in the course of the disease and prior to the appearance of overt clinical symptoms (561,572,573,574,575,576,577,578,579,580,581). A recent *in vivo* PET study of HD patients supports these findings, demonstrating profound decreases in CB₁ receptor availability throughout the gray matter of the cerebrum, cerebellum, and brainstem of HD patients even in early stages of the disease (582). Additional pre-clinical and post-mortem studies in HD patients indicate that the decrease in CB₁ receptor levels appears to be accompanied by an increase in CB₂ receptor levels in glial elements, astrocytes, and in reactive microglial cells (577,583). Thus, a significant amount of pre-clinical evidence and some limited clinical evidence suggests that changes in the endocannabinoid system are tightly linked to the pathophysiology of HD (577,580,581,582).

One pre-clinical study in a mouse model of HD reported no beneficial effects of Δ^9 -THC (10 mg/kg/day) (584), while another study reported that Δ^9 -THC (2 mg/kg/day) was associated with decreased pathology and delayed onset of HD-like symptoms compared to untreated HD mice (579).

Clinical data

With regard to clinical studies, one double-blind, placebo-controlled, 15-week, crossover trial of 15 patients with HD taking 10 mg/kg/day of oral cannabidiol did not report improvement in symptoms associated with HD (585). A randomized, double-blind, placebo-controlled, crossover pilot study found little or no beneficial effect of nabilone over placebo in patients with HD (586). However, nabilone was well tolerated in this patient population and did not appear to exacerbate chorea or HD-associated psychosis, although some adverse effects such as drowsiness and forgetfulness were noted. Patients were concomitantly taking other HD medications. The results from single-patient case studies are mixed. In one study, daily doses of 1.5 mg nabilone increased choreatic movements (587), while in another case improved mood and decreased chorea were noted in a patient who had smoked cannabis and who then continued on 1 mg nabilone b.i.d. (588).

4.8.1.3 Parkinson's disease

Endocannabinoid ligands, their synthesizing and degrading enzymes, and cannabinoid-activated receptors are highly abundant in the basal ganglia, the brain structures primarily affected in Parkinson's disease (PD) (560). Newly diagnosed PD patients and those undergoing PD medication washout were reported to have more than double the level of anandamide in their cerebrospinal fluid compared to controls, and these results parallel those seen in animal models of PD where dopamine cell loss is accompanied by elevations in anandamide levels (589). In animal models of PD the levels of CB₁ receptors appear to be downregulated during the early, pre-symptomatic stages of the disease, but during the intermediate and advanced phases of the disease there is an increase in CB₁ receptor density and function and an increase in endocannabinoid levels (590,591). Together, these studies suggest a complex link between the pathophysiology of PD and changes in the endocannabinoid system.

Results from animal studies suggest cannabinoid receptor agonists induce hypokinesia and thus are reported to be unlikely as suitable first-line treatments for PD (560,592). On the other hand, cannabinoid-induced hypokinesia could be useful in attenuating the dyskinesia observed in PD patients on long-term levodopa treatment (592). Cannabinoids having mixed CB₁ antagonist/CB₂ agonist properties as well as anti-oxidant effects (such as THCv) may possibly hold some therapeutic potential, but much further research is required to determine whether the beneficial effects of THCv observed in animal models of PD can find applicability in humans (593).

Clinical data

The results of clinical trials examining the role of cannabinoids (cannabis, nabilone and a standardized oral cannabis extract) in the treatment of PD are mixed. One study involving five patients suffering from idiopathic PD found no improvement in tremor after a single episode of smoking cannabis (1 g cigarette containing 2.9% Δ^9 -THC, 29 mg total available Δ^9 -THC), whereas all subjects benefited from the

administration of levodopa and apomorphine (594). A small randomized clinical trial of the synthetic cannabinoid nabilone (0.03 mg/kg) in seven patients with PD found that the treatment reduced levodopa-induced dyskinesia (595). In contrast, a four-week, randomized double-blind, crossover study demonstrated that an oral cannabis extract (2.5 mg Δ^9 -THC and 1.25 mg cannabidiol per capsule, b.i.d.; maximum daily dose 0.25 mg/kg Δ^9 -THC) did not produce any pro- or anti-parkinsonian action (596).

4.8.1.4 Tourette's syndrome

Anecdotal and case-reports have suggested amelioration of symptoms associated with Tourette's syndrome when smoking cannabis (597,598). A two-day, randomized, double-blind, placebo-controlled, crossover trial of single oral doses of Δ^9 -THC (5, 7.5, or 10 mg) in 12 adult patients with Tourette's syndrome showed plasma concentration-related improvements in control of motor and vocal tics and obsessive-compulsive behaviour, with no serious side effects; although transient, mild side effects (e.g. headache, nausea, ataxia, fatigue, anxiety) were noted in five patients (599). In contrast to healthy cannabis users, neither a 5 mg nor a 10 mg dose of Δ^9 -THC caused cognitive impairment in patients with Tourette's syndrome (599). This study was followed up by a six-week, randomized, double-blind, placebo-controlled trial by the same research group. The authors reported a significant difference in tic reduction compared to placebo in some patients, and no detrimental effects on neuropsychological performance during or after treatment with 10 mg doses of Δ^9 -THC (600). The major limitations of all three clinical studies were their small sample size and their relatively short duration.

A Cochrane Collaboration Review examining the efficacy and safety of cannabinoids in treating tics, premonitory urges, and obsessive compulsive symptoms in patients with Tourette's syndrome concluded that there was insufficient evidence to support the use of cannabinoids in treating tics and obsessive compulsive behaviour in persons suffering from Tourette's syndrome (601).

4.8.2 Glaucoma

Glaucoma is a multi-factorial disease characterized by the progressive degeneration of the optic nerve and the death of retinal ganglion cells (RGC) ultimately leading to irreversible blindness (602). Increased intra-ocular pressure (IOP) has been implicated in the pathophysiology of glaucoma; however, inadequate blood supply to the optic nerve, oxidative damage, and apoptosis of RGCs are also contributing factors (265,602,603,604). An endocannabinoid system exists in a number of ocular tissues, and post-mortem studies have detected decreased levels of endocannabinoids in such tissues taken from glaucoma patients (605).

Ocular (as well as systemic) administration of cannabinoids typically lowers IOP by up to 30% (see (265) for a full reference list). How cannabinoids reduce IOP is unclear, but several possible mechanisms have been proposed including reduction of capillary pressure, decreased aqueous humour production, and improved aqueous humour uveoscleral outflow and outflow facility (606,607,608,609,610).

A well-controlled pilot study of six patients with ocular hypertension or early primary open-angle glaucoma reported that single sub-lingual doses of 5 mg Δ^9 -THC (applied by means of an oro-mucosal spray) significantly but temporarily reduced IOP 2 h after administration (264). A single sub-lingual dose of 20 mg cannabidiol (CBD) (containing ~ 1 mg Δ^9 -THC) had no effect, while a single sub-lingual dose 40 mg of CBD (containing ~ 2 mg Δ^9 -THC) caused a significant transient increase in IOP 4 h after administration (264). A non-randomized, unmasked, uncontrolled clinical study reported some improvement in IOP after oral ingestion of Δ^9 -THC (2.5 or 5 mg q.i.d., up to a maximum of 20 mg/day; treatment duration range 3 - 36 weeks) in patients with end-stage, open-angle glaucoma not responsive to medications or surgery (611). Some patients appeared to develop tolerance to the intra-ocular pressure-lowering effects of Δ^9 -THC, and almost half discontinued treatment due to Δ^9 -THC-associated toxicity (e.g. dizziness, dry mouth, sleepiness, depression, confusion) (611). Aside from lowering IOP, cannabinoids such as Δ^9 -THC and CBD may also have neuroprotective effects which could also be useful in the management of glaucoma (265,612,613,614,615,616,617,618,619,620,621). Results from a survey carried out among 1 516 glaucoma patients at tertiary glaucoma clinics in Toronto and Montreal suggested that approximately 13% of these patients claimed they used complementary and alternative medicines to treat glaucoma, and from among these patients 2.3% reported using cannabis to treat their glaucoma (622).

In conclusion, while smoking or eating cannabis has been shown to reduce IOP (623,624,625), cannabinoid-based therapy appears to be limited by the short duration of cannabinoid action (3 - 4 h) and unwanted physical and psychotropic effects.

4.8.3 Asthma

There is some historical and anecdotal evidence for cannabis as a treatment for asthma (626). In terms of pre-clinical data, there is some evidence suggesting a role for the endocannabinoid system in regulating bronchial smooth muscle tone (627) and studies in animals with classical and synthetic cannabinoids suggest a possible role for cannabinoid-based compounds in the treatment of asthma (628,629,630).

Early clinical studies demonstrated significant decreases in airway resistance and increases in specific airway conductance in healthy, habitual cannabis smokers shortly after smoking cannabis (631,632). This effect has been largely attributed to the bronchodilatory properties of Δ^9 -THC (633). However, for asthmatics, the benefits of smoking cannabis are likely to be minimal. While smoking cannabis appears to decrease bronchospasm, increase bronchodilatation, and modestly improve respiratory function in some asthmatics in the short-term (634,635,636), cannabis smoke contains noxious gases and particulates that irritate and damage the respiratory system (633); hence, it is not a viable long-term therapy for asthma. Nevertheless, alternate methods of Δ^9 -THC delivery by aerosol or oral administration have been studied. Doses of 100 and 200 μ g of aerosolized Δ^9 -THC significantly improved ventilatory function in asthmatics and were generally well tolerated (637,638). In another study, 5 - 20 mg of aerosolized Δ^9 -THC rapidly and effectively increased airway conductance in healthy subjects, but caused either bronchodilatation or bronchoconstriction in asthmatics (639). Oral administration of 10 mg Δ^9 -THC or 2 mg nabilone did not produce clinically significant bronchodilatation in patients with reversible airways obstruction (626,640,641).

4.8.4 Hypertension

CB₁ receptors are expressed on various peripheral tissues including the heart and vasculature, and cannabinoid agonists and endocannabinoids decrease arterial blood pressure and cardiac contractility (reviewed in (642)). There are very few studies on the effects of cannabis or cannabinoids on hypertension. In one early study, inhalation of cannabis smoke from cigarettes containing 2.8% Δ^9 -THC caused a greater and longer-lasting decrease of arterial blood pressure in hypertensive subjects compared to normotensives (643). In one case-report, a woman with longstanding idiopathic intra-cranial hypertension reported improvement in her symptoms after smoking cannabis or after treatment with dronabinol (10 mg b.i.d initially, then 5 mg b.i.d.).

There are no reports on the use of low-dose cannabinoids as supplementary therapy in hypertension.

4.8.5 Psychiatric disorders

There are anecdotal and, in some cases, historical claims regarding the beneficial effects of cannabis and cannabinoids in the treatment of a variety of psychiatric disorders including anxiety, depression, sleep disorders, post-traumatic stress disorder, and withdrawal symptoms associated with drug abuse/addiction. The following sections provide information gathered from the scientific and medical literature regarding the use of cannabis and cannabinoids in the treatment of such disorders.

4.8.5.1 Anxiety and depression

Long-term cannabis users report reductions in anxiety, increased relaxation, and relief from tension (147). One survey conducted among over 4 400 respondents suggested that those who consumed cannabis daily or weekly reported a decrease in depressed mood, and an increase in positive affect, compared to respondents who claimed they never consumed cannabis (644). However, the study suffered from a number of serious drawbacks and should be interpreted with this in mind.

Pre-clinical and clinical evidence indicates important roles for the endocannabinoid system in both anxiety and depression. Results from animal studies suggest low doses of CB₁ receptor agonists reduce anxiety-like behaviour and increase anti-depressant-like responses (645,646). CB₁ receptor agonists appear to enhance central serotonergic and noradrenergic neurotransmission similar to the actions of anti-depressant medications (647,648). On the other hand, high-level stimulation of the CB₁ receptor, or administration of CB₁ receptor antagonists, reverse this response and can also trigger depression (155,647,649,650).

Suppression of endocannabinoid signalling is sufficient to induce a depressive-like state both in animals and in humans (reviewed in (651)). Furthermore, basal serum concentrations of both anandamide and 2-arachidonoylglycerol (2-AG) have been found to be significantly reduced in women with major depression (652). These findings suggest proper endocannabinoid tone plays an important role in regulating mood.

Clinical data for cannabis and THC

While the routine use of cannabis or prescription cannabinoid medications to treat primary anxiety or depression should be viewed with caution, and especially discouraged in patients with a history of psychotic disorders (see section 7.7.3.3), limited clinical evidence indicates that these drugs may present alternative therapeutic avenues in patients suffering from anxiety or depression secondary to certain chronic diseases. For example, in a study of HIV+ patients who reported using cannabis to manage their symptoms, 93% cited an improvement in anxiety and 86% cited an improvement in depression (653). It is important to note that 47% of those surveyed reported deterioration in memory. In another study of HIV+ cannabis smokers, high-dose dronabinol (5 mg q.i.d., for a total daily dose of 20 mg, for two days, followed by 10 mg q.i.d., for a total daily dose of 40 mg, for 14 days) was associated with an increase in self-reported "positive affect" (feeling "content"), but no change was observed in measures of anxiety or "negative affect" (193). The dosage employed in this study was eight times the recommended starting dose for appetite stimulation (i.e. 2.5 mg b.i.d), and double the maximal daily recommended dose. Improved mood was also reported as a beneficial effect of cannabis consumption in patients suffering from multiple sclerosis (654). Improvements in anxiety or depression were equally noted in a study of patients suffering from chronic neuropathic pain who smoked cannabis (172). It may be interesting to note here that rimonabant, a CB₁ receptor antagonist initially marketed as an anti-obesity medication, was withdrawn from the market because its use was associated with a significant incidence of anxiety, depression, and suicide, underscoring the role of the CB₁ receptor in regulating mood (650,655).

Cannabidiol

Increasing evidence suggests a role for cannabidiol (CBD) in decreasing anxiety, although the extent to which CBD (at the concentrations commonly found in cannabis) is able to achieve this effect remains uncertain (181,656). Pre-clinical studies have shown that CBD and CBD-derivatives decreased anxiety-like behaviour in a rat model of anxiety (657). An early clinical study showed that CBD (1 mg/kg) attenuated, but did not completely block, the anxiogenic effects of THC (0.5 mg/kg) in eight healthy volunteers with a history of marijuana use (97). A double-blind, crossover clinical study showed that a single dose of CBD (400 mg) significantly decreased anticipatory anxiety but increased mental sedation, although the findings were deemed to be preliminary and follow-up studies were suggested (658). Single-photon emission computed tomography (SPECT) brain imaging studies showed that in contrast to placebo, CBD decreased regional cerebral blood flow in the limbic and paralimbic cortical areas, regions implicated in the pathophysiology of anxiety (658). Furthermore, a randomized, double-blind, placebo-controlled study showed that 600 mg of CBD attenuated brain activity (blood oxygenation level-dependent response) in these cortical regions in response to anxiogenic stimuli (104). In contrast, 10 mg Δ^9 -THC increased anxiety at baseline or in response to anxiogenic stimuli, but the brain regions affected by Δ^9 -THC differed from those affected by CBD (104). A more recent double-blind, randomized, placebo-controlled clinical study showed that 600 mg of orally-administered CBD was associated with a significant reduction in anxiety, cognitive impairment, and discomfort in patients suffering from generalized social anxiety disorder subjected to a simulated public-speaking test (659). The authors caution that the study was preliminary in nature, with additional larger and well-controlled studies required to substantiate this effect. Although the precise mechanism by which CBD exerts its anxiolytic effects is not well established, it may act either by decreasing blood flow to brain regions associated with the processing of anxiety or fear-based stimuli (as mentioned above), or possibly through the modulation of serotonergic neurotransmission (660,661).

4.8.5.2 Sleep disorders

Pre-clinical data

There is some evidence to suggest a role for the endocannabinoid system in sleep. Subjects deprived of sleep for a 24 h period had increased levels of oleoylethanolamide (OEA), a natural analog of anandamide, in their cerebrospinal fluid but not in serum, whereas levels of anandamide were unchanged (662). In rats, both acute and sub-chronic administration of anandamide induces sleep (663). Cannabis and Δ^9 -THC are known to have a number of effects on sleep. In general, it appears that these substances decrease sleep latency and are associated with greater ease in getting to sleep, but they consistently reduce total rapid-eye movement (REM) sleep and REM density (reviewed in (161)). Furthermore, due to the long half-life of THC, sedative effects typically persist into the day following cannabinoid administration (161).

Clinical data

A number of clinical studies point to a potential beneficial role for smoked cannabis or prescription cannabinoids (dronabinol, nabilone, nabiximols) in the treatment of sleep difficulties or disturbances associated with chronic pain (cancer pain, chronic non-cancer pain, diabetic peripheral neuropathy), HIV-associated anorexia-cachexia, multiple sclerosis, amyotrophic lateral sclerosis, spinal cord injury, rheumatoid arthritis, fibromyalgia, inflammatory bowel disease, multiple sclerosis-associated bladder dysfunction, post-traumatic stress disorder, and chemosensory alterations and anorexia-cachexia associated with advanced cancer (157,158,165,166,167,172,193,259,348,354,362,364,378,432,438,443,448,449,494,506). In most of these studies, the effect on sleep was measured as a secondary outcome. Although presented elsewhere throughout the text in the relevant sections, brief summaries of these studies are presented below.

Dronabinol

A four-week, randomized, double-blind, crossover pilot study of 19 patients suffering from amyotrophic lateral sclerosis (ALS) taking 2.5 - 10 mg per day of dronabinol reported improvements in sleep (443). Two studies reported that dronabinol (20 - 40 mg total Δ^9 -THC/day) and smoked cannabis (~800 mg cigarettes containing 2 or 3.9% THC, administered four times per day for four days, corresponding to an estimated daily amount of 64 - 125 mg of Δ^9 -THC) produced improvements in mood and sleep in patients with HIV/AIDS-associated anorexia-cachexia (166,167). A study of HIV+ cannabis smokers treated with dronabinol for 14 days (10 mg q.i.d., 40 mg daily) reported improvements in both objective and subjective measures of sleep, but only during the first eight days of the treatment regimen (193). A two-centre, phase II, randomized, double-blind, placebo-controlled 22-day pilot study carried out in adult patients suffering from chemosensory alterations and poor-appetite associated with advanced cancer of various etiologies reported statistically significant improvements in measures of quality of sleep and relaxation with dronabinol treatment (2.5 mg b.i.d.) compared to placebo (362).

Nabilone

An off-label, retrospective, descriptive study of 20 adult patients suffering from chronic non-cancer pain of various etiologies (post-operative or traumatic pain, reflex sympathetic dystrophy, arthritis, Crohn's disease, neuropathic pain, interstitial cystitis, HIV-associated myopathy, post-polio syndrome, idiopathic inguinal pain, chronic headaches) reported beneficial effects of nabilone (1 - 2 mg/day) on sleep (494). An enriched-enrolment, randomized-withdrawal, flexible-dose, double-blind, placebo-controlled, parallel assignment efficacy study of nabilone (1 - 4 mg/day), as an adjuvant in the treatment of diabetic peripheral neuropathic pain, reported statistically significant improvements in sleep and overall patient status (364). An open-label, non-placebo-controlled trial of nabilone for post-traumatic stress disorder reported that nabilone treatment was associated with an improvement in sleep time, cessation or lessening of nightmare severity, and cessation of night sweats (348). Dosing of nabilone was 0.5 mg, 1 h prior to bedtime; effective dose range was 0.2 mg - 4 mg nightly with all doses kept below 6 mg daily. A two-week, randomized, double-blind, active-control, crossover study of 29 patients suffering from fibromyalgia reported that nabilone (0.5 - 1.0 mg before bedtime) improved sleep in this patient population (354).

Smoked cannabis

Surveys carried out among patients suffering from multiple sclerosis reported cannabis-associated improvements in sleep in this patient population (164,165). Reported dosages of smoked cannabis varied from a few puffs, to 1 g or more, at a time (165). A cross-sectional survey of patients suffering from fibromyalgia reported that subjects claimed using cannabis (by smoking and/or eating) for a variety of symptoms associated with fibromyalgia, including sleep disturbance (158). A cross-sectional survey of 291

patients with inflammatory bowel disease (Crohn's disease or ulcerative colitis) reported that one of the reasons patients used cannabis was to improve sleep (157). A two-week, randomized, double-blind, placebo-controlled, cross-over study of patients suffering from chronic neuropathic pain reported that those who smoked 25 mg of cannabis containing 9.4% Δ^9 -THC, three times per day for five days (2.35 mg total available Δ^9 -THC per cigarette, or 7.05 mg total Δ^9 -THC per day), fell asleep more easily and more quickly, and experienced fewer periods of wakefulness (172).

Orally administered prescription cannabinoid medications (Cannador and nabiximols)

A double-blind, placebo-controlled, phase III study, involving patients with stable multiple sclerosis (the Multiple Sclerosis and Extract of Cannabis trial—i.e. "MUSEC") reported that a 12-week treatment with an oral cannabis extract ("Cannador") (2.5 mg Δ^9 -THC and 0.9 mg cannabidiol/dose) was associated with a statistically significant improvement in sleep compared to placebo (432). The majority of the patients using cannabis extract used total daily doses of 10, 15, or 25 mg of Δ^9 -THC with corresponding doses of 3.6, 5.4, and 9 mg of CBD. Results from double-blind, crossover, placebo-controlled studies of oral Δ^9 -THC and/or Δ^9 -THC : CBD extract (nabiximols, marketed as Sativex[®]) suggested modest improvements in pain, spasticity, muscle spasms, and sleep quality in patients with spinal cord injury (378,448,449). A preliminary clinical study assessing the effectiveness of nabiximols (Sativex[®]) in pain caused by rheumatoid arthritis reported a modest, but statistically significant, analgesic effect and consequent improvement in quality of sleep (259). The mean daily dose in the final treatment week was 5.4 pump actuations (equivalent to 14.6 mg Δ^9 -THC and 13.5 mg CBD). A sixteen-week, open-label pilot study of cannabis-based extracts (a course of Sativex[®] treatment followed by maintenance with 2.5 mg Δ^9 -THC only) for bladder dysfunction in 15 patients with advanced multiple sclerosis reported significant decreases in nocturia and improvement in patient self-assessment of sleep quality (438).

The recently published Canadian Guidelines for the Diagnosis and Management of Fibromyalgia Syndrome (endorsed by the Canadian Pain Society and the Canadian Rheumatology Association) recommend that with regards to possible treatments, a trial of a prescribed pharmacologic cannabinoid may be considered in a patient with fibromyalgia, particularly in the setting of important sleep disturbance (this recommendation was based on Level 3, Grade C evidence) (506).

Data from withdrawal studies

Heavy cannabis users (mean number of joints smoked per week = 100) who abruptly discontinued cannabis use have been shown to exhibit changes in polysomnographic sleep measures, including lower total sleep times, less slow wave sleep, longer sleep onset, shorter REM latency, and worse sleep efficiency and continuity parameters compared to controls (664). Trouble getting to sleep, nightmares and/or strange dreams, and night sweats were frequently cited items associated with cannabis withdrawal (222). These sleep disturbances progress over the first two weeks of abstinence (665). Furthermore, sleep disturbances resulting from abrupt discontinuation of cannabis use may trigger users to relapse (274,665). The symptoms observed during abstinence from cannabis may alternatively reveal a pre-existing sleep disorder masked by the drug.

4.8.5.3 Post-traumatic stress disorder (PTSD)

Post-traumatic stress disorder (PTSD) refers to the development of a cluster of characteristic symptoms that follow exposure to an extreme traumatic stressor and which appears to involve aberrant memory processing and impaired adaptation to changed environmental conditions (666). Characteristic symptoms include persistent, intrusive recollections, or a re-experiencing of the original traumatic event (through dreams, nightmares, and dissociative flashbacks), numbing and avoidance, and increased arousal (348).

Role of the endocannabinoid system in PTSD

Increasing evidence suggests an important role for the endocannabinoid system in PTSD. The endocannabinoid system has been associated with the regulation of emotional states and cognitive processes, and neuroanatomical studies have detected the presence of endocannabinoid system elements in a number of brain structures involved in learning and memory, and in structures which also play central roles in fear conditioning and response (reviewed in (666)). Furthermore, similarities exist between the expression of fear and anxiety in humans suffering from phobias, PTSD, or other anxiety disorders, and the expression of conditioned fear in animals. Therefore, the use of certain animal behavioural models to study PTSD is feasible and relevant (666,667).

Pre-clinical data

A number of pre-clinical studies demonstrate that deletion of the CB₁ receptor or its inhibition by pharmacological antagonists prevent the extinction of aversive memories (i.e. learned inhibition of fear), a naturally adaptive process (667,668,669,670). Conversely, in some cases, CB₁ receptor agonism or increased endocannabinoid-mediated neurotransmission appear to enhance extinction to some degree (667,670), but further research is required to clarify and substantiate this effect. However, no studies have yet investigated the effects of Δ^9 -THC *per se* on the extinction of aversive memories. Taken together, the evidence from pre-clinical studies suggests a role for the endocannabinoid system in the extinction of aversive memories, and raises the possibility that the endocannabinoid system may be a valid therapeutic target for the treatment of diseases associated with inappropriate retention of aversive memories or inadequate responses to aversive situations, such as PTSD or phobias (668).

Clinical data

Although anecdotal evidence suggests a role for cannabis in the management of PTSD symptoms, no properly controlled clinical trials on this topic exist. In fact the only clinical trial reported to date examining the effect of cannabinoids in PTSD is an open-label, non-placebo-controlled trial of nabilone for PTSD (348). Forty-seven patients diagnosed with PTSD (according to DSM-IV-TR criteria), having at least a two-year history of PTSD-related nightmares refractory to conventional therapies, a minimum of once weekly nightmares, and with no prior history of sensitivity to cannabinoids or evidence of psychotic reactions, were admitted into the study. Patients did not discontinue any concomitant psychotropic medications, and were started on 0.5 mg nabilone, 1 h prior to bedtime. All doses were kept below 6 mg daily. The effective dose range varied between 0.2 mg and 4 mg nightly. Seventy-two percent of patients self-reported total cessation or lessening of severity of nightmares (treatment duration 4 - 12 months or longer). Other self-reported benefits included an improvement in sleep time, a reduction in daytime flashbacks, and cessation of night sweats. Reported side effects included light-headedness, amnesia, dizziness, and headache. No tolerance to nabilone was observed in this clinical trial.

4.8.5.4 Alcohol and opioid withdrawal symptoms (drug withdrawal symptoms)**Alcohol**

There is evidence to suggest complex functional interactions between ethanol and the endocannabinoid system (reviewed in (671)). Acute administration of ethanol in animals is associated with brain region-specific changes in endocannabinoid levels and in the expression of endocannabinoid system components (e.g. CB₁ receptor, FAAH) (671). Furthermore, modulation of endocannabinoid system components through genetic ablation of CB₁ receptor or FAAH expression, or by pharmacological inhibition of CB₁ receptor or FAAH activity, generally results in decreased ethanol consumption in animal models (although a few exceptions have been noted) (671). In contrast, activation of the CB₁ receptor appears to mediate the reinforcing properties of ethanol, facilitates ethanol consumption, and enhances re-instatement of ethanol self-administration in animal models (671). In the case of chronic ethanol consumption, the available evidence suggests long-term exposure to ethanol is in some cases associated with brain region-specific decreases in CB₁ receptor mRNA/protein expression and CB₁ receptor activity, as well as a decrease in FAAH expression and function (671). There is also some limited evidence gathered from animal studies that suggests the endocannabinoid system may be involved in the modulation of alcohol withdrawal symptoms, with CB₁ receptor agonism exacerbating withdrawal severity (671).

Opioids

Anecdotal information and findings from some animal studies suggest that cannabinoids might be useful in treating the symptoms associated with opioid withdrawal (512,672,673,674,675), but there are no supporting clinical studies in this regard. The overlapping neuroanatomical distribution, convergent neurochemical mechanisms, and comparable functional neurobiological properties of the cannabinoid and opioid systems may help explain why cannabinoids could substitute for opioids to potentially alleviate withdrawal symptoms associated with opioid abstinence (511). However, further research is required on this subject.

4.8.5.5 Schizophrenia and psychosis

The endocannabinoid system and psychotic disorders

There is increasing evidence implicating the endocannabinoid system in schizophrenia and psychosis (676). For example, levels of anandamide were reported to be significantly elevated in the cerebrospinal fluid and serum of patients with initial prodromal states of psychosis (677). In addition, anandamide levels were also elevated in the cerebrospinal fluid and serum of anti-psychotic-naïve patients with active schizophrenia (678,679). Post-mortem studies investigating CB₁ receptor densities in the brains of schizophrenic patients have also noted an upregulation of CB₁ receptor levels in the frontal and cingulate brain regions, areas of the brain typically afflicted in schizophrenia (676). While the precise role of the endocannabinoid system in psychosis and schizophrenia remains to be fully elucidated, it appears that such psychiatric disorders are accompanied by changes in the levels of endocannabinoids such as anandamide, as well as changes in CB₁ receptor expression level. Although it remains to be confirmed, one hypothesis holds that the endocannabinoid system may function as a feedback mechanism, negatively regulating dopamine release and dampening the hyperdopaminergic activity observed in the brains of schizophrenic subjects (676,680).

Substance use disorders and psychotic disorders

Interestingly, patients with severe mental illnesses such as schizophrenia are known to have high rates of substance use disorders, with cannabis being one of the substances most often used or misused by this population (681,682). Two competing hypotheses have tried to explain why patients with severe mental illnesses such as schizophrenia also have co-morbid substance abuse. The “self-medication” hypothesis, in the context of psychiatric disorders, posits that those who suffer from such disorders (e.g. schizophrenics) consume cannabis in order to alleviate specific psychopathological symptoms or alternatively to diminish the side effects resulting from the use of medications (682,683). While the “self-medication” hypothesis presents a compassionate, interesting, and attractive explanation to understand why schizophrenics have co-morbid substance abuse disorders, the hypothesis appears to have fallen out of favour (684). On the other hand, the “addiction-vulnerability” hypothesis claims that substance abuse vulnerability and schizophrenic symptoms share a common neuropathology (685). In other words, this hypothesis rests on the idea that certain pathological alterations in brain structure and function will predispose certain individuals to developing both schizophrenia and substance abuse disorders.

Cannabis/THC and psychosis

Regardless of which hypothesis is correct, there is much scientific evidence to suggest a positive association between cannabis use and the development of psychosis, especially in people susceptible to psychotic disorders but also in adolescents (138,139,141,143,144). Furthermore, controlled clinical studies carried out in those with no history of psychotic disorders reported the manifestation of transient schizophrenia-like symptoms induced by the intravenous administration of Δ^9 -THC (140). Likewise, intravenous administration of Δ^9 -THC in schizophrenics was associated with transient exacerbation of core psychotic symptoms (139).

Genetic factors

A number of studies have investigated the influence of potential genetic factors in the development of psychosis and schizophrenia, and more specifically as a function of interaction with cannabis use. Some studies have focused on the role of genetic polymorphisms at the catechol-O-methyltransferase gene (*COMT*) (686,687,688,689,690), and others have focused on polymorphisms at the *AKT1* gene (691,692,693). Taken together, the data from these studies strongly suggest that single-nucleotide polymorphisms at either the *COMT* or *AKT1* genes interact with cannabis use to predict the age at onset, as well as the likelihood of developing psychosis or schizophrenia in vulnerable individuals. Please consult section 7.7.3 for additional information on the adverse psychiatric effects associated with the use of cannabis and psychoactive cannabinoids (such as THC), and the role of genetic predisposition on the risk of developing a psychotic disorder. The findings presented above and in section 7.7.3 suggest that cannabis use, as well as exposure to Δ^9 -THC alone, would not be beneficial, and in fact would actually be harmful to those who may be suffering from psychotic disorders, or who may have a genetic predisposition or family history of psychosis or schizophrenia.

Cannabidiol

A number of pre-clinical and clinical studies have suggested that, in contrast to THC, other cannabinoids such as cannabidiol (CBD) may in fact have anti-psychotic properties and may benefit psychotic patients (694,695). For example, studies in certain rat and mouse models of psychosis suggest that CBD (at doses of